0	BACKGROUND	O
1	:	O
2	Ischemic	O
3	heart	O
4	disease	O
5	is	O
6	the	O
7	primary	O
8	cause	O
9	of	O
10	morbidity	O
11	and	O
12	mortality	O
13	among	O
14	diabetics	O
15	,	O
16	especially	O
17	those	O
18	who	O
19	became	O
20	ill	O
21	at	O
22	a	O
23	young	O
24	age	O
25	.	O

0	More	O
1	importantly	O
2	,	O
3	this	O
4	fusion	O
5	converted	O
6	a	O
7	less	O
8	effective	O
9	vaccine	O
10	into	O
11	one	O
12	with	O
13	significant	O
14	potency	O
15	against	O
16	established	O
17	E7	O
18	-	O
19	expressing	O
20	metastatic	O
21	tumors	O
22	.	O

0	Reverse	O
1	transcription	O
2	-	O
3	PCR	O
4	analysis	O
5	of	O
6	mRNA	O
7	from	O
8	patients	O
9	shows	O
10	that	O
11	each	O
12	of	O
13	these	O
14	five	O
15	mutations	O
16	results	O
17	in	O
18	aberrant	O
19	splicing	O
20	.	O

0	Using	O
1	the	O
2	postural	O
3	and	O
4	force	O
5	data	O
6	as	O
7	input	O
8	to	O
9	a	O
10	3	O
11	-	O
12	D	O
13	biomechanical	O
14	model	O
15	,	O
16	the	O
17	lumbosacral	O
18	spinal	O
19	compression	O
20	was	O
21	calculated	O
22	.	O

0	Sequence	O
1	analysis	O
2	revealed	O
3	significant	O
4	differences	O
5	between	O
6	the	O
7	5	O
8	'	O
9	region	O
10	of	O
11	the	O
12	beta	O
13	subunit	O
14	gene	O
15	and	O
16	the	O
17	corresponding	O
18	regions	O
19	of	O
20	the	O
21	homologous	O
22	GlyR	O
23	alpha	O
24	subunit	O
25	genes	O
26	;	O
27	it	O
28	also	O
29	identified	O
30	a	O
31	novel	O
32	exon	O
33	(	O
34	exon	O
35	0	O
36	)	O
37	that	O
38	encodes	O
39	most	O
40	of	O
41	the	O
42	5	O
43	'-	O
44	untranslated	O
45	portion	O
46	of	O
47	the	O
48	GlyR	O
49	beta	O
50	mRNA	O
51	.	O

0	Therefore	O
1	,	O
2	we	O
3	suggested	O
4	that	O
5	both	O
6	proteins	O
7	might	O
8	belong	O
9	to	O
10	the	O
11	PLTP	O
12	family	O
13	.	O

0	Influence	O
1	of	O
2	compression	O
3	therapy	O
4	on	O
5	symptoms	O
6	following	O
7	soft	O
8	tissue	O
9	injury	O
10	from	O
11	maximal	O
12	eccentric	O
13	exercise	O
14	.	O

0	STAT5A	O
1	mutations	O
2	in	O
3	the	O
4	Src	O
5	homology	O
6	2	O
7	(	O
8	SH2	O
9	)	O
10	and	O
11	SH3	O
12	domains	O
13	did	O
14	not	O
15	alter	O
16	the	O
17	BTK	O
18	-	O
19	mediated	O
20	tyrosine	O
21	phosphorylation	O
22	.	O

0	In	O
1	the	O
2	present	O
3	work	O
4	,	O
5	the	O
6	complete	O
7	genome	O
8	sequences	O
9	of	O
10	Pyrococcus	O
11	horikoshii	O
12	and	O
13	Pyrococcus	O
14	abyssi	O
15	,	O
16	two	O
17	species	O
18	in	O
19	a	O
20	genus	O
21	of	O
22	hyperthermophilic	O
23	archaeon	O
24	(	O
25	archaebacterium	O
26	),	O
27	were	O
28	compared	O
29	to	O
30	detect	O
31	large	O
32	genome	O
33	polymorphisms	O
34	linked	O
35	with	O
36	restriction	O
37	-	O
38	modification	O
39	gene	O
40	homologs	O
41	.	O

0	In	O
1	addition	O
2	,	O
3	these	O
4	patients	O
5	show	O
6	both	O
7	quantitative	O
8	and	O
9	qualitative	O
10	differences	O
11	in	O
12	their	O
13	infectious	O
14	microbiological	O
15	spectrum	O
16	,	O
17	mainly	O
18	in	O
19	clean	O
20	-	O
21	contaminated	O
22	,	O
23	contaminated	O
24	and	O
25	dirty	O
26	surgical	O
27	procedures	O
28	.	O

0	Here	O
1	we	O
2	show	O
3	that	O
4	PKC	O
5	and	O
6	p44	O
7	/	O
8	p42MAPK	O
9	signalings	O
10	are	O
11	required	O
12	for	O
13	the	O
14	HBx	O
15	-	O
16	induced	O
17	Sp1	O
18	-	O
19	mediated	O
20	IGF	O
21	-	O
22	II	O
23	P4	O
24	transcriptional	O
25	activity	O
26	since	O
27	(	O
28	i	O
29	)	O
30	PKC	O
31	activation	O
32	by	O
33	PMA	O
34	or	O
35	PKC	O
36	expression	O
37	vector	O
38	increases	O
39	Sp1	O
40	phosphorylation	O
41	and	O
42	P4	O
43	activity	O
44	in	O
45	HBx	O
46	-	O
47	transfected	O
48	HepG2	O
49	cells	O
50	;	O
51	(	O
52	ii	O
53	)	O
54	PKC	O
55	inhibition	O
56	by	O
57	PKC	O
58	inhibitor	O
59	Go6976	O
60	reduces	O
61	Sp1	O
62	phosphorylation	O
63	,	O
64	P4	O
65	activity	O
66	,	O
67	and	O
68	IGF	O
69	-	O
70	II	O
71	mRNA	O
72	in	O
73	HBx	O
74	-	O
75	transfected	O
76	HepG2	O
77	cells	O
78	;	O
79	and	O
80	(	O
81	iii	O
82	)	O
83	the	O
84	inhibition	O
85	of	O
86	MEK	O
87	activation	O
88	by	O
89	U0126	O
90	reduces	O
91	Sp1	O
92	phosphorylation	O
93	,	O
94	P4	O
95	activity	O
96	and	O
97	IGF	O
98	-	O
99	II	O
100	mRNA	O
101	in	O
102	HBx	O
103	-	O
104	transfected	O
105	HepG2	O
106	cells	O
107	.	O

0	We	O
1	show	O
2	that	O
3	p73	O
4	can	O
5	transcriptionally	O
6	inhibit	O
7	a	O
8	number	O
9	of	O
10	cellular	O
11	and	O
12	viral	O
13	promoters	O
14	.	O

0	Similarly	O
1	,	O
2	curcumin	O
3	(	O
4	diferuloylmethane	O
5	),	O
6	an	O
7	anti	O
8	-	O
9	inflammatory	O
10	agent	O
11	,	O
12	suppressed	O
13	OSM	O
14	-	O
15	stimulated	O
16	STAT1	O
17	phosphorylation	O
18	,	O
19	DNA	O
20	-	O
21	binding	O
22	activity	O
23	of	O
24	STAT1	O
25	,	O
26	and	O
27	c	O
28	-	O
29	Jun	O
30	N	O
31	-	O
32	terminal	O
33	kinase	O
34	activation	O
35	without	O
36	affecting	O
37	JAK1	O
38	,	O
39	JAK2	O
40	,	O
41	JAK3	O
42	,	O
43	ERK1	O
44	/	O
45	2	O
46	,	O
47	and	O
48	p38	O
49	phosphorylation	O
50	.	O

0	The	O
1	effects	O
2	of	O
3	the	O
4	transfected	O
5	receptors	O
6	were	O
7	associated	O
8	with	O
9	antagonism	O
10	of	O
11	activator	O
12	protein	O
13	1	O
14	(	O
15	AP	O
16	-	O
17	1	O
18	)	O
19	activity	O
20	.	O

0	Furthermore	O
1	,	O
2	the	O
3	soluble	O
4	forms	O
5	of	O
6	ATF6	O
7	and	O
8	the	O
9	G13	O
10	gene	O
11	product	O
12	are	O
13	unable	O
14	to	O
15	bind	O
16	to	O
17	several	O
18	point	O
19	mutants	O
20	of	O
21	the	O
22	cis	O
23	-	O
24	acting	O
25	ER	O
26	stress	O
27	response	O
28	element	O
29	in	O
30	vitro	O
31	that	O
32	hardly	O
33	respond	O
34	to	O
35	ER	O
36	stress	O
37	in	O
38	vivo	O
39	.	O

0	PURPOSE	O
1	:	O
2	The	O
3	objective	O
4	of	O
5	this	O
6	study	O
7	was	O
8	to	O
9	assess	O
10	first	O
11	embryo	O
12	cleavage	O
13	(	O
14	FEC	O
15	)	O
16	25	O
17	-	O
18	27	O
19	h	O
20	after	O
21	intracytoplasmic	O
22	sperm	O
23	injection	O
24	(	O
25	ICSI	O
26	)	O
27	as	O
28	a	O
29	parameter	O
30	for	O
31	the	O
32	embryo	O
33	selection	O
34	process	O
35	.	O

0	RESULTS	O
1	:	O
2	A	O
3	significant	O
4	correlation	O
5	(	O
6	p	O
7	<	O
8	0	O
9	.	O
10	001	O
11	)	O
12	was	O
13	observed	O
14	for	O
15	mean	O
16	wall	O
17	thickness	O
18	and	O
19	vessel	O
20	wall	O
21	area	O
22	between	O
23	MRI	O
24	and	O
25	histopathology	O
26	(	O
27	r	O
28	=	O
29	0	O
30	.	O
31	87	O
32	and	O
33	r	O
34	=	O
35	0	O
36	.	O
37	85	O
38	,	O
39	respectively	O
40	).	O

0	Molecular	O
1	cloning	O
2	,	O
3	genomic	O
4	mapping	O
5	,	O
6	and	O
7	expression	O
8	of	O
9	two	O
10	secretor	O
11	blood	O
12	group	O
13	alpha	O
14	(	O
15	1	O
16	,	O
17	2	O
18	)	O
19	fucosyltransferase	O
20	genes	O
21	differentially	O
22	regulated	O
23	in	O
24	mouse	O
25	uterine	O
26	epithelium	O
27	and	O
28	gastrointestinal	O
29	tract	O
30	.	O

0	We	O
1	show	O
2	that	O
3	several	O
4	heme	O
5	-	O
6	responsive	O
7	mechanisms	O
8	combine	O
9	to	O
10	regulate	O
11	DAN	O
12	/	O
13	TIR	O
14	gene	O
15	expression	O
16	.	O

0	No	O
1	'	O
2	TATA	O
3	'	O
4	motif	O
5	was	O
6	identified	O
7	near	O
8	either	O
9	the	O
10	GABPalpha	O
11	or	O
12	ATPsynCF6	O
13	transcription	O
14	start	O
15	sites	O
16	.	O

0	These	O
1	results	O
2	indicate	O
3	the	O
4	presence	O
5	of	O
6	TATA	O
7	-	O
8	unified	O
9	transcription	O
10	systems	O
11	in	O
12	contemporary	O
13	eukaryotes	O
14	and	O
15	provide	O
16	insight	O
17	into	O
18	the	O
19	residual	O
20	need	O
21	for	O
22	TBP	O
23	by	O
24	all	O
25	three	O
26	Pols	O
27	in	O
28	other	O
29	eukaryotes	O
30	despite	O
31	a	O
32	lack	O
33	of	O
34	TATA	O
35	elements	O
36	in	O
37	their	O
38	promoters	O
39	.	O

0	Different	O
1	thermoluminescent	O
2	detectors	O
3	(	O
4	TLD	O
5	)	O
6	have	O
7	been	O
8	used	O
9	to	O
10	measure	O
11	the	O
12	contribution	O
13	of	O
14	the	O
15	low	O
16	linear	O
17	energy	O
18	transfer	O
19	component	O
20	(	O
21	LET	O
22	<	O
23	10	O
24	keV	O
25	/	O
26	micrometer	O
27	)	O
28	and	O
29	plastic	O
30	nuclear	O
31	track	O
32	detectors	O
33	(	O
34	PNTD	O
35	)	O
36	for	O
37	the	O
38	high	O
39	linear	O
40	energy	O
41	tranfer	O
42	(	O
43	LET	O
44	)	O
45	component	O
46	.	O

0	However	O
1	,	O
2	the	O
3	beta5L	O
4	splice	O
5	variant	O
6	was	O
7	found	O
8	only	O
9	in	O
10	the	O
11	retina	O
12	.	O

0	This	O
1	analysis	O
2	supports	O
3	the	O
4	use	O
5	of	O
6	fluticasone	O
7	propionate	O
8	88	O
9	microg	O
10	twice	O
11	daily	O
12	as	O
13	first	O
14	-	O
15	line	O
16	treatment	O
17	in	O
18	patients	O
19	with	O
20	persistent	O
21	asthma	O
22	previously	O
23	treated	O
24	with	O
25	short	O
26	-	O
27	acting	O
28	beta2	O
29	-	O
30	agonist	O
31	alone	O
32	.	O

0	The	O
1	mice	O
2	are	O
3	phenotypically	O
4	normal	O
5	and	O
6	do	O
7	not	O
8	develop	O
9	spontaneous	O
10	tumors	O
11	at	O
12	an	O
13	early	O
14	age	O
15	,	O
16	in	O
17	contrast	O
18	to	O
19	knock	O
20	-	O
21	out	O
22	(	O
23	p53	O
24	(-/-))	O
25	strains	O
26	with	O
27	a	O
28	defective	O
29	p53	O
30	gene	O
31	.	O

0	Furthermore	O
1	,	O
2	stable	O
3	expression	O
4	of	O
5	a	O
6	constitutively	O
7	active	O
8	form	O
9	of	O
10	chicken	O
11	Notch1	O
12	or	O
13	Notch2	O
14	in	O
15	a	O
16	B	O
17	cell	O
18	line	O
19	results	O
20	in	O
21	a	O
22	down	O
23	-	O
24	regulation	O
25	of	O
26	surface	O
27	IgM	O
28	expression	O
29	,	O
30	which	O
31	is	O
32	accompanied	O
33	by	O
34	the	O
35	reduction	O
36	of	O
37	IgH	O
38	gene	O
39	transcripts	O
40	.	O

0	On	O
1	Cox	O
2	proportional	O
3	hazards	O
4	regression	O
5	adenocarcinoma	O
6	(	O
7	P	O
8	=	O
9	0	O
10	.	O
11	006	O
12	),	O
13	the	O
14	development	O
15	of	O
16	BPF	O
17	(	O
18	P	O
19	=	O
20	0	O
21	.	O
22	003	O
23	),	O
24	older	O
25	age	O
26	(	O
27	P	O
28	=	O
29	0	O
30	.	O
31	03	O
32	)	O
33	and	O
34	higher	O
35	pathological	O
36	stage	O
37	(	O
38	P	O
39	=	O
40	0	O
41	.	O
42	02	O
43	)	O
44	were	O
45	independent	O
46	adverse	O
47	predictors	O
48	of	O
49	survival	O
50	.	O

0	We	O
1	found	O
2	that	O
3	RhoA	O
4	can	O
5	initiate	O
6	a	O
7	linear	O
8	kinase	O
9	cascade	O
10	leading	O
11	to	O
12	the	O
13	activation	O
14	of	O
15	ERK6	O
16	(	O
17	p38	O
18	gamma	O
19	),	O
20	a	O
21	recently	O
22	identified	O
23	member	O
24	of	O
25	the	O
26	p38	O
27	family	O
28	of	O
29	MAPKs	O
30	.	O

0	Twenty	O
1	-	O
2	six	O
3	(	O
4	55	O
5	%)	O
6	(	O
7	95	O
8	%	O
9	CI	O
10	,	O
11	41	O
12	-	O
13	69	O
14	%)	O
15	patients	O
16	experienced	O
17	>	O
18	or	O
19	=	O
20	grade	O
21	3	O
22	acute	O
23	toxicity	O
24	(	O
25	RTOG	O
26	).	O

0	We	O
1	hypothesize	O
2	that	O
3	proprioception	O
4	may	O
5	be	O
6	used	O
7	to	O
8	calibrate	O
9	the	O
10	efference	O
11	copy	O
12	during	O
13	development	O
14	and	O
15	in	O
16	response	O
17	to	O
18	perturbations	O
19	by	O
20	signaling	O
21	potential	O
22	mismatches	O
23	between	O
24	eye	O
25	movement	O
26	information	O
27	derived	O
28	from	O
29	the	O
30	efferent	O
31	command	O
32	and	O
33	the	O
34	actual	O
35	motion	O
36	of	O
37	the	O
38	eye	O
39	transduced	O
40	by	O
41	the	O
42	proprioceptive	O
43	organs	O
44	.	O

0	Thus	O
1	,	O
2	BALB	O
3	/	O
4	c	O
5	mice	O
6	appear	O
7	to	O
8	be	O
9	the	O
10	most	O
11	appropriate	O
12	strain	O
13	of	O
14	mice	O
15	to	O
16	perform	O
17	studies	O
18	on	O
19	the	O
20	possible	O
21	connection	O
22	between	O
23	infection	O
24	with	O
25	T	O
26	.	O
27	canis	O
28	and	O
29	allergic	O
30	asthma	O
31	.	O

0	They	O
1	correspond	O
2	to	O
3	nucleotides	O
4	equivalent	O
5	to	O
6	base	O
7	-	O
8	pair	O
9	C1	O
10	-	O
11	G72	O
12	and	O
13	discriminator	O
14	base	O
15	A73	O
16	in	O
17	the	O
18	amino	O
19	acid	O
20	-	O
21	acceptor	O
22	branch	O
23	of	O
24	the	O
25	molecule	O
26	.	O

0	Our	O
1	results	O
2	suggest	O
3	that	O
4	the	O
5	central	O
6	role	O
7	of	O
8	the	O
9	Notch	O
10	-	O
11	CBF1	O
12	/	O
13	RBP	O
14	-	O
15	Jkappa	O
16	signaling	O
17	pathway	O
18	in	O
19	cell	O
20	fate	O
21	decisions	O
22	renders	O
23	it	O
24	susceptible	O
25	to	O
26	pathways	O
27	of	O
28	viral	O
29	replication	O
30	and	O
31	oncogenic	O
32	conversion	O
33	.	O

0	High	O
1	-	O
2	affinity	O
3	binding	O
4	of	O
5	NF	O
6	-	O
7	1	O
8	to	O
9	PSE	O
10	-	O
11	B	O
12	,	O
13	but	O
14	not	O
15	to	O
16	PSE	O
17	-	O
18	A	O
19	,	O
20	was	O
21	confirmed	O
22	by	O
23	competition	O
24	of	O
25	DNA	O
26	-	O
27	protein	O
28	interactions	O
29	by	O
30	using	O
31	NF	O
32	-	O
33	1	O
34	DNA	O
35	elements	O
36	and	O
37	antibodies	O
38	.	O

0	The	O
1	first	O
2	case	O
3	of	O
4	HCV	O
5	seroconversion	O
6	in	O
7	Portugal	O
8	after	O
9	the	O
10	introduction	O
11	of	O
12	HCV	O
13	NAT	O
14	screening	O
15	.	O

0	Substitutions	O
1	in	O
2	the	O
3	YFV	O
4	Ag	O
5	-	O
6	binding	O
7	region	O
8	(	O
9	ABR	O
10	)	O
11	occur	O
12	at	O
13	four	O
14	of	O
15	the	O
16	eight	O
17	highly	O
18	conserved	O
19	residues	O
20	that	O
21	are	O
22	essential	O
23	for	O
24	binding	O
25	of	O
26	peptide	O
27	-	O
28	Ag	O
29	in	O
30	the	O
31	class	O
32	Ia	O
33	molecules	O
34	.	O

0	The	O
1	Novacor	O
2	Left	O
3	Ventricular	O
4	Assist	O
5	System	O
6	(	O
7	LVAS	O
8	)	O
9	(	O
10	Novacor	O
11	Corp	O
12	,	O
13	Oakland	O
14	,	O
15	CA	O
16	)	O
17	was	O
18	initially	O
19	console	O
20	-	O
21	based	O
22	and	O
23	has	O
24	been	O
25	available	O
26	since	O
27	1993	O
28	in	O
29	a	O
30	wearable	O
31	configuration	O
32	.	O

0	Ileal	O
1	digestibilities	O
2	of	O
3	DM	O
4	,	O
5	OM	O
6	,	O
7	CP	O
8	,	O
9	total	O
10	dietary	O
11	fiber	O
12	(	O
13	TDF	O
14	),	O
15	fat	O
16	and	O
17	gross	O
18	energy	O
19	(	O
20	GE	O
21	)	O
22	were	O
23	lower	O
24	(	O
25	P	O
26	<	O
27	0	O
28	.	O
29	05	O
30	)	O
31	for	O
32	dogs	O
33	fed	O
34	diets	O
35	containing	O
36	supplemental	O
37	fiber	O
38	compared	O
39	with	O
40	dogs	O
41	fed	O
42	the	O
43	control	O
44	diet	O
45	.	O

0	In	O
1	addition	O
2	,	O
3	the	O
4	consensus	O
5	amino	O
6	acid	O
7	motif	O
8	for	O
9	serine	O
10	threonine	O
11	receptor	O
12	kinases	O
13	was	O
14	also	O
15	present	O
16	.	O

0	Here	O
1	,	O
2	we	O
3	show	O
4	that	O
5	the	O
6	phorbol	O
7	ester	O
8	PMA	O
9	decreases	O
10	both	O
11	basal	O
12	and	O
13	dexamethasone	O
14	/	O
15	cAMP	O
16	-	O
17	induced	O
18	expression	O
19	of	O
20	a	O
21	luciferase	O
22	gene	O
23	under	O
24	the	O
25	control	O
26	of	O
27	the	O
28	G6Pase	O
29	promoter	O
30	in	O
31	transiently	O
32	transfected	O
33	H4IIE	O
34	hepatoma	O
35	cells	O
36	.	O

0	The	O
1	difference	O
2	between	O
3	the	O
4	patients	O
5	and	O
6	the	O
7	controls	O
8	was	O
9	statistically	O
10	significant	O
11	(	O
12	p	O
13	=	O
14	0	O
15	.	O
16	03	O
17	).	O

0	Altogether	O
1	,	O
2	we	O
3	confirm	O
4	that	O
5	all	O
6	genes	O
7	of	O
8	the	O
9	Rad52	O
10	recombinational	O
11	repair	O
12	pathway	O
13	are	O
14	required	O
15	for	O
16	the	O
17	survival	O
18	of	O
19	rad27	O
20	Delta	O
21	strains	O
22	at	O
23	both	O
24	permissive	O
25	(	O
26	23	O
27	degrees	O
28	C	O
29	)	O
30	and	O
31	semipermissive	O
32	(	O
33	30	O
34	degrees	O
35	C	O
36	)	O
37	temperatures	O
38	for	O
39	growth	O
40	.	O

0	Neuron	O
1	-	O
2	specific	O
3	Bcl	O
4	-	O
5	2	O
6	homology	O
7	3	O
8	domain	O
9	-	O
10	only	O
11	splice	O
12	variant	O
13	of	O
14	Bak	O
15	is	O
16	anti	O
17	-	O
18	apoptotic	O
19	in	O
20	neurons	O
21	,	O
22	but	O
23	pro	O
24	-	O
25	apoptotic	O
26	in	O
27	non	O
28	-	O
29	neuronal	O
30	cells	O
31	.	O

0	The	O
1	mechanism	O
2	of	O
3	the	O
4	induction	O
5	of	O
6	3beta	O
7	-	O
8	HSD	O
9	type	O
10	1	O
11	gene	O
12	expression	O
13	was	O
14	further	O
15	characterized	O
16	in	O
17	ZR	O
18	-	O
19	75	O
20	-	O
21	1	O
22	human	O
23	breast	O
24	cancer	O
25	cells	O
26	.	O

0	Contagious	O
1	bovine	O
2	pleuropneumonia	O
3	is	O
4	a	O
5	major	O
6	threat	O
7	for	O
8	cattle	O
9	in	O
10	Africa	O
11	.	O

0	Treatment	O
1	includes	O
2	both	O
3	medical	O
4	and	O
5	surgical	O
6	options	O
7	,	O
8	with	O
9	medical	O
10	therapy	O
11	further	O
12	subclassified	O
13	into	O
14	pharmacologic	O
15	and	O
16	pneumatic	O
17	dilation	O
18	.	O

0	Since	O
1	the	O
2	latter	O
3	is	O
4	very	O
5	small	O
6	for	O
7	physiological	O
8	flows	O
9	,	O
10	the	O
11	result	O
12	is	O
13	that	O
14	alpha	O
15	<	O
16	1	O
17	even	O
18	at	O
19	relatively	O
20	high	O
21	values	O
22	of	O
23	the	O
24	Reynolds	O
25	number	O
26	(	O
27	i	O
28	.	O
29	e	O
30	.,	O
31	for	O
32	non	O
33	-	O
34	negligible	O
35	inertia	O
36	)	O
37	and	O
38	we	O
39	validate	O
40	our	O
41	perturbation	O
42	theory	O
43	results	O
44	by	O
45	comparison	O
46	with	O
47	a	O
48	numerical	O
49	integration	O
50	of	O
51	the	O
52	full	O
53	model	O
54	.	O

0	This	O
1	plus	O
2	the	O
3	reduced	O
4	phosphorylation	O
5	of	O
6	p27	O
7	by	O
8	MAPK	O
9	enhanced	O
10	the	O
11	stability	O
12	of	O
13	p27	O
14	that	O
15	associated	O
16	with	O
17	nuclear	O
18	Cdk2	O
19	at	O
20	high	O
21	stoichiometry	O
22	and	O
23	inhibited	O
24	its	O
25	kinase	O
26	activity	O
27	.	O

0	Similar	O
1	data	O
2	were	O
3	also	O
4	obtained	O
5	when	O
6	either	O
7	dominant	O
8	negative	O
9	EGFR	O
10	-	O
11	CD533	O
12	or	O
13	dominant	O
14	negative	O
15	Ras	O
16	N17	O
17	were	O
18	used	O
19	to	O
20	block	O
21	MAPK	O
22	activation	O
23	.	O

0	The	O
1	assay	O
2	herein	O
3	described	O
4	allows	O
5	the	O
6	comparison	O
7	of	O
8	relative	O
9	FGFR	O
10	expression	O
11	levels	O
12	,	O
13	both	O
14	within	O
15	a	O
16	single	O
17	RNA	O
18	pool	O
19	and	O
20	among	O
21	multiple	O
22	RNA	O
23	pool	O
24	samples	O
25	.	O

0	This	O
1	was	O
2	most	O
3	pronounced	O
4	during	O
5	the	O
6	initial	O
7	phase	O
8	of	O
9	Erk	O
10	activation	O
11	.	O

0	DESIGN	O
1	:	O
2	Prospective	O
3	cohort	O
4	study	O
5	with	O
6	a	O
7	20	O
8	y	O
9	follow	O
10	-	O
11	up	O
12	period	O
13	,	O
14	the	O
15	First	O
16	National	O
17	Health	O
18	and	O
19	Examination	O
20	Survey	O
21	(	O
22	NHANES	O
23	1	O
24	)	O
25	Epidemiologic	O
26	Follow	O
27	-	O
28	up	O
29	Study	O
30	(	O
31	NHEFS	O
32	).	O

0	To	O
1	assess	O
2	the	O
3	maximum	O
4	oxygen	O
5	uptake	O
6	(	O
7	V	O
8	'	O
9	O2	O
10	max	O
11	)	O
12	of	O
13	Hong	O
14	Kong	O
15	Chinese	O
16	children	O
17	and	O
18	to	O
19	explore	O
20	its	O
21	association	O
22	with	O
23	respiratory	O
24	illnesses	O
25	,	O
26	we	O
27	conducted	O
28	the	O
29	Multistage	O
30	Fitness	O
31	Test	O
32	(	O
33	MFT	O
34	),	O
35	a	O
36	20	O
37	-	O
38	m	O
39	shuttle	O
40	run	O
41	test	O
42	,	O
43	in	O
44	1	O
45	,	O
46	427	O
47	schoolchildren	O
48	aged	O
49	between	O
50	8	O
51	-	O
52	12	O
53	years	O
54	.	O

0	After	O
1	all	O
2	doses	O
3	of	O
4	d	O
5	-	O
6	amphetamine	O
7	,	O
8	responding	O
9	occurred	O
10	largely	O
11	on	O
12	the	O
13	saline	O
14	key	O
15	under	O
16	both	O
17	schedules	O
18	.	O

0	A	O
1	novel	O
2	myeloid	O
3	-	O
4	restricted	O
5	zebrafish	O
6	CCAAT	O
7	/	O
8	enhancer	O
9	-	O
10	binding	O
11	protein	O
12	with	O
13	a	O
14	potent	O
15	transcriptional	O
16	activation	O
17	domain	O
18	.	O

0	METHODS	O
1	:	O
2	Humphrey	O
3	Field	O
4	Analyzer	O
5	model	O
6	630	O
7	(	O
8	HFA	O
9	I	O
10	,	O
11	program	O
12	30	O
13	-	O
14	2	O
15	with	O
16	a	O
17	rectangular	O
18	6	O
19	degrees	O
20	x	O
21	6	O
22	degrees	O
23	grid	O
24	)	O
25	was	O
26	used	O
27	as	O
28	the	O
29	conventional	O
30	perimetric	O
31	method	O
32	.	O

0	These	O
1	data	O
2	reveal	O
3	a	O
4	complex	O
5	network	O
6	of	O
7	interactions	O
8	between	O
9	GTPases	O
10	in	O
11	the	O
12	ARF	O
13	family	O
14	and	O
15	their	O
16	effectors	O
17	and	O
18	reveal	O
19	a	O
20	potential	O
21	for	O
22	cross	O
23	-	O
24	talk	O
25	not	O
26	demonstrated	O
27	previously	O
28	.	O

0	Net	O
1	lift	O
2	and	O
3	combined	O
4	drag	O
5	from	O
6	all	O
7	8	O
8	bearings	O
9	of	O
10	the	O
11	4	O
12	-	O
13	bladed	O
14	impeller	O
15	are	O
16	compared	O
17	with	O
18	predictions	O
19	based	O
20	on	O
21	2	O
22	-	O
23	D	O
24	theory	O
25	.	O

0	In	O
1	the	O
2	course	O
3	of	O
4	screening	O
5	for	O
6	transcription	O
7	factors	O
8	which	O
9	interact	O
10	with	O
11	the	O
12	human	O
13	myeloperoxidase	O
14	(	O
15	MPO	O
16	)	O
17	promoter	O
18	we	O
19	,	O
20	for	O
21	the	O
22	first	O
23	time	O
24	,	O
25	identified	O
26	and	O
27	cloned	O
28	the	O
29	cDNA	O
30	and	O
31	genomic	O
32	DNA	O
33	for	O
34	human	O
35	HBP1	O
36	(	O
37	HMG	O
38	-	O
39	Box	O
40	containing	O
41	protein	O
42	1	O
43	),	O
44	a	O
45	member	O
46	of	O
47	the	O
48	high	O
49	mobility	O
50	group	O
51	of	O
52	non	O
53	-	O
54	histone	O
55	chromosomal	O
56	proteins	O
57	.	O

0	Therefore	O
1	,	O
2	vitamin	O
3	D3	O
4	analogues	O
5	have	O
6	a	O
7	substantial	O
8	antipsoriatic	O
9	effect	O
10	.	O

0	Methylation	O
1	at	O
2	both	O
3	cytosine	O
4	residues	O
5	in	O
6	the	O
7	E2F	O
8	element	O
9	((	O
10	m	O
11	)	O
12	CG	O
13	(	O
14	m	O
15	)	O
16	CG	O
17	)	O
18	generated	O
19	a	O
20	new	O
21	methylcytosine	O
22	-	O
23	specific	O
24	DNA	O
25	-	O
26	protein	O
27	complex	O
28	.	O

0	Hepatitis	O
1	A	O
2	infected	O
3	food	O
4	handler	O
5	at	O
6	an	O
7	Edmonton	O
8	,	O
9	Alberta	O
10	retail	O
11	food	O
12	facility	O
13	:	O
14	public	O
15	health	O
16	protection	O
17	strategies	O
18	.	O

0	The	O
1	co	O
2	-	O
3	existence	O
4	of	O
5	TE	O
6	domains	O
7	within	O
8	modular	O
9	PKSs	O
10	along	O
11	with	O
12	physically	O
13	separated	O
14	,	O
15	monofunctional	O
16	TEs	O
17	(	O
18	TE	O
19	IIs	O
20	)	O
21	has	O
22	been	O
23	reported	O
24	for	O
25	a	O
26	number	O
27	of	O
28	modular	O
29	polyketide	O
30	and	O
31	non	O
32	-	O
33	ribosomal	O
34	peptide	O
35	synthases	O
36	(	O
37	NRPS	O
38	).	O

0	Two	O
1	independent	O
2	transgenic	O
3	lines	O
4	were	O
5	produced	O
6	,	O
7	and	O
8	both	O
9	showed	O
10	expression	O
11	of	O
12	the	O
13	Gus	O
14	gene	O
15	specifically	O
16	in	O
17	the	O
18	endosperm	O
19	during	O
20	mid	O
21	-	O
22	development	O
23	(	O
24	first	O
25	detected	O
26	10	O
27	-	O
28	12	O
29	d	O
30	after	O
31	anthesis	O
32	).	O

0	Treadmill	O
1	training	O
2	at	O
3	least	O
4	for	O
5	2	O
6	weeks	O
7	can	O
8	reduce	O
9	the	O
10	infarction	O
11	size	O
12	and	O
13	edema	O
14	caused	O
15	by	O
16	MCA	O
17	occlusion	O
18	(	O
19	P	O
20	<	O
21	0	O
22	.	O
23	01	O
24	).	O

0	Mechanism	O
1	in	O
2	the	O
3	sequential	O
4	control	O
5	of	O
6	cell	O
7	morphology	O
8	and	O
9	S	O
10	phase	O
11	entry	O
12	by	O
13	epidermal	O
14	growth	O
15	factor	O
16	involves	O
17	distinct	O
18	MEK	O
19	/	O
20	ERK	O
21	activations	O
22	.	O

0	We	O
1	randomly	O
2	assigned	O
3	1	O
4	,	O
5	219	O
6	subjects	O
7	to	O
8	receive	O
9	either	O
10	the	O
11	standard	O
12	three	O
13	-	O
14	times	O
15	-	O
16	weekly	O
17	(	O
18	TIW	O
19	)	O
20	interferon	O
21	alfa	O
22	-	O
23	2b	O
24	dose	O
25	(	O
26	3	O
27	MIU	O
28	)	O
29	or	O
30	the	O
31	once	O
32	-	O
33	weekly	O
34	(	O
35	QW	O
36	)	O
37	peginterferon	O
38	alfa	O
39	-	O
40	2b	O
41	(	O
42	0	O
43	.	O
44	5	O
45	,	O
46	1	O
47	.	O
48	0	O
49	,	O
50	or	O
51	1	O
52	.	O
53	5	O
54	microg	O
55	/	O
56	kg	O
57	).	O

0	These	O
1	data	O
2	suggest	O
3	that	O
4	proper	O
5	direct	O
6	binding	O
7	of	O
8	Nhp2p	O
9	to	O
10	H	O
11	/	O
12	ACA	O
13	snoRNAs	O
14	is	O
15	required	O
16	for	O
17	the	O
18	assembly	O
19	of	O
20	H	O
21	/	O
22	ACA	O
23	snoRNPs	O
24	and	O
25	hence	O
26	for	O
27	the	O
28	stability	O
29	of	O
30	some	O
31	of	O
32	their	O
33	components	O
34	.	O

0	The	O
1	decrements	O
2	in	O
3	cerebrovascular	O
4	resistance	O
5	induced	O
6	by	O
7	hexamethonium	O
8	,	O
9	in	O
10	mm	O
11	Hg	O
12	ml	O
13	(-	O
14	1	O
15	).	O
16	min	O
17	(-	O
18	1	O
19	),	O
20	were	O
21	:	O
22	under	O
23	control	O
24	.	O

0	Here	O
1	we	O
2	provide	O
3	the	O
4	first	O
5	evidence	O
6	for	O
7	the	O
8	involvement	O
9	of	O
10	GCN1	O
11	-	O
12	GCN2	O
13	interaction	O
14	in	O
15	activation	O
16	of	O
17	GCN2	O
18	per	O
19	se	O
20	.	O

0	As	O
1	a	O
2	reflection	O
3	of	O
4	uncertainties	O
5	in	O
6	the	O
7	estimates	O
8	for	O
9	individual	O
10	sources	O
11	,	O
12	the	O
13	90th	O
14	percentiles	O
15	of	O
16	PCDD	O
17	/	O
18	F	O
19	releases	O
20	for	O
21	1999	O
22	ranged	O
23	up	O
24	to	O
25	4	O
26	.	O
27	1	O
28	g	O
29	I	O
30	-	O
31	TEQ	O
32	/	O
33	y	O
34	.	O

0	To	O
1	test	O
2	the	O
3	hypothesis	O
4	that	O
5	these	O
6	elements	O
7	are	O
8	required	O
9	for	O
10	promoter	O
11	activity	O
12	,	O
13	we	O
14	compared	O
15	the	O
16	reporter	O
17	expression	O
18	activity	O
19	of	O
20	segments	O
21	containing	O
22	mutations	O
23	of	O
24	these	O
25	elements	O
26	with	O
27	activity	O
28	of	O
29	the	O
30	parent	O
31	Hlx	O
32	promoter	O
33	sequence	O
34	.	O

0	Using	O
1	RACE	O
2	techniques	O
3	we	O
4	have	O
5	cloned	O
6	and	O
7	sequenced	O
8	one	O
9	of	O
10	the	O
11	hamster	O
12	liver	O
13	3	O
14	-	O
15	hydroxy	O
16	-	O
17	hexobarbital	O
18	dehydrogenases	O
19	which	O
20	catalyze	O
21	not	O
22	only	O
23	cyclic	O
24	alcohols	O
25	but	O
26	also	O
27	17beta	O
28	-	O
29	hydroxy	O
30	-	O
31	steroids	O
32	and	O
33	3alpha	O
34	-	O
35	hydroxysteroids	O
36	.	O

0	Concerted	O
1	transcriptional	O
2	activation	O
3	of	O
4	the	O
5	low	O
6	density	O
7	lipoprotein	O
8	receptor	O
9	gene	O
10	by	O
11	insulin	O
12	and	O
13	luteinizing	O
14	hormone	O
15	in	O
16	cultured	O
17	porcine	O
18	granulosa	O
19	-	O
20	luteal	O
21	cells	O
22	:	O
23	possible	O
24	convergence	O
25	of	O
26	protein	O
27	kinase	O
28	a	O
29	,	O
30	phosphatidylinositol	O
31	3	O
32	-	O
33	kinase	O
34	,	O
35	and	O
36	mitogen	O
37	-	O
38	activated	O
39	protein	O
40	kinase	O
41	signaling	O
42	pathways	O
43	.	O

0	Human	O
1	T	O
2	-	O
3	cell	O
4	leukemia	O
5	virus	O
6	type	O
7	I	O
8	(	O
9	HTLV	O
10	-	O
11	I	O
12	)	O
13	Tax	O
14	is	O
15	a	O
16	potent	O
17	transcriptional	O
18	regulator	O
19	that	O
20	can	O
21	activate	O
22	or	O
23	repress	O
24	specific	O
25	cellular	O
26	genes	O
27	and	O
28	that	O
29	has	O
30	been	O
31	proposed	O
32	to	O
33	contribute	O
34	to	O
35	leukemogenesis	O
36	in	O
37	adult	O
38	T	O
39	-	O
40	cell	O
41	leukemia	O
42	.	O

0	Also	O
1	,	O
2	small	O
3	,	O
4	sense	O
5	and	O
6	antisense	O
7	approximately	O
8	22	O
9	nt	O
10	RNAs	O
11	,	O
12	derived	O
13	from	O
14	the	O
15	satRNA	O
16	,	O
17	were	O
18	associated	O
19	with	O
20	the	O
21	replicating	O
22	satellite	O
23	.	O

0	Deletional	O
1	analyses	O
2	of	O
3	VDR	O
4	indicated	O
5	that	O
6	GRIP1	O
7	and	O
8	RAC3	O
9	required	O
10	an	O
11	intact	O
12	VDR	O
13	activation	O
14	function	O
15	(	O
16	AF	O
17	-	O
18	2	O
19	)	O
20	domain	O
21	for	O
22	efficient	O
23	interaction	O
24	as	O
25	well	O
26	as	O
27	additional	O
28	but	O
29	distinct	O
30	regions	O
31	of	O
32	the	O
33	VDR	O
34	.	O

0	RESULTS	O
1	:	O
2	During	O
3	the	O
4	stabilization	O
5	period	O
6	,	O
7	PaCO2	O
8	(	O
9	mean	O
10	+/-	O
11	SD	O
12	)	O
13	was	O
14	33	O
15	+/-	O
16	5	O
17	mm	O
18	Hg	O
19	,	O
20	and	O
21	arrhythmias	O
22	were	O
23	not	O
24	detected	O
25	.	O

0	TT	O
1	cells	O
2	,	O
3	a	O
4	human	O
5	MTC	O
6	cell	O
7	line	O
8	expressing	O
9	MEN	O
10	2A	O
11	type	O
12	RET	O
13	,	O
14	display	O
15	transcriptionally	O
16	active	O
17	RelA	O
18	(	O
19	p65	O
20	)	O
21	in	O
22	the	O
23	nucleus	O
24	.	O

0	The	O
1	human	O
2	protein	O
3	sequence	O
4	exhibits	O
5	a	O
6	putative	O
7	DNA	O
8	-	O
9	binding	O
10	domain	O
11	similar	O
12	to	O
13	that	O
14	seen	O
15	in	O
16	rat	O
17	HBP1	O
18	and	O
19	shows	O
20	homology	O
21	with	O
22	the	O
23	activation	O
24	and	O
25	repressor	O
26	domains	O
27	previously	O
28	demonstrated	O
29	in	O
30	the	O
31	rat	O
32	protein	O
33	.	O

0	In	O
1	contrast	O
2	the	O
3	human	O
4	and	O
5	mouse	O
6	BCNT	O
7	proteins	O
8	contain	O
9	one	O
10	repeat	O
11	unit	O
12	and	O
13	lack	O
14	the	O
15	RTE	O
16	-	O
17	1	O
18	-	O
19	derived	O
20	portion	O
21	.	O

0	Direct	O
1	superoxide	O
2	scavenging	O
3	activity	O
4	of	O
5	nonsteroidal	O
6	anti	O
7	-	O
8	inflammatory	O
9	drugs	O
10	:	O
11	determination	O
12	by	O
13	electron	O
14	spin	O
15	resonance	O
16	using	O
17	the	O
18	spin	O
19	trap	O
20	method	O
21	.	O

0	A	O
1	single	O
2	nucleotide	O
3	polymorphism	O
4	(	O
5	SNP	O
6	)	O
7	in	O
8	exon	O
9	2	O
10	,	O
11	which	O
12	is	O
13	tightly	O
14	liked	O
15	to	O
16	another	O
17	SNP	O
18	(	O
19	GTG83	O
20	/	O
21	ATG83	O
22	),	O
23	creates	O
24	an	O
25	additional	O
26	alternative	O
27	in	O
28	-	O
29	frame	O
30	AUG	O
31	in	O
32	B	O
33	-	O
34	type	O
35	MTH1	O
36	mRNAs	O
37	yielding	O
38	the	O
39	fourth	O
40	MTH1	O
41	polypeptide	O
42	,	O
43	p26	O
44	that	O
45	possesses	O
46	an	O
47	additional	O
48	mitochondrial	O
49	targeting	O
50	signal	O
51	.	O

0	Six	O
1	of	O
2	the	O
3	gstC	O
4	'	O
5	mutants	O
6	,	O
7	primarily	O
8	in	O
9	the	O
10	C	O
11	-	O
12	terminal	O
13	half	O
14	of	O
15	C	O
16	',	O
17	exhibited	O
18	a	O
19	defect	O
20	in	O
21	the	O
22	ability	O
23	to	O
24	bind	O
25	L	O
26	protein	O
27	.	O

0	We	O
1	developed	O
2	a	O
3	system	O
4	for	O
5	domain	O
6	shuffling	O
7	to	O
8	establish	O
9	the	O
10	function	O
11	of	O
12	C1	O
13	domains	O
14	from	O
15	human	O
16	Raf	O
17	kinase	O
18	and	O
19	rat	O
20	PKC	O
21	eta	O
22	in	O
23	yeast	O
24	.	O

0	Expression	O
1	of	O
2	herpes	O
3	simplex	O
4	virus	O
5	type	O
6	2	O
7	US3	O
8	affects	O
9	the	O
10	Cdc42	O
11	/	O
12	Rac	O
13	pathway	O
14	and	O
15	attenuates	O
16	c	O
17	-	O
18	Jun	O
19	N	O
20	-	O
21	terminal	O
22	kinase	O
23	activation	O
24	.	O

0	Inhibition	O
1	of	O
2	constitutive	O
3	NF	O
4	-	O
5	kappaB	O
6	activity	O
7	results	O
8	in	O
9	cell	O
10	death	O
11	of	O
12	TT	O
13	cells	O
14	and	O
15	blocks	O
16	focus	O
17	formation	O
18	induced	O
19	by	O
20	oncogenic	O
21	forms	O
22	of	O
23	RET	O
24	in	O
25	NIH	O
26	3T3	O
27	cells	O
28	.	O

0	Corneal	O
1	scrapping	O
2	and	O
3	deep	O
4	stromal	O
5	biopsy	O
6	were	O
7	obtained	O
8	and	O
9	stained	O
10	for	O
11	microscopic	O
12	evaluation	O
13	with	O
14	periodic	O
15	acid	O
16	-	O
17	Schiff	O
18	,	O
19	Giemsa	O
20	,	O
21	and	O
22	Gomori	O
23	'	O
24	s	O
25	methenamine	O
26	silver	O
27	stains	O
28	.	O

0	ICAM	O
1	-	O
2	1	O
3	has	O
4	been	O
5	suggested	O
6	a	O
7	predictor	O
8	of	O
9	the	O
10	onset	O
11	of	O
12	GO	O
13	.	O

0	Once	O
1	ICP	O
2	reaches	O
3	critical	O
4	values	O
5	(>	O
6	30	O
7	mm	O
8	Hg	O
9	)	O
10	herniation	O
11	occurs	O
12	,	O
13	usually	O
14	within	O
15	2	O
16	to	O
17	5	O
18	days	O
19	.	O

0	The	O
1	present	O
2	data	O
3	also	O
4	demonstrate	O
5	that	O
6	ectopic	O
7	expression	O
8	of	O
9	blr1	O
10	increased	O
11	JNK	O
12	/	O
13	SAPK	O
14	activity	O
15	,	O
16	but	O
17	JNK	O
18	/	O
19	SAPK	O
20	activation	O
21	was	O
22	not	O
23	needed	O
24	for	O
25	accelerated	O
26	RA	O
27	-	O
28	induced	O
29	differentiation	O
30	and	O
31	growth	O
32	arrest	O
33	.	O

0	Here	O
1	,	O
2	we	O
3	identify	O
4	Rsc3	O
5	and	O
6	Rsc30	O
7	as	O
8	novel	O
9	components	O
10	of	O
11	the	O
12	essential	O
13	yeast	O
14	remodeler	O
15	RSC	O
16	complex	O
17	.	O

0	The	O
1	pharmacokinetic	O
2	profiles	O
3	of	O
4	digoxin	O
5	and	O
6	warfarin	O
7	were	O
8	not	O
9	altered	O
10	by	O
11	the	O
12	simultaneous	O
13	and	O
14	continued	O
15	administration	O
16	of	O
17	sevelamer	O
18	.	O

0	Forskolin	O
1	treatment	O
2	(	O
3	10	O
4	microM	O
5	)	O
6	of	O
7	the	O
8	transfected	O
9	cells	O
10	for	O
11	3	O
12	--	O
13	6	O
14	h	O
15	maximally	O
16	induced	O
17	luciferase	O
18	threefold	O
19	.	O

0	E2F1	O
1	-	O
2	mediated	O
3	transcriptional	O
4	inhibition	O
5	of	O
6	the	O
7	plasminogen	O
8	activator	O
9	inhibitor	O
10	type	O
11	1	O
12	gene	O
13	.	O

0	In	O
1	this	O
2	report	O
3	this	O
4	technique	O
5	was	O
6	applied	O
7	to	O
8	human	O
9	breast	O
10	carcinoma	O
11	MDA	O
12	-	O
13	MB231	O
14	cells	O
15	overexpressing	O
16	human	O
17	MPG	O
18	in	O
19	order	O
20	to	O
21	assess	O
22	whether	O
23	up	O
24	-	O
25	regulation	O
26	of	O
27	the	O
28	initial	O
29	step	O
30	in	O
31	BER	O
32	alters	O
33	the	O
34	activity	O
35	of	O
36	selected	O
37	other	O
38	BER	O
39	(	O
40	hOGG1	O
41	and	O
42	APE	O
43	/	O
44	ref	O
45	-	O
46	1	O
47	)	O
48	or	O
49	direct	O
50	reversal	O
51	(	O
52	MGMT	O
53	)	O
54	repair	O
55	activities	O
56	.	O

0	Chlamydia	O
1	and	O
2	cervical	O
3	cancer	O
4	:	O
5	a	O
6	real	O
7	association	O
8	?	O

0	In	O
1	children	O
2	unable	O
3	to	O
4	perform	O
5	forced	O
6	expiratory	O
7	maneuvers	O
8	(	O
9	n	O
10	=	O
11	25	O
12	),	O
13	FOT	O
14	,	O
15	contrary	O
16	to	O
17	the	O
18	interrupter	O
19	technique	O
20	,	O
21	clearly	O
22	identified	O
23	a	O
24	subgroup	O
25	of	O
26	young	O
27	children	O
28	with	O
29	high	O
30	resistance	O
31	values	O
32	at	O
33	baseline	O
34	,	O
35	which	O
36	returned	O
37	to	O
38	normal	O
39	after	O
40	bronchodilation	O
41	.	O

0	Together	O
1	,	O
2	these	O
3	results	O
4	identify	O
5	HPK1	O
6	as	O
7	a	O
8	new	O
9	component	O
10	of	O
11	TCR	O
12	signaling	O
13	.	O

0	Pro	O
1	-	O
2	inflammatory	O
3	cytokine	O
4	,	O
5	tumor	O
6	necrosis	O
7	factor	O
8	-	O
9	alpha	O
10	(	O
11	TNF	O
12	-	O
13	alpha	O
14	),	O
15	produced	O
16	from	O
17	adipose	O
18	tissues	O
19	in	O
20	obese	O
21	subjects	O
22	,	O
23	is	O
24	known	O
25	to	O
26	play	O
27	a	O
28	predominant	O
29	role	O
30	in	O
31	inducing	O
32	insulin	O
33	resistance	O
34	.	O

0	The	O
1	Schistosoma	O
2	mansoni	O
3	homologue	O
4	(	O
5	SmSmad2	O
6	)	O
7	was	O
8	overexpressed	O
9	in	O
10	bacteria	O
11	as	O
12	a	O
13	Sj26	O
14	-	O
15	GST	O
16	fusion	O
17	protein	O
18	and	O
19	used	O
20	to	O
21	raise	O
22	specific	O
23	antibodies	O
24	.	O

0	To	O
1	study	O
2	the	O
3	in	O
4	vivo	O
5	role	O
6	of	O
7	p16	O
8	.	O
9	7	O
10	,	O
11	a	O
12	phi29	O
13	mutant	O
14	containing	O
15	a	O
16	suppressible	O
17	mutation	O
18	in	O
19	gene	O
20	16	O
21	.	O
22	7	O
23	was	O
24	constructed	O
25	.	O

0	The	O
1	differences	O
2	in	O
3	the	O
4	CPIgG	O
5	,	O
6	CRP	O
7	,	O
8	and	O
9	fibrinogen	O
10	levels	O
11	in	O
12	patients	O
13	who	O
14	were	O
15	diagnosed	O
16	with	O
17	ACS	O
18	versus	O
19	those	O
20	who	O
21	were	O
22	not	O
23	(	O
24	non	O
25	-	O
26	ACS	O
27	)	O
28	were	O
29	evaluated	O
30	.	O

0	There	O
1	are	O
2	many	O
3	different	O
4	proposals	O
5	for	O
6	the	O
7	statistical	O
8	analysis	O
9	of	O
10	data	O
11	to	O
12	determine	O
13	early	O
14	onset	O
15	of	O
16	action	O
17	.	O

0	Coexpression	O
1	of	O
2	the	O
3	p120	O
4	(	O
5	ctn	O
6	)	O
7	protein	O
8	with	O
9	an	O
10	N	O
11	-	O
12	terminal	O
13	deletion	O
14	,	O
15	which	O
16	eliminates	O
17	some	O
18	potential	O
19	tyrosine	O
20	phosphorylation	O
21	sites	O
22	,	O
23	or	O
24	the	O
25	protein	O
26	with	O
27	a	O
28	single	O
29	amino	O
30	acid	O
31	substitution	O
32	(	O
33	tyrosine	O
34	at	O
35	217	O
36	to	O
37	phenylalanine	O
38	)	O
39	resulted	O
40	in	O
41	an	O
42	increase	O
43	in	O
44	the	O
45	aggregation	O
46	of	O
47	v	O
48	-	O
49	Src	O
50	-	O
51	transformed	O
52	EL	O
53	and	O
54	EalphaCL	O
55	cells	O
56	.	O

0	We	O
1	find	O
2	that	O
3	our	O
4	response	O
5	function	O
6	is	O
7	well	O
8	approximated	O
9	by	O
10	the	O
11	GSER	O
12	only	O
13	within	O
14	a	O
15	particular	O
16	frequency	O
17	range	O
18	determined	O
19	by	O
20	the	O
21	material	O
22	parameters	O
23	of	O
24	both	O
25	the	O
26	bead	O
27	and	O
28	the	O
29	network	O
30	.	O

0	The	O
1	novel	O
2	approach	O
3	to	O
4	insulin	O
5	administration	O
6	known	O
7	as	O
8	chronic	O
9	intermittent	O
10	intravenous	O
11	insulin	O
12	therapy	O
13	(	O
14	CIIIT	O
15	)	O
16	delivers	O
17	insulin	O
18	in	O
19	a	O
20	pulsatile	O
21	fashion	O
22	and	O
23	achieves	O
24	physiological	O
25	insulin	O
26	concentration	O
27	in	O
28	the	O
29	portal	O
30	vein	O
31	.	O

0	This	O
1	article	O
2	comparatively	O
3	evaluates	O
4	five	O
5	Generic	O
6	Systems	O
7	that	O
8	describe	O
9	the	O
10	basic	O
11	alternatives	O
12	to	O
13	composting	O
14	facility	O
15	design	O
16	and	O
17	control	O
18	.	O

0	With	O
1	a	O
2	GC	O
3	content	O
4	of	O
5	45	O
6	%	O
7	the	O
8	one	O
9	segment	O
10	would	O
11	correspond	O
12	to	O
13	"	O
14	isochore	O
15	H1	O
16	"	O
17	and	O
18	the	O
19	other	O
20	segment	O
21	(	O
22	39	O
23	%	O
24	GC	O
25	in	O
26	human	O
27	,	O
28	40	O
29	%	O
30	GC	O
31	in	O
32	mouse	O
33	)	O
34	to	O
35	"	O
36	isochore	O
37	L1	O
38	/	O
39	L2	O
40	".	O

0	A	O
1	review	O
2	of	O
3	the	O
4	literature	O
5	identified	O
6	8	O
7	comprehensive	O
8	clinical	O
9	studies	O
10	,	O
11	all	O
12	of	O
13	which	O
14	failed	O
15	to	O
16	document	O
17	any	O
18	relationship	O
19	between	O
20	NF1	O
21	and	O
22	intracranial	O
23	aneurysms	O
24	.	O

0	Serial	O
1	US	O
2	images	O
3	were	O
4	obtained	O
5	before	O
6	and	O
7	20	O
8	,	O
9	30	O
10	,	O
11	40	O
12	,	O
13	50	O
14	,	O
15	60	O
16	,	O
17	90	O
18	,	O
19	120	O
20	,	O
21	150	O
22	,	O
23	180	O
24	,	O
25	240	O
26	,	O
27	and	O
28	300	O
29	s	O
30	after	O
31	intravenous	O
32	injection	O
33	of	O
34	2	O
35	g	O
36	of	O
37	contrast	O
38	agent	O
39	using	O
40	conventional	O
41	and	O
42	harmonic	O
43	PD	O
44	US	O
45	.	O

0	Eight	O
1	CAD	O
2	patients	O
3	who	O
4	were	O
5	matched	O
6	to	O
7	the	O
8	treated	O
9	patients	O
10	for	O
11	age	O
12	(+/-	O
13	3	O
14	years	O
15	),	O
16	baseline	O
17	low	O
18	density	O
19	lipoprotein	O
20	(+/-	O
21	5	O
22	mg	O
23	/	O
24	dL	O
25	),	O
26	and	O
27	triglycerides	O
28	(+/-	O
29	50	O
30	mg	O
31	/	O
32	dL	O
33	)	O
34	but	O
35	who	O
36	had	O
37	never	O
38	been	O
39	treated	O
40	with	O
41	lipid	O
42	-	O
43	lowering	O
44	drugs	O
45	were	O
46	selected	O
47	as	O
48	controls	O
49	.	O

0	Here	O
1	we	O
2	present	O
3	evidence	O
4	that	O
5	the	O
6	distal	O
7	half	O
8	(	O
9	Stem	O
10	2	O
11	)	O
12	of	O
13	the	O
14	conserved	O
15	base	O
16	-	O
17	paired	O
18	stem	O
19	structure	O
20	found	O
21	in	O
22	all	O
23	hY	O
24	RNAs	O
25	also	O
26	plays	O
27	a	O
28	critical	O
29	role	O
30	in	O
31	the	O
32	export	O
33	process	O
34	.	O

0	The	O
1	contrasting	O
2	effects	O
3	of	O
4	dopaminergic	O
5	stimulation	O
6	on	O
7	the	O
8	motor	O
9	performance	O
10	and	O
11	on	O
12	some	O
13	aspects	O
14	of	O
15	cognitive	O
16	processing	O
17	suggest	O
18	the	O
19	existence	O
20	of	O
21	complex	O
22	interactions	O
23	within	O
24	pre	O
25	-	O
26	and	O
27	postsynaptic	O
28	brain	O
29	dopamine	O
30	receptors	O
31	,	O
32	and	O
33	an	O
34	intervention	O
35	of	O
36	segregated	O
37	basal	O
38	ganglia	O
39	-	O
40	prefrontal	O
41	cortex	O
42	loops	O
43	in	O
44	motor	O
45	and	O
46	cognitive	O
47	behaviour	O
48	.	O

0	The	O
1	size	O
2	of	O
3	the	O
4	infarct	O
5	was	O
6	determined	O
7	using	O
8	the	O
9	creatine	O
10	kinase	O
11	integral	O
12	method	O
13	.	O

0	These	O
1	corrections	O
2	do	O
3	not	O
4	involve	O
5	sequences	O
6	predicted	O
7	to	O
8	function	O
9	as	O
10	transcription	O
11	factor	O
12	binding	O
13	sites	O
14	.	O

0	A	O
1	comprehensive	O
2	neuropsychological	O
3	battery	O
4	was	O
5	administered	O
6	to	O
7	48	O
8	veterans	O
9	with	O
10	Gulf	O
11	War	O
12	Illness	O
13	(	O
14	GWI	O
15	)	O
16	characterized	O
17	by	O
18	severe	O
19	fatigue	O
20	(	O
21	GV	O
22	-	O
23	F	O
24	)	O
25	and	O
26	39	O
27	healthy	O
28	veterans	O
29	(	O
30	GV	O
31	-	O
32	H	O
33	).	O

0	Quantitative	O
1	PCR	O
2	studies	O
3	indicated	O
4	that	O
5	synthesis	O
6	and	O
7	transport	O
8	of	O
9	vector	O
10	DNA	O
11	into	O
12	the	O
13	nucleus	O
14	were	O
15	similar	O
16	for	O
17	macrophages	O
18	infected	O
19	with	O
20	the	O
21	clone	O
22	239	O
23	and	O
24	316	O
25	pseudotypes	O
26	,	O
27	suggesting	O
28	that	O
29	the	O
30	restriction	O
31	for	O
32	SIVmac239	O
33	infection	O
34	is	O
35	after	O
36	reverse	O
37	transcription	O
38	and	O
39	nuclear	O
40	import	O
41	of	O
42	viral	O
43	DNA	O
44	.	O

0	EXAFS	O
1	measurements	O
2	around	O
3	the	O
4	Ge	O
5	-	O
6	K	O
7	edge	O
8	have	O
9	been	O
10	carried	O
11	out	O
12	for	O
13	liquid	O
14	Ge	O
15	-	O
16	Si	O
17	alloys	O
18	for	O
19	the	O
20	first	O
21	time	O
22	to	O
23	investigate	O
24	the	O
25	local	O
26	structure	O
27	around	O
28	a	O
29	Ge	O
30	atom	O
31	.	O

0	Hp	O
1	positive	O
2	relatives	O
3	of	O
4	gastric	O
5	cancer	O
6	had	O
7	a	O
8	markedly	O
9	higher	O
10	prevalence	O
11	of	O
12	atrophy	O
13	than	O
14	those	O
15	with	O
16	Hp	O
17	negativity	O
18	without	O
19	cancer	O
20	relatives	O
21	(	O
22	29	O
23	vs	O
24	.	O

0	Thus	O
1	,	O
2	replication	O
3	fork	O
4	movement	O
5	near	O
6	HML	O
7	pauses	O
8	at	O
9	a	O
10	silent	O
11	origin	O
12	which	O
13	is	O
14	competent	O
15	for	O
16	replication	O
17	initiation	O
18	but	O
19	kept	O
20	silent	O
21	through	O
22	Orc2p	O
23	,	O
24	a	O
25	component	O
26	of	O
27	the	O
28	replication	O
29	initiator	O
30	.	O

0	Cardiac	O
1	markers	O
2	troponin	O
3	T	O
4	,	O
5	CK	O
6	-	O
7	MB	O
8	mass	O
9	and	O
10	myoglobin	O
11	were	O
12	helpful	O
13	in	O
14	the	O
15	differential	O
16	diagnosis	O
17	of	O
18	chest	O
19	pain	O
20	,	O
21	even	O
22	when	O
23	the	O
24	ECG	O
25	was	O
26	unremarkable	O
27	or	O
28	nonspecific	O
29	.	O

0	RESULTS	O
1	:	O
2	A	O
3	novel	O
4	gene	O
5	was	O
6	cloned	O
7	.	O

0	Both	O
1	pancreatic	O
2	and	O
3	intestinal	O
4	cell	O
5	lines	O
6	were	O
7	found	O
8	to	O
9	express	O
10	a	O
11	number	O
12	of	O
13	POU	O
14	(	O
15	OCT	O
16	binding	O
17	)	O
18	homeodomain	O
19	proteins	O
20	examined	O
21	by	O
22	electrophoretic	O
23	mobility	O
24	shift	O
25	assay	O
26	.	O

0	In	O
1	conclusion	O
2	,	O
3	USPIO	O
4	-	O
5	enhanced	O
6	MRI	O
7	data	O
8	were	O
9	capable	O
10	to	O
11	characterize	O
12	tumor	O
13	microvessel	O
14	properties	O
15	in	O
16	this	O
17	breast	O
18	cancer	O
19	model	O
20	:	O
21	microvascular	O
22	permeability	O
23	(	O
24	determined	O
25	using	O
26	USPIO	O
27	)	O
28	correlated	O
29	significantly	O
30	with	O
31	tumor	O
32	grade	O
33	.	O

0	Radiolabeled	O
1	biantennary	O
2	N	O
3	-	O
4	glycans	O
5	synthesized	O
6	by	O
7	Pro	O
8	(-)	O
9	5Lec20	O
10	were	O
11	proportionately	O
12	less	O
13	ricin	O
14	-	O
15	bound	O
16	than	O
17	similar	O
18	species	O
19	from	O
20	parental	O
21	CHO	O
22	cells	O
23	,	O
24	and	O
25	Lec20	O
26	cell	O
27	extracts	O
28	had	O
29	a	O
30	markedly	O
31	reduced	O
32	ability	O
33	to	O
34	transfer	O
35	Gal	O
36	to	O
37	GlcNAc	O
38	-	O
39	terminating	O
40	acceptors	O
41	.	O

0	CONCLUSION	O
1	:	O
2	The	O
3	training	O
4	of	O
5	novices	O
6	using	O
7	MIST	O
8	-	O
9	VR	O
10	yields	O
11	quantifiable	O
12	changes	O
13	in	O
14	skill	O
15	that	O
16	are	O
17	transferable	O
18	to	O
19	a	O
20	simple	O
21	real	O
22	task	O
23	and	O
24	are	O
25	similar	O
26	to	O
27	the	O
28	results	O
29	achieved	O
30	with	O
31	conventional	O
32	training	O
33	.	O

0	To	O
1	investigate	O
2	the	O
3	convergent	O
4	role	O
5	of	O
6	the	O
7	insulin	O
8	/	O
9	IGF	O
10	-	O
11	I	O
12	effector	O
13	pathway	O
14	mediating	O
15	bihormonal	O
16	stimulation	O
17	of	O
18	LDL	O
19	receptor	O
20	promoter	O
21	expression	O
22	,	O
23	transfected	O
24	granulosa	O
25	-	O
26	luteal	O
27	cells	O
28	were	O
29	pretreated	O
30	for	O
31	30	O
32	min	O
33	with	O
34	two	O
35	specific	O
36	inhibitors	O
37	of	O
38	phophatidylinositol	O
39	3	O
40	-	O
41	kinase	O
42	,	O
43	wortmannin	O
44	(	O
45	100	O
46	nM	O
47	)	O
48	and	O
49	LY	O
50	294002	O
51	(	O
52	10	O
53	microM	O
54	),	O
55	or	O
56	of	O
57	mitogen	O
58	-	O
59	activated	O
60	protein	O
61	kinase	O
62	kinase	O
63	,	O
64	PD	O
65	98059	O
66	(	O
67	50	O
68	microM	O
69	),	O
70	U0126	O
71	(	O
72	10	O
73	microM	O
74	),	O
75	or	O
76	the	O
77	latter	O
78	'	O
79	s	O
80	inactive	O
81	derivative	O
82	,	O
83	U0124	O
84	(	O
85	10	O
86	microM	O
87	).	O

0	Instead	O
1	,	O
2	affective	O
3	flattening	O
4	was	O
5	associated	O
6	with	O
7	both	O
8	dopamine	O
9	receptor	O
10	sensitivity	O
11	and	O
12	psychomotor	O
13	slowing	O
14	.	O

0	Other	O
1	therapies	O
2	are	O
3	also	O
4	available	O
5	,	O
6	including	O
7	hypertonic	O
8	saline	O
9	solution	O
10	,	O
11	THAM	O
12	(	O
13	Tris	O
14	-	O
15	hydroxy	O
16	-	O
17	methyl	O
18	-	O
19	aminomethane	O
20	)	O
21	buffer	O
22	,	O
23	and	O
24	high	O
25	-	O
26	dose	O
27	barbiturates	O
28	.	O

0	CONCLUSION	O
1	:	O
2	There	O
3	are	O
4	no	O
5	differences	O
6	in	O
7	the	O
8	measurement	O
9	data	O
10	derived	O
11	from	O
12	this	O
13	method	O
14	and	O
15	actual	O
16	measurement	O
17	data	O
18	from	O
19	an	O
20	object	O
21	created	O
22	by	O
23	the	O
24	computer	O
25	-	O
26	aided	O
27	dental	O
28	design	O
29	program	O
30	.	O

0	NF	O
1	-	O
2	kappaB	O
3	pathway	O
4	activation	O
5	occurs	O
6	during	O
7	transformation	O
8	induced	O
9	by	O
10	a	O
11	number	O
12	of	O
13	classical	O
14	oncogenes	O
15	,	O
16	including	O
17	Bcr	O
18	/	O
19	Abl	O
20	,	O
21	Ras	O
22	and	O
23	Rac	O
24	,	O
25	and	O
26	is	O
27	necessary	O
28	for	O
29	full	O
30	transforming	O
31	potential	O
32	.	O

0	Our	O
1	results	O
2	indicate	O
3	that	O
4	Gab1	O
5	is	O
6	involved	O
7	in	O
8	the	O
9	control	O
10	of	O
11	egr	O
12	-	O
13	1	O
14	expression	O
15	regulated	O
16	by	O
17	insulin	O
18	.	O

0	The	O
1	human	O
2	cytomegalovirus	O
3	(	O
4	HCMV	O
5	)	O
6	major	O
7	immediate	O
8	-	O
9	early	O
10	protein	O
11	IE2	O
12	is	O
13	a	O
14	nuclear	O
15	phosphoprotein	O
16	that	O
17	is	O
18	believed	O
19	to	O
20	be	O
21	a	O
22	key	O
23	regulator	O
24	in	O
25	both	O
26	lytic	O
27	and	O
28	latent	O
29	infections	O
30	.	O

0	Unexpectedly	O
1	,	O
2	Arg1	O
3	-	O
4	expressing	O
5	COS1	O
6	cells	O
7	showed	O
8	no	O
9	significant	O
10	proteinase	O
11	activity	O
12	to	O
13	various	O
14	synthesized	O
15	substrates	O
16	under	O
17	neutral	O
18	or	O
19	acidic	O
20	conditions	O
21	in	O
22	this	O
23	study	O
24	.	O

0	METHODS	O
1	:	O
2	126	O
3	patients	O
4	with	O
5	histologically	O
6	confirmed	O
7	MFH	O
8	were	O
9	analyzed	O
10	.	O

0	Regression	O
1	analyses	O
2	showed	O
3	that	O
4	SOREMP	O
5	dream	O
6	occurrences	O
7	were	O
8	significantly	O
9	related	O
10	to	O
11	the	O
12	amount	O
13	of	O
14	REM	O
15	sleep	O
16	,	O
17	while	O
18	NREMP	O
19	dream	O
20	occurrences	O
21	were	O
22	related	O
23	to	O
24	arousals	O
25	from	O
26	NREM	O
27	sleep	O
28	.	O

0	[	O
1	Diabetologia	O
2	(	O
3	2001	O
4	)	O
5	44	O
6	[	O
7	Suppl	O
8	3	O
9	]:	O
10	B37	O
11	-	O
12	B44	O
13	]	O

0	RESULTS	O
1	:	O
2	In	O
3	vivo	O
4	,	O
5	there	O
6	was	O
7	a	O
8	wide	O
9	distribution	O
10	with	O
11	the	O
12	coefficient	O
13	of	O
14	variation	O
15	(	O
16	SD	O
17	/	O
18	mean	O
19	x	O
20	100	O
21	%)	O
22	for	O
23	different	O
24	valve	O
25	sizes	O
26	ranging	O
27	from	O
28	21	O
29	%	O
30	to	O
31	39	O
32	%	O
33	in	O
34	the	O
35	St	O
36	Jude	O
37	Medical	O
38	valve	O
39	and	O
40	from	O
41	25	O
42	%	O
43	to	O
44	33	O
45	%	O
46	in	O
47	the	O
48	Omnicarbon	O
49	valve	O
50	.	O

0	A	O
1	microsporidian	O
2	,	O
3	Nosema	O
4	algerae	O
5	Vavra	O
6	and	O
7	undeen	O
8	,	O
9	was	O
10	found	O
11	parasitizing	O
12	larvae	O
13	and	O
14	adults	O
15	of	O
16	a	O
17	laboratory	O
18	colony	O
19	of	O
20	Culex	O
21	pipiens	O
22	L	O
23	.	O
24	originated	O
25	from	O
26	Gharbia	O
27	Governorate	O
28	.	O

0	Nearly	O
1	all	O
2	isolates	O
3	of	O
4	S	O
5	.	O
6	intermedius	O
7	and	O
8	most	O
9	isolates	O
10	of	O
11	S	O
12	.	O
13	constellatus	O
14	,	O
15	but	O
16	only	O
17	19	O
18	%	O
19	of	O
20	those	O
21	of	O
22	S	O
23	.	O
24	anginosus	O
25	,	O
26	were	O
27	associated	O
28	with	O
29	abscess	O
30	.	O

0	One	O
1	of	O
2	the	O
3	conserved	O
4	RNA	O
5	subdomains	O
6	,	O
7	designated	O
8	P3	O
9	,	O
10	has	O
11	previously	O
12	been	O
13	shown	O
14	to	O
15	be	O
16	required	O
17	for	O
18	nucleolar	O
19	localization	O
20	.	O

0	A	O
1	total	O
2	of	O
3	25	O
4	patients	O
5	with	O
6	malignant	O
7	brain	O
8	tumours	O
9	were	O
10	investigated	O
11	.	O

0	Interventions	O
1	aimed	O
2	at	O
3	these	O
4	specific	O
5	mediators	O
6	and	O
7	processes	O
8	may	O
9	be	O
10	successful	O
11	in	O
12	reducing	O
13	the	O
14	very	O
15	significant	O
16	human	O
17	and	O
18	economic	O
19	costs	O
20	of	O
21	vascular	O
22	access	O
23	dysfunction	O
24	.	O

0	We	O
1	used	O
2	stored	O
3	plasma	O
4	samples	O
5	from	O
6	409	O
7	patients	O
8	in	O
9	the	O
10	National	O
11	Institute	O
12	of	O
13	Neurological	O
14	Diseases	O
15	and	O
16	Stroke	O
17	(	O
18	NINDS	O
19	)	O
20	tissue	O
21	plasminogen	O
22	activator	O
23	(	O
24	t	O
25	-	O
26	PA	O
27	)	O
28	Stroke	O
29	Trial	O
30	to	O
31	examine	O
32	the	O
33	relationship	O
34	between	O
35	an	O
36	apolipoprotein	O
37	(	O
38	Apo	O
39	)	O
40	E2	O
41	or	O
42	an	O
43	Apo	O
44	E4	O
45	phenotype	O
46	and	O
47	a	O
48	favorable	O
49	outcome	O
50	3	O
51	months	O
52	after	O
53	stroke	O
54	,	O
55	the	O
56	risk	O
57	of	O
58	intracerebral	O
59	hemorrhage	O
60	,	O
61	and	O
62	the	O
63	response	O
64	to	O
65	intravenous	O
66	t	O
67	-	O
68	PA	O
69	therapy	O
70	.	O

0	These	O
1	results	O
2	were	O
3	robust	O
4	to	O
5	changes	O
6	in	O
7	the	O
8	baseline	O
9	assumptions	O
10	of	O
11	the	O
12	model	O
13	.	O

0	Cis	O
1	-	O
2	acting	O
3	CCAAT	O
4	elements	O
5	are	O
6	frequently	O
7	found	O
8	in	O
9	eukaryotic	O
10	promoter	O
11	regions	O
12	.	O

0	The	O
1	binary	O
2	and	O
3	tertiary	O
4	combinations	O
5	of	O
6	plant	O
7	-	O
8	derived	O
9	molluscicides	O
10	Azadirachta	O
11	indica	O
12	and	O
13	Cedrus	O
14	deodara	O
15	oil	O
16	with	O
17	synergists	O
18	MGK	O
19	-	O
20	264	O
21	,	O
22	piperonyl	O
23	butoxide	O
24	(	O
25	PB	O
26	)	O
27	and	O
28	fruit	O
29	powder	O
30	of	O
31	Embelia	O
32	ribes	O
33	were	O
34	used	O
35	against	O
36	the	O
37	Lymnaea	O
38	acuminata	O
39	.	O

0	This	O
1	article	O
2	reports	O
3	the	O
4	design	O
5	and	O
6	development	O
7	of	O
8	an	O
9	ECG	O
10	simulator	O
11	intended	O
12	for	O
13	use	O
14	in	O
15	the	O
16	testing	O
17	,	O
18	calibration	O
19	and	O
20	maintenance	O
21	of	O
22	electrocardiographic	O
23	equipment	O
24	.	O

0	Exchanging	O
1	the	O
2	human	O
3	propeptide	O
4	in	O
5	this	O
6	chimera	O
7	with	O
8	either	O
9	the	O
10	murine	O
11	MIC	O
12	-	O
13	1	O
14	or	O
15	TGF	O
16	-	O
17	beta1	O
18	propeptide	O
19	resulted	O
20	in	O
21	secretion	O
22	of	O
23	the	O
24	unprocessed	O
25	,	O
26	monomeric	O
27	chimera	O
28	,	O
29	suggesting	O
30	a	O
31	specific	O
32	interaction	O
33	between	O
34	the	O
35	human	O
36	MIC	O
37	-	O
38	1	O
39	propeptide	O
40	and	O
41	mature	O
42	peptide	O
43	.	O

0	RESULTS	O
1	:	O
2	The	O
3	analyzed	O
4	fragment	O
5	has	O
6	significant	O
7	activity	O
8	in	O
9	EpCAM	O
10	positive	O
11	cells	O
12	,	O
13	and	O
14	it	O
15	is	O
16	regulated	O
17	negatively	O
18	by	O
19	tumor	O
20	necrosis	O
21	factor	O
22	alpha	O
23	(	O
24	TNFalpha	O
25	).	O

0	The	O
1	mutant	O
2	receptors	O
3	,	O
4	as	O
5	well	O
6	as	O
7	sBMPR	O
8	-	O
9	IA	O
10	,	O
11	were	O
12	expressed	O
13	as	O
14	fusion	O
15	proteins	O
16	with	O
17	thioredoxin	O
18	in	O
19	Escherichia	O
20	coli	O
21	,	O
22	and	O
23	purified	O
24	using	O
25	reverse	O
26	phase	O
27	high	O
28	performance	O
29	liquid	O
30	chromatography	O
31	(	O
32	RP	O
33	-	O
34	HPLC	O
35	)	O
36	after	O
37	digestion	O
38	with	O
39	enterokinase	O
40	.	O

0	The	O
1	dual	O
2	specificity	O
3	kinases	O
4	mitogen	O
5	-	O
6	activated	O
7	protein	O
8	kinase	O
9	(	O
10	MAPK	O
11	)	O
12	kinase	O
13	(	O
14	MKK	O
15	)	O
16	7	O
17	and	O
18	MKK4	O
19	are	O
20	the	O
21	only	O
22	molecules	O
23	known	O
24	to	O
25	directly	O
26	activate	O
27	the	O
28	stress	O
29	kinases	O
30	stress	O
31	-	O
32	activated	O
33	protein	O
34	kinases	O
35	(	O
36	SAPKs	O
37	)/	O
38	c	O
39	-	O
40	Jun	O
41	N	O
42	-	O
43	terminal	O
44	kinases	O
45	(	O
46	JNKs	O
47	)	O
48	in	O
49	response	O
50	to	O
51	environmental	O
52	or	O
53	mitogenic	O
54	stimuli	O
55	.	O

0	This	O
1	unique	O
2	work	O
3	needs	O
4	to	O
5	be	O
6	edited	O
7	critically	O
8	and	O
9	afterwards	O
10	translated	O
11	into	O
12	Urdu	O
13	and	O
14	other	O
15	languages	O
16	for	O
17	the	O
18	benefit	O
19	of	O
20	the	O
21	present	O
22	day	O
23	students	O
24	and	O
25	scholars	O
26	.	O

0	RANTES	O
1	(	O
2	regulated	O
3	upon	O
4	activation	O
5	,	O
6	normally	O
7	T	O
8	-	O
9	cell	O
10	expressed	O
11	and	O
12	presumably	O
13	secreted	O
14	)	O
15	is	O
16	a	O
17	CC	O
18	chemokine	O
19	which	O
20	recruits	O
21	and	O
22	activates	O
23	monocytes	O
24	,	O
25	lymphocytes	O
26	,	O
27	and	O
28	eosinophils	O
29	,	O
30	all	O
31	cell	O
32	types	O
33	present	O
34	in	O
35	the	O
36	lung	O
37	inflammatory	O
38	infiltrate	O
39	induced	O
40	by	O
41	RSV	O
42	infection	O
43	.	O

0	Gabapentin	O
1	for	O
2	opiod	O
3	-	O
4	related	O
5	myoclonus	O
6	in	O
7	cancer	O
8	patients	O
9	.	O

0	Recently	O
1	,	O
2	it	O
3	was	O
4	shown	O
5	that	O
6	purified	O
7	RAG1	O
8	/	O
9	2	O
10	proteins	O
11	can	O
12	cleave	O
13	DNA	O
14	hairpins	O
15	in	O
16	vitro	O
17	,	O
18	but	O
19	the	O
20	same	O
21	activity	O
22	was	O
23	also	O
24	described	O
25	for	O
26	a	O
27	protein	O
28	complex	O
29	of	O
30	the	O
31	DNA	O
32	repair	O
33	proteins	O
34	Nbs1	O
35	/	O
36	Mre11	O
37	/	O
38	Rad50	O
39	.	O

0	APC	O
1	-	O
2	resistance	O
3	was	O
4	determined	O
5	with	O
6	a	O
7	functional	O
8	method	O
9	with	O
10	high	O
11	sensitivity	O
12	and	O
13	specificity	O
14	for	O
15	the	O
16	factor	O
17	V	O
18	Leiden	O
19	mutation	O
20	.	O

0	A	O
1	picture	O
2	is	O
3	emerging	O
4	showing	O
5	a	O
6	gradient	O
7	of	O
8	function	O
9	among	O
10	p53	O
11	,	O
12	p73	O
13	,	O
14	p63	O
15	ranging	O
16	from	O
17	tumor	O
18	suppression	O
19	to	O
20	development	O
21	.	O

0	High	O
1	plasma	O
2	AVP	O
3	levels	O
4	observed	O
5	in	O
6	the	O
7	two	O
8	cases	O
9	suggest	O
10	that	O
11	SSRIs	O
12	stimulate	O
13	AVP	O
14	secretion	O
15	,	O
16	thereby	O
17	causing	O
18	SIADH	O
19	.	O

0	Mutation	O
1	of	O
2	the	O
3	octamer	O
4	element	O
5	also	O
6	significantly	O
7	reduced	O
8	the	O
9	ability	O
10	of	O
11	HDAC1	O
12	to	O
13	confer	O
14	repression	O
15	of	O
16	inducible	O
17	HLA	O
18	-	O
19	DRA	O
20	promoter	O
21	activation	O
22	.	O

0	Requirements	O
1	for	O
2	the	O
3	nuclear	O
4	-	O
5	cytoplasmic	O
6	translocation	O
7	of	O
8	infected	O
9	-	O
10	cell	O
11	protein	O
12	0	O
13	of	O
14	herpes	O
15	simplex	O
16	virus	O
17	1	O
18	.	O

0	The	O
1	system	O
2	,	O
3	designed	O
4	to	O
5	exploit	O
6	the	O
7	relatively	O
8	constant	O
9	small	O
10	intestine	O
11	transit	O
12	time	O
13	,	O
14	consists	O
15	of	O
16	a	O
17	drug	O
18	-	O
19	containing	O
20	core	O
21	coated	O
22	with	O
23	a	O
24	polymeric	O
25	matrix	O
26	formed	O
27	by	O
28	a	O
29	channeling	O
30	agent	O
31	(	O
32	NaCl	O
33	,	O
34	mannitol	O
35	,	O
36	and	O
37	Emdex	O
38	)	O
39	and	O
40	an	O
41	inert	O
42	polymer	O
43	(	O
44	Eudragit	O
45	RS100	O
46	).	O

0	The	O
1	activity	O
2	of	O
3	Rac1	O
4	leads	O
5	to	O
6	STAT3	O
7	translocation	O
8	to	O
9	the	O
10	nucleus	O
11	coincident	O
12	with	O
13	STAT3	O
14	-	O
15	dependent	O
16	gene	O
17	expression	O
18	.	O

0	Treatment	O
1	of	O
2	ischemic	O
3	heart	O
4	disease	O
5	in	O
6	the	O
7	elderly	O

0	To	O
1	avoid	O
2	misinterpretations	O
3	,	O
4	special	O
5	reference	O
6	values	O
7	should	O
8	be	O
9	applied	O
10	for	O
11	preadolescents	O
12	,	O
13	at	O
14	least	O
15	with	O
16	regard	O
17	to	O
18	FVC	O
19	and	O
20	FEV1	O
21	.	O

0	STUDY	O
1	OBJECTIVE	O
2	:	O
3	This	O
4	study	O
5	assessed	O
6	several	O
7	methodological	O
8	aspects	O
9	related	O
10	to	O
11	the	O
12	quality	O
13	of	O
14	published	O
15	controlled	O
16	clinical	O
17	trials	O
18	(	O
19	CCTs	O
20	)	O
21	in	O
22	relation	O
23	to	O
24	the	O
25	participation	O
26	of	O
27	an	O
28	epidemiologist	O
29	/	O
30	biostatistician	O
31	(	O
32	E	O
33	/	O
34	B	O
35	).	O

0	To	O
1	the	O
2	best	O
3	of	O
4	our	O
5	knowledge	O
6	,	O
7	SNTCS	O
8	is	O
9	highly	O
10	malignant	O
11	.	O

0	Northern	O
1	blot	O
2	analysis	O
3	with	O
4	one	O
5	of	O
6	the	O
7	PARNAs	O
8	revealed	O
9	a	O
10	highly	O
11	abundant	O
12	signal	O
13	of	O
14	approximately	O
15	2	O
16	.	O
17	0	O
18	kilobases	O
19	(	O
20	kb	O
21	)	O
22	present	O
23	in	O
24	all	O
25	cell	O
26	lines	O
27	tested	O
28	.	O

0	The	O
1	effect	O
2	of	O
3	crude	O
4	oil	O
5	spillage	O
6	on	O
7	growth	O
8	,	O
9	productivity	O
10	and	O
11	nutrient	O
12	uptake	O
13	of	O
14	maize	O
15	(	O
16	Zea	O
17	mays	O
18	L	O
19	.)	O
20	was	O
21	assessed	O
22	in	O
23	a	O
24	pot	O
25	experiment	O
26	using	O
27	an	O
28	Evwreni	O
29	manifold	O
30	sample	O
31	of	O
32	a	O
33	petroleum	O
34	development	O
35	company	O
36	,	O
37	which	O
38	had	O
39	a	O
40	specific	O
41	gravity	O
42	of	O
43	0	O
44	.	O
45	8778	O
46	.	O

0	10	O
1	.	O
2	0	O
3	+/-	O
4	2	O
5	.	O
6	0	O
7	pmol	O
8	/	O
9	24	O
10	h	O
11	,	O
12	P	O
13	<	O
14	0	O
15	.	O
16	01	O
17	)	O
18	and	O
19	remained	O
20	elevated	O
21	.	O

0	Pitx2	O
1	rescues	O
2	the	O
3	GABAergic	O
4	differentiation	O
5	defect	O
6	and	O
7	partially	O
8	rescues	O
9	the	O
10	axon	O
11	guidance	O
12	and	O
13	behavioral	O
14	phenotypes	O
15	of	O
16	unc	O
17	-	O
18	30	O
19	mutants	O
20	,	O
21	indicating	O
22	a	O
23	high	O
24	degree	O
25	of	O
26	functional	O
27	conservation	O
28	between	O
29	these	O
30	evolutionarily	O
31	related	O
32	genes	O
33	.	O

0	Phosphatidylinositol	O
1	3	O
2	-	O
3	kinase	O
4	potentiates	O
5	,	O
6	but	O
7	does	O
8	not	O
9	trigger	O
10	,	O
11	T	O
12	cell	O
13	proliferation	O
14	mediated	O
15	by	O
16	the	O
17	IL	O
18	-	O
19	2	O
20	receptor	O
21	.	O

0	In	O
1	addition	O
2	,	O
3	stonin	O
4	2	O
5	binds	O
6	to	O
7	the	O
8	C2B	O
9	domains	O
10	of	O
11	synaptotagmins	O
12	I	O
13	and	O
14	II	O
15	.	O

0	Sequence	O
1	comparison	O
2	and	O
3	binding	O
4	studies	O
5	of	O
6	the	O
7	18	O
8	-	O
9	bp	O
10	MOK2	O
11	-	O
12	binding	O
13	sites	O
14	present	O
15	in	O
16	intron	O
17	2	O
18	of	O
19	human	O
20	,	O
21	bovine	O
22	,	O
23	and	O
24	mouse	O
25	IRBP	O
26	genes	O
27	show	O
28	that	O
29	the	O
30	3	O
31	'-	O
32	half	O
33	sequence	O
34	is	O
35	the	O
36	essential	O
37	core	O
38	element	O
39	for	O
40	MOK2	O
41	binding	O
42	.	O

0	Measurements	O
1	were	O
2	obtained	O
3	:	O
4	(	O
5	i	O
6	)	O
7	just	O
8	after	O
9	the	O
10	traumatic	O
11	exposure	O
12	(	O
13	D0	O
14	);	O
15	(	O
16	ii	O
17	)	O
18	3	O
19	days	O
20	after	O
21	this	O
22	first	O
23	measurement	O
24	(	O
25	D3	O
26	);	O
27	and	O
28	(	O
29	iii	O
30	)	O
31	30	O
32	days	O
33	after	O
34	(	O
35	D30	O
36	).	O

0	Long	O
1	-	O
2	term	O
3	results	O
4	with	O
5	MACOP	O
6	-	O
7	B	O
8	and	O
9	radiation	O
10	therapy	O
11	for	O
12	aggressive	O
13	lymphomas	O
14	]	O
15	BACKGROUND	O
16	:	O
17	Long	O
18	-	O
19	term	O
20	results	O
21	are	O
22	needed	O
23	to	O
24	evaluate	O
25	chemotherapy	O
26	regimens	O
27	and	O
28	prognostic	O
29	factors	O
30	in	O
31	non	O
32	-	O
33	Hodgkin	O
34	'	O
35	s	O
36	lymphomas	O
37	(	O
38	NHL	O
39	).	O

0	From	O
1	the	O
2	above	O
3	results	O
4	,	O
5	we	O
6	might	O
7	infer	O
8	that	O
9	the	O
10	seizure	O
11	type	O
12	of	O
13	TLE	O
14	and	O
15	a	O
16	high	O
17	frequency	O
18	of	O
19	seizure	O
20	are	O
21	two	O
22	major	O
23	independent	O
24	precipitate	O
25	factors	O
26	for	O
27	abnormal	O
28	latencies	O
29	of	O
30	P300	O
31	in	O
32	the	O
33	epileptic	O
34	patients	O
35	.	O

0	Rapamycin	O
1	(	O
2	FRAP	O
3	/	O
4	mTOR	O
5	inhibitor	O
6	)	O
7	blocked	O
8	4E	O
9	-	O
10	BP1	O
11	phosphorylation	O
12	causing	O
13	a	O
14	predominance	O
15	of	O
16	the	O
17	alpha	O
18	(	O
19	hypophosphorylated	O
20	)	O
21	band	O
22	.	O

0	We	O
1	investigate	O
2	the	O
3	reaction	O
4	kinetics	O
5	of	O
6	small	O
7	spherical	O
8	particles	O
9	with	O
10	inertia	O
11	,	O
12	obeying	O
13	coalescence	O
14	type	O
15	of	O
16	reaction	O
17	,	O
18	B	O
19	+	O
20	B	O
21	-->	O
22	B	O
23	,	O
24	and	O
25	being	O
26	advected	O
27	by	O
28	hydrodynamical	O
29	flows	O
30	with	O
31	time	O
32	-	O
33	periodic	O
34	forcing	O
35	.	O

0	Corticosteroid	O
1	-	O
2	mediated	O
3	transcriptional	O
4	inhibition	O
5	was	O
6	greater	O
7	for	O
8	MR	O
9	/	O
10	GR	O
11	in	O
12	combination	O
13	than	O
14	for	O
15	MR	O
16	or	O
17	GR	O
18	alone	O
19	.	O

0	These	O
1	data	O
2	define	O
3	a	O
4	conserved	O
5	pathway	O
6	wherein	O
7	sequential	O
8	histone	O
9	modifications	O
10	establish	O
11	a	O
12	"	O
13	histone	O
14	code	O
15	"	O
16	essential	O
17	for	O
18	the	O
19	epigenetic	O
20	inheritance	O
21	of	O
22	heterochromatin	O
23	assembly	O
24	.	O

0	The	O
1	bovine	O
2	PGHS	O
3	-	O
4	2	O
5	cDNA	O
6	was	O
7	cloned	O
8	by	O
9	a	O
10	combination	O
11	of	O
12	reverse	O
13	transcription	O
14	-	O
15	polymerase	O
16	chain	O
17	reaction	O
18	and	O
19	cDNA	O
20	library	O
21	screening	O
22	.	O

0	Telomerase	O
1	is	O
2	a	O
3	ribonucleoprotein	O
4	complex	O
5	that	O
6	synthesizes	O
7	telomeric	O
8	DNA	O
9	onto	O
10	chromosomes	O
11	using	O
12	its	O
13	RNA	O
14	component	O
15	as	O
16	template	O
17	.	O

0	The	O
1	iterative	O
2	method	O
3	proposed	O
4	by	O
5	Bengtsson	O
6	[	O
7	Appl	O
8	.	O

0	Several	O
1	distinct	O
2	apoptotic	O
3	stimuli	O
4	induce	O
5	the	O
6	expression	O
7	and	O
8	caspase	O
9	-	O
10	dependent	O
11	cleavage	O
12	of	O
13	hTAF	O
14	(	O
15	II	O
16	)	O
17	80	O
18	delta	O
19	.	O
20	hTAF	O
21	(	O
22	II	O
23	)	O
24	80	O
25	delta	O
26	,	O
27	unlike	O
28	hTAF	O
29	(	O
30	II	O
31	)	O
32	80	O
33	,	O
34	forms	O
35	a	O
36	TFIID	O
37	-	O
38	like	O
39	complex	O
40	lacking	O
41	hTAF	O
42	(	O
43	II	O
44	)	O
45	31	O
46	.	O

0	With	O
1	NEU	O
2	overexpression	O
3	,	O
4	nodal	O
5	control	O
6	decreased	O
7	from	O
8	72	O
9	%	O
10	to	O
11	34	O
12	%	O
13	(	O
14	p	O
15	=	O
16	.	O
17	008	O
18	).	O

0	The	O
1	mouse	O
2	platelet	O
3	-	O
4	derived	O
5	growth	O
6	factor	O
7	(	O
8	PDGF	O
9	)	O
10	beta	O
11	-	O
12	receptor	O
13	promoter	O
14	contains	O
15	a	O
16	CCAAT	O
17	motif	O
18	,	O
19	and	O
20	NF	O
21	-	O
22	Y	O
23	plays	O
24	an	O
25	essential	O
26	role	O
27	in	O
28	its	O
29	transcription	O
30	.	O

0	Biol	O
1	.	O

0	The	O
1	loop	O
2	domain	O
3	of	O
4	heat	O
5	shock	O
6	transcription	O
7	factor	O
8	1	O
9	dictates	O
10	DNA	O
11	-	O
12	binding	O
13	specificity	O
14	and	O
15	responses	O
16	to	O
17	heat	O
18	stress	O
19	.	O

0	This	O
1	activation	O
2	was	O
3	then	O
4	blocked	O
5	by	O
6	CGS	O
7	12066A	O
8	.	O

0	Among	O
1	the	O
2	transcription	O
3	factors	O
4	known	O
5	to	O
6	interact	O
7	with	O
8	Groucho	O
9	-	O
10	related	O
11	protein	O
12	,	O
13	only	O
14	RUNX1	O
15	was	O
16	appreciably	O
17	downregulated	O
18	by	O
19	E2A	O
20	-	O
21	HLF	O
22	.	O

0	A	O
1	new	O
2	intron	O
3	of	O
4	476	O
5	base	O
6	pairs	O
7	was	O
8	found	O
9	in	O
10	the	O
11	middle	O
12	of	O
13	the	O
14	5	O
15	'-	O
16	untranslated	O
17	leader	O
18	sequence	O
19	and	O
20	was	O
21	shown	O
22	to	O
23	robustly	O
24	enhance	O
25	the	O
26	promoter	O
27	activity	O
28	.	O

0	Our	O
1	findings	O
2	further	O
3	our	O
4	understanding	O
5	of	O
6	how	O
7	ZBP	O
8	-	O
9	89	O
10	modulates	O
11	cell	O
12	proliferation	O
13	and	O
14	reveals	O
15	a	O
16	novel	O
17	mechanism	O
18	by	O
19	which	O
20	the	O
21	p53	O
22	protein	O
23	is	O
24	stabilized	O
25	.	O

0	In	O
1	the	O
2	free	O
3	-	O
4	swimming	O
5	rotatory	O
6	test	O
7	mice	O
8	spend	O
9	most	O
10	of	O
11	the	O
12	time	O
13	swimming	O
14	close	O
15	to	O
16	the	O
17	wall	O
18	of	O
19	the	O
20	container	O
21	attempting	O
22	to	O
23	escape	O
24	from	O
25	an	O
26	aversive	O
27	test	O
28	situation	O
29	.	O

0	As	O
1	well	O
2	,	O
3	mixtures	O
4	of	O
5	(	O
6	LA	O
7	)(	O
8	12	O
9	)	O
10	with	O
11	the	O
12	longer	O
13	chain	O
14	PEs	O
15	exhibit	O
16	unusual	O
17	biomodal	O
18	enthalpy	O
19	variations	O
20	,	O
21	suggesting	O
22	peptide	O
23	immiscibility	O
24	in	O
25	thicker	O
26	gel	O
27	state	O
28	bilayers	O
29	.	O

0	At	O
1	the	O
2	time	O
3	of	O
4	the	O
5	blind	O
6	therapeutic	O
7	doses	O
8	,	O
9	Tg	O
10	-	O
11	off	O
12	values	O
13	ranged	O
14	from	O
15	8	O
16	to	O
17	608	O
18	microg	O
19	/	O
20	l	O
21	.	O

0	Nephrotoxicity	O
1	after	O
2	orthotopic	O
3	liver	O
4	transplantation	O
5	in	O
6	cyclosporin	O
7	A	O
8	and	O
9	FK	O
10	506	O
11	-	O
12	treated	O
13	patients	O
14	.	O

0	In	O
1	contrast	O
2	to	O
3	MPc3	O
4	,	O
5	data	O
6	indicate	O
7	that	O
8	the	O
9	Pc	O
10	protein	O
11	M33	O
12	does	O
13	not	O
14	interact	O
15	with	O
16	AF9	O
17	.	O

0	Hydrocoele	O
1	is	O
2	common	O
3	in	O
4	men	O
5	in	O
6	Wuchereria	O
7	bancrofti	O
8	-	O
9	endemic	O
10	areas	O
11	,	O
12	the	O
13	treatment	O
14	for	O
15	which	O
16	is	O
17	currently	O
18	surgical	O
19	intervention	O
20	.	O

0	Of	O
1	the	O
2	patients	O
3	in	O
4	each	O
5	regimen	O
6	who	O
7	reached	O
8	study	O
9	end	O
10	points	O
11	,	O
12	17	O
13	of	O
14	29	O
15	(	O
16	59	O
17	%)	O
18	were	O
19	in	O
20	regimen	O
21	A	O
22	,	O
23	11	O
24	of	O
25	20	O
26	(	O
27	55	O
28	%)	O
29	were	O
30	in	O
31	regimen	O
32	B	O
33	,	O
34	and	O
35	28	O
36	of	O
37	43	O
38	(	O
39	65	O
40	%)	O
41	were	O
42	in	O
43	regimen	O
44	C	O
45	met	O
46	the	O
47	treatment	O
48	success	O
49	criterion	O
50	.	O

0	One	O
1	maternal	O
2	death	O
3	,	O
4	reduced	O
5	body	O
6	weight	O
7	,	O
8	and	O
9	reduced	O
10	weight	O
11	gain	O
12	were	O
13	noted	O
14	at	O
15	the	O
16	high	O
17	dose	O
18	;	O
19	confirmed	O
20	pregnancy	O
21	rates	O
22	were	O
23	84	O
24	to	O
25	100	O
26	%	O
27	for	O
28	each	O
29	group	O
30	.	O

0	Karger	O
1	AG	O
2	,	O
3	Basel	O

0	In	O
1	regards	O
2	to	O
3	the	O
4	latter	O
5	activity	O
6	,	O
7	it	O
8	has	O
9	been	O
10	shown	O
11	that	O
12	S3	O
13	contains	O
14	vigorous	O
15	N	O
16	-	O
17	glycosylase	O
18	activity	O
19	for	O
20	the	O
21	removal	O
22	of	O
23	8	O
24	-	O
25	oxoguanine	O
26	residues	O
27	in	O
28	DNA	O
29	that	O
30	leaves	O
31	baseless	O
32	sites	O
33	in	O
34	their	O
35	places	O
36	.	O

0	We	O
1	describe	O
2	a	O
3	total	O
4	of	O
5	39	O
6	DEAH	O
7	helicases	O
8	in	O
9	these	O
10	four	O
11	species	O
12	.	O

0	A	O
1	prospective	O
2	trial	O
3	was	O
4	undertaken	O
5	to	O
6	determine	O
7	(	O
8	1	O
9	)	O
10	clinical	O
11	characteristics	O
12	of	O
13	patients	O
14	with	O
15	chest	O
16	pain	O
17	;	O
18	(	O
19	2	O
20	)	O
21	value	O
22	of	O
23	cardiac	O
24	markers	O
25	troponin	O
26	T	O
27	,	O
28	myoglobin	O
29	and	O
30	CK	O
31	-	O
32	MB	O
33	mass	O
34	in	O
35	differentiating	O
36	cardiac	O
37	and	O
38	noncardiac	O
39	chest	O
40	pain	O
41	;	O
42	(	O
43	3	O
44	)	O
45	the	O
46	proportion	O
47	of	O
48	patients	O
49	with	O
50	ACS	O
51	in	O
52	whom	O
53	these	O
54	markers	O
55	provided	O
56	helpful	O
57	additional	O
58	information	O
59	on	O
60	admission	O
61	and	O
62	afterwards	O
63	.	O

0	Inactivity	O
1	of	O
2	the	O
3	human	O
4	cytomegalovirus	O
5	(	O
6	HCMV	O
7	)	O
8	major	O
9	immediate	O
10	-	O
11	early	O
12	regulatory	O
13	region	O
14	(	O
15	MIERR	O
16	),	O
17	which	O
18	is	O
19	composed	O
20	of	O
21	promoter	O
22	,	O
23	enhancer	O
24	,	O
25	unique	O
26	region	O
27	,	O
28	and	O
29	modulator	O
30	,	O
31	is	O
32	linked	O
33	to	O
34	lack	O
35	of	O
36	HCMV	O
37	replication	O
38	in	O
39	latently	O
40	infected	O
41	cells	O
42	and	O
43	in	O
44	other	O
45	nonpermissive	O
46	cell	O
47	types	O
48	,	O
49	including	O
50	human	O
51	embryonal	O
52	NTera2	O
53	carcinoma	O
54	(	O
55	NT2	O
56	)	O
57	cells	O
58	.	O

0	The	O
1	observed	O
2	triplexes	O
3	depend	O
4	on	O
5	the	O
6	length	O
7	of	O
8	the	O
9	repeat	O
10	.	O

0	Statistical	O
1	Analysis	O
2	included	O
3	ANOVA	O
4	,	O
5	the	O
6	Pearson	O
7	Product	O
8	Moment	O
9	Correlation	O
10	Coefficient	O
11	,	O
12	Principal	O
13	Components	O
14	Analysis	O
15	and	O
16	Discriminant	O
17	Function	O
18	Analysis	O
19	and	O
20	the	O
21	calculation	O
22	of	O
23	Cronbach	O
24	'	O
25	s	O
26	alpha	O
27	(	O
28	alpha	O
29	)	O
30	RESULTS	O
31	:	O
32	Both	O
33	Sensitivity	O
34	and	O
35	specificity	O
36	exceed	O
37	90	O
38	.	O
39	00	O
40	at	O
41	23	O
42	/	O
43	24	O
44	,	O
45	Chronbach	O
46	'	O
47	s	O
48	alpha	O
49	for	O
50	the	O
51	total	O
52	scale	O
53	was	O
54	equal	O
55	to	O
56	0	O
57	.	O
58	95	O
59	.	O

0	BACKGROUND	O
1	:	O
2	Previous	O
3	studies	O
4	have	O
5	indicated	O
6	that	O
7	the	O
8	60	O
9	-,	O
10	30	O
11	-,	O
12	28	O
13	-	O
14	and	O
15	12	O
16	-	O
17	item	O
18	versions	O
19	of	O
20	the	O
21	General	O
22	Health	O
23	Questionnaire	O
24	(	O
25	GHQ	O
26	)	O
27	are	O
28	liable	O
29	to	O
30	retest	O
31	effects	O
32	,	O
33	especially	O
34	when	O
35	administered	O
36	multiple	O
37	times	O
38	with	O
39	short	O
40	intervals	O
41	.	O

0	Cross	O
1	-	O
2	linking	O
3	FcalphaR	O
4	on	O
5	wt	O
6	-	O
7	ITAM	O
8	or	O
9	IIA	O
10	-	O
11	ITAM	O
12	cells	O
13	triggered	O
14	equivalent	O
15	PI	O
16	3	O
17	-	O
18	kinase	O
19	-	O
20	dependent	O
21	activation	O
22	of	O
23	PKBalpha	O
24	.	O

0	An	O
1	F222W	O
2	:	O
3	W21F	O
4	rGST	O
5	A1	O
6	-	O
7	1	O
8	double	O
9	mutant	O
10	provides	O
11	a	O
12	direct	O
13	fluorescence	O
14	probe	O
15	of	O
16	changes	O
17	in	O
18	the	O
19	environment	O
20	of	O
21	the	O
22	C	O
23	-	O
24	terminal	O
25	residue	O
26	.	O

0	Binding	O
1	of	O
2	serum	O
3	response	O
4	factor	O
5	to	O
6	CArG	O
7	box	O
8	sequences	O
9	is	O
10	necessary	O
11	but	O
12	not	O
13	sufficient	O
14	to	O
15	restrict	O
16	gene	O
17	expression	O
18	to	O
19	arterial	O
20	smooth	O
21	muscle	O
22	cells	O
23	.	O

0	They	O
1	consist	O
2	of	O
3	at	O
4	least	O
5	two	O
6	separable	O
7	components	O
8	,	O
9	one	O
10	heat	O
11	stable	O
12	and	O
13	the	O
14	other	O
15	heat	O
16	labile	O
17	.	O

0	No	O
1	preferential	O
2	VH	O
3	/	O
4	VL	O
5	-	O
6	chains	O
7	correlated	O
8	with	O
9	any	O
10	of	O
11	the	O
12	12	O
13	different	O
14	antigen	O
15	reactivities	O
16	,	O
17	even	O
18	for	O
19	mAbs	O
20	with	O
21	nearly	O
22	identical	O
23	cross	O
24	-	O
25	reactivities	O
26	.	O

0	These	O
1	results	O
2	were	O
3	compared	O
4	with	O
5	the	O
6	estimates	O
7	of	O
8	penetration	O
9	from	O
10	steady	O
11	-	O
12	state	O
13	calculations	O
14	,	O
15	square	O
16	root	O
17	of	O
18	time	O
19	calculations	O
20	,	O
21	and	O
22	a	O
23	biologically	O
24	based	O
25	mathematical	O
26	model	O
27	.	O

0	Based	O
1	on	O
2	this	O
3	analysis	O
4	,	O
5	we	O
6	propose	O
7	that	O
8	the	O
9	interactions	O
10	of	O
11	Sos	O
12	with	O
13	the	O
14	switch	O
15	1	O
16	and	O
17	switch	O
18	2	O
19	regions	O
20	of	O
21	Ras	O
22	have	O
23	distinct	O
24	functional	O
25	consequences	O
26	:	O
27	the	O
28	interaction	O
29	with	O
30	switch	O
31	2	O
32	mediates	O
33	the	O
34	anchoring	O
35	of	O
36	Ras	O
37	to	O
38	Sos	O
39	,	O
40	whereas	O
41	the	O
42	interaction	O
43	with	O
44	switch	O
45	1	O
46	leads	O
47	to	O
48	disruption	O
49	of	O
50	the	O
51	nucleotide	O
52	-	O
53	binding	O
54	site	O
55	and	O
56	GDP	O
57	dissociation	O
58	.	O

0	Thus	O
1	,	O
2	the	O
3	interaction	O
4	of	O
5	Tat	O
6	with	O
7	the	O
8	components	O
9	of	O
10	this	O
11	rel	O
12	/	O
13	AP1	O
14	cooperative	O
15	complex	O
16	seems	O
17	to	O
18	induce	O
19	quantitative	O
20	and	O
21	qualitative	O
22	alterations	O
23	of	O
24	this	O
25	complex	O
26	as	O
27	activation	O
28	progresses	O
29	,	O
30	resulting	O
31	in	O
32	a	O
33	decrease	O
34	of	O
35	IL	O
36	-	O
37	2	O
38	gene	O
39	transcription	O
40	.	O

0	SIT	O
1	(	O
2	SHP2	O
3	-	O
4	interacting	O
5	transmembrane	O
6	adaptor	O
7	protein	O
8	)	O
9	is	O
10	a	O
11	recently	O
12	identified	O
13	transmembrane	O
14	adaptor	O
15	protein	O
16	,	O
17	which	O
18	is	O
19	expressed	O
20	in	O
21	lymphocytes	O
22	.	O

0	In	O
1	this	O
2	manuscript	O
3	we	O
4	demonstrate	O
5	that	O
6	two	O
7	tandem	O
8	Ets	O
9	sites	O
10	in	O
11	the	O
12	mouse	O
13	GL	O
14	alpha	O
15	promoter	O
16	bind	O
17	the	O
18	transcription	O
19	factors	O
20	Elf	O
21	-	O
22	1	O
23	and	O
24	PU	O
25	.	O
26	1	O
27	,	O
28	and	O
29	that	O
30	the	O
31	3	O
32	'	O
33	site	O
34	is	O
35	essential	O
36	for	O
37	expression	O
38	of	O
39	a	O
40	luciferase	O
41	reporter	O
42	gene	O
43	driven	O
44	by	O
45	the	O
46	GL	O
47	alpha	O
48	promoter	O
49	.	O

0	ICA	O
1	in	O
2	the	O
3	reference	O
4	solution	O
5	was	O
6	characterised	O
7	by	O
8	LC	O
9	and	O
10	time	O
11	-	O
12	of	O
13	-	O
14	flight	O
15	(	O
16	TOF	O
17	)	O
18	MS	O
19	and	O
20	quantified	O
21	by	O
22	LC	O
23	chemiluminescent	O
24	nitrogen	O
25	detection	O
26	(	O
27	LC	O
28	-	O
29	CLND	O
30	).	O

0	These	O
1	disorders	O
2	include	O
3	low	O
4	-	O
5	back	O
6	pain	O
7	,	O
8	saddle	O
9	anesthesia	O
10	,	O
11	bilateral	O
12	sciatica	O
13	,	O
14	then	O
15	motor	O
16	weakness	O
17	of	O
18	the	O
19	lower	O
20	extremities	O
21	or	O
22	chronic	O
23	paraplegia	O
24	and	O
25	,	O
26	bladder	O
27	dysfunction	O
28	.	O

0	C	O
1	.	O
2	elegans	O
3	embryogenesis	O
4	begins	O
5	with	O
6	a	O
7	stereotyped	O
8	sequence	O
9	of	O
10	asymmetric	O
11	cell	O
12	divisions	O
13	that	O
14	are	O
15	largely	O
16	responsible	O
17	for	O
18	establishing	O
19	the	O
20	nematode	O
21	body	O
22	plan	O
23	.	O

0	Additionally	O
1	,	O
2	a	O
3	CaCO3	O
4	-	O
5	CO2	O
6	/	O
7	N2	O
8	buffered	O
9	solution	O
10	was	O
11	necessary	O
12	to	O
13	maintain	O
14	a	O
15	pH	O
16	of	O
17	8	O
18	.	O

0	Mss4	O
1	also	O
2	acts	O
3	as	O
4	a	O
5	relatively	O
6	inefficient	O
7	guanine	O
8	nucleotide	O
9	exchange	O
10	factor	O
11	(	O
12	GEF	O
13	).	O

0	Effects	O
1	of	O
2	3	O
3	'	O
4	terminus	O
5	modifications	O
6	on	O
7	mRNA	O
8	functional	O
9	decay	O
10	during	O
11	in	O
12	vitro	O
13	protein	O
14	synthesis	O
15	.	O

0	Disciplinary	O
1	action	O
2	for	O
3	DNA	O
4	violation	O
5	.	O

0	This	O
1	is	O
2	necessary	O
3	if	O
4	psychiatric	O
5	diagnoses	O
6	are	O
7	ultimately	O
8	going	O
9	to	O
10	be	O
11	refined	O
12	and	O
13	validated	O
14	against	O
15	biological	O
16	criteria	O
17	.	O

0	We	O
1	also	O
2	demonstrate	O
3	that	O
4	the	O
5	spo20	O
6	(+)	O
7	gene	O
8	product	O
9	is	O
10	structurally	O
11	homologous	O
12	to	O
13	Saccharomyces	O
14	cerevisiae	O
15	Sec14	O
16	,	O
17	the	O
18	major	O
19	phosphatidylinositol	O
20	transfer	O
21	protein	O
22	of	O
23	budding	O
24	yeast	O
25	.	O

0	In	O
1	addition	O
2	,	O
3	another	O
4	derivative	O
5	of	O
6	pCMVJS21	O
7	(	O
8	pCMVJS21DeltaGP	O
9	)	O
10	in	O
11	which	O
12	the	O
13	gag	O
14	,	O
15	pol	O
16	(	O
17	and	O
18	orf	O
19	-	O
20	x	O
21	)	O
22	coding	O
23	sequences	O
24	were	O
25	deleted	O
26	also	O
27	gave	O
28	transformed	O
29	foci	O
30	.	O

0	It	O
1	is	O
2	shown	O
3	that	O
4	,	O
5	for	O
6	any	O
7	periodic	O
8	input	O
9	,	O
10	the	O
11	map	O
12	representing	O
13	the	O
14	relation	O
15	between	O
16	input	O
17	phases	O
18	at	O
19	consecutive	O
20	discharge	O
21	times	O
22	can	O
23	be	O
24	restricted	O
25	to	O
26	a	O
27	piecewise	O
28	continuous	O
29	,	O
30	orientation	O
31	preserving	O
32	circle	O
33	map	O
34	.	O

0	Decreased	O
1	serum	O
2	ceruloplasmin	O
3	and	O
4	copper	O
5	levels	O
6	in	O
7	cervical	O
8	dystonia	O
9	.	O

0	Northern	O
1	blot	O
2	analysis	O
3	of	O
4	RNAs	O
5	from	O
6	a	O
7	number	O
8	of	O
9	mouse	O
10	tissues	O
11	reveals	O
12	that	O
13	Atp6i	O
14	is	O
15	expressed	O
16	predominantly	O
17	in	O
18	osteoclasts	O
19	,	O
20	and	O
21	this	O
22	predominant	O
23	expression	O
24	was	O
25	confirmed	O
26	by	O
27	reverse	O
28	-	O
29	transcription	O
30	polymerase	O
31	chain	O
32	reaction	O
33	(	O
34	RT	O
35	-	O
36	PCR	O
37	)	O
38	assay	O
39	and	O
40	immunohistochemical	O
41	analysis	O
42	.	O

0	Behavioural	O
1	tests	O
2	with	O
3	192	O
4	specimen	O
5	of	O
6	the	O
7	roman	O
8	garden	O
9	snail	O
10	Helix	O
11	pomatia	O
12	L	O
13	.	O
14	were	O
15	performed	O
16	in	O
17	order	O
18	to	O
19	clarify	O
20	whether	O
21	the	O
22	thermopreferendum	O
23	of	O
24	this	O
25	pulmonate	O
26	is	O
27	influenced	O
28	not	O
29	only	O
30	by	O
31	the	O
32	temperature	O
33	of	O
34	the	O
35	substratum	O
36	but	O
37	also	O
38	by	O
39	air	O
40	temperature	O
41	.	O

0	As	O
1	well	O
2	,	O
3	IFN	O
4	-	O
5	gamma	O
6	-	O
7	induced	O
8	expression	O
9	of	O
10	IRF	O
11	-	O
12	1	O
13	and	O
14	its	O
15	binding	O
16	to	O
17	the	O
18	IRF	O
19	element	O
20	is	O
21	inhibited	O
22	.	O

0	Baseline	O
1	BMD	O
2	values	O
3	were	O
4	significantly	O
5	lower	O
6	in	O
7	the	O
8	oligo	O
9	-	O
10	amenorrheic	O
11	group	O
12	than	O
13	in	O
14	the	O
15	two	O
16	others	O
17	at	O
18	the	O
19	level	O
20	of	O
21	lumbar	O
22	spine	O
23	(	O
24	anteroposterior	O
25	view	O
26	:	O
27	0	O
28	.	O
29	941	O
30	+/-	O
31	0	O
32	.	O
33	039	O
34	in	O
35	oligo	O
36	-	O
37	amenorrheic	O
38	vs	O
39	1	O
40	.	O
41	077	O
42	+/-	O
43	0	O
44	.	O
45	029	O
46	or	O
47	1	O
48	.	O
49	051	O
50	+/-	O
51	0	O
52	.	O
53	017	O
54	g	O
55	x	O
56	cm	O
57	(-	O
58	2	O
59	),	O
60	P	O
61	<	O
62	0	O
63	.	O
64	005	O
65	,	O
66	in	O
67	the	O
68	eumenorrheic	O
69	and	O
70	contraceptive	O
71	user	O
72	groups	O
73	,	O
74	respectively	O
75	)	O
76	but	O
77	not	O
78	in	O
79	weight	O
80	-	O
81	bearing	O
82	bone	O
83	such	O
84	as	O
85	proximal	O
86	and	O
87	midshaft	O
88	femur	O
89	.	O

0	The	O
1	glucose	O
2	/	O
3	insulin	O
4	stimulation	O
5	was	O
6	inhibited	O
7	by	O
8	the	O
9	addition	O
10	of	O
11	polyunsaturated	O
12	fatty	O
13	acids	O
14	.	O

0	We	O
1	report	O
2	the	O
3	results	O
4	of	O
5	a	O
6	detailed	O
7	policy	O
8	analysis	O
9	comparing	O
10	2	O
11	CJD	O
12	-	O
13	related	O
14	decisions	O
15	:	O
16	a	O
17	1995	O
18	recall	O
19	of	O
20	blood	O
21	from	O
22	a	O
23	donor	O
24	with	O
25	classic	O
26	CJD	O
27	and	O
28	the	O
29	1999	O
30	decision	O
31	to	O
32	defer	O
33	donations	O
34	from	O
35	individuals	O
36	with	O
37	a	O
38	6	O
39	-	O
40	month	O
41	travel	O
42	history	O
43	to	O
44	the	O
45	UK	O
46	between	O
47	1980	O
48	and	O
49	1996	O
50	due	O
51	to	O
52	concerns	O
53	related	O
54	to	O
55	variant	O
56	CJD	O
57	.	O

0	The	O
1	5	O
2	'	O
3	flanking	O
4	sequence	O
5	of	O
6	the	O
7	3B	O
8	gene	O
9	is	O
10	extremely	O
11	A	O
12	+	O
13	T	O
14	rich	O
15	but	O
16	contains	O
17	five	O
18	G	O
19	/	O
20	C	O
21	rich	O
22	stretches	O
23	,	O
24	each	O
25	approximately	O
26	7bp	O
27	long	O
28	,	O
29	which	O
30	have	O
31	strong	O
32	sequence	O
33	similarity	O
34	to	O
35	the	O
36	G	O
37	boxes	O
38	found	O
39	upstream	O
40	of	O
41	other	O
42	developmentally	O
43	regulated	O
44	Dictyostelium	O
45	genes	O
46	.	O

0	PACAP	O
1	mRNA	O
2	was	O
3	widely	O
4	expressed	O
5	in	O
6	most	O
7	human	O
8	tissues	O
9	;	O
10	in	O
11	transfected	O
12	cells	O
13	,	O
14	PACAP	O
15	was	O
16	diffusely	O
17	expressed	O
18	in	O
19	the	O
20	cytoplasm	O
21	.	O

0	The	O
1	proportion	O
2	of	O
3	the	O
4	biopsies	O
5	found	O
6	to	O
7	be	O
8	seropositive	O
9	for	O
10	HBs	O
11	antigen	O
12	was	O
13	27	O
14	.	O
15	9	O
16	%,	O
17	and	O
18	these	O
19	showed	O
20	either	O
21	MGN	O
22	or	O
23	MPGN	O
24	pattern	O
25	.	O

0	In	O
1	the	O
2	present	O
3	study	O
4	,	O
5	we	O
6	have	O
7	determined	O
8	the	O
9	ICBP90	O
10	gene	O
11	structure	O
12	by	O
13	screening	O
14	of	O
15	a	O
16	human	O
17	placenta	O
18	genomic	O
19	library	O
20	and	O
21	PCR	O
22	analysis	O
23	.	O

0	In	O
1	the	O
2	stable	O
3	transfectants	O
4	(	O
5	BM3	O
6	cells	O
7	)	O
8	expressing	O
9	a	O
10	mutant	O
11	bacterial	O
12	P450	O
13	AA	O
14	epoxygenase	O
15	,	O
16	F87V	O
17	BM3	O
18	,	O
19	which	O
20	was	O
21	genetically	O
22	engineered	O
23	to	O
24	metabolize	O
25	arachidonic	O
26	acid	O
27	only	O
28	to	O
29	14	O
30	,	O
31	15	O
32	-	O
33	EET	O
34	,	O
35	AA	O
36	did	O
37	not	O
38	induce	O
39	apoptosis	O
40	and	O
41	protected	O
42	against	O
43	agonist	O
44	-	O
45	induced	O
46	apoptosis	O
47	.	O

0	The	O
1	revitalization	O
2	of	O
3	surgery	O
4	for	O
5	Parkinson	O
6	'	O
7	s	O
8	disease	O
9	(	O
10	PD	O
11	)	O
12	has	O
13	fueled	O
14	discussion	O
15	about	O
16	the	O
17	best	O
18	methodology	O
19	to	O
20	define	O
21	the	O
22	target	O
23	.	O

0	Foreigners	O
1	return	O
2	.	O

0	She	O
1	drank	O
2	alcohol	O
3	once	O
4	or	O
5	twice	O
6	a	O
7	week	O
8	and	O
9	regularly	O
10	took	O
11	an	O
12	analgesic	O
13	preparation	O
14	,	O
15	containing	O
16	aspirin	O
17	and	O
18	acetaminophen	O
19	,	O
20	for	O
21	alleviation	O
22	of	O
23	headaches	O
24	.	O

0	The	O
1	authors	O
2	did	O
3	not	O
4	detect	O
5	any	O
6	significant	O
7	correlations	O
8	between	O
9	parameters	O
10	of	O
11	the	O
12	lipids	O
13	of	O
14	bone	O
15	marrow	O
16	and	O
17	leptin	O
18	levels	O
19	in	O
20	serum	O
21	and	O
22	bone	O
23	marrow	O
24	.	O

0	When	O
1	the	O
2	blood	O
3	clot	O
4	is	O
5	formed	O
6	in	O
7	the	O
8	vitreous	O
9	cavity	O
10	,	O
11	intravitreal	O
12	injection	O
13	of	O
14	t	O
15	-	O
16	PA	O
17	can	O
18	convert	O
19	plasminogen	O
20	to	O
21	plasmin	O
22	and	O
23	remove	O
24	the	O
25	clot	O
26	.	O

0	When	O
1	this	O
2	CCAAT	O
3	box	O
4	was	O
5	inserted	O
6	into	O
7	a	O
8	heterologous	O
9	promoter	O
10	construct	O
11	,	O
12	OA	O
13	induction	O
14	was	O
15	dependent	O
16	on	O
17	an	O
18	intact	O
19	CCAAT	O
20	box	O
21	.	O

0	Encouraged	O
1	by	O
2	a	O
3	Dutch	O
4	study	O
5	using	O
6	etidronate	O
7	/	O
8	fluoride	O
9	in	O
10	corticoid	O
11	-	O
12	induced	O
13	osteoporosis	O
14	,	O
15	we	O
16	performed	O
17	a	O
18	pilot	O
19	study	O
20	in	O
21	33	O
22	men	O
23	with	O
24	severe	O
25	established	O
26	primary	O
27	osteoporosis	O
28	giving	O
29	cyclically	O
30	etidronate	O
31	for	O
32	14	O
33	days	O
34	followed	O
35	by	O
36	fluoride	O
37	plus	O
38	calcium	O
39	/	O
40	vitamin	O
41	D	O
42	for	O
43	76	O
44	days	O
45	.	O

0	Far	O
1	Western	O
2	blot	O
3	analysis	O
4	suggested	O
5	that	O
6	the	O
7	tandem	O
8	SH2	O
9	domains	O
10	of	O
11	SHP2	O
12	bind	O
13	to	O
14	Gab1	O
15	in	O
16	a	O
17	specific	O
18	orientation	O
19	,	O
20	in	O
21	which	O
22	the	O
23	N	O
24	-	O
25	SH2	O
26	domain	O
27	binds	O
28	to	O
29	phosphotyrosine	O
30	(	O
31	Tyr	O
32	(	O
33	P	O
34	))-	O
35	627	O
36	and	O
37	the	O
38	C	O
39	-	O
40	SH2	O
41	domain	O
42	binds	O
43	to	O
44	Tyr	O
45	(	O
46	P	O
47	)-	O
48	659	O
49	.	O

0	Electrophoretic	O
1	mobility	O
2	shift	O
3	assays	O
4	and	O
5	coimmunoprecipitation	O
6	studies	O
7	suggest	O
8	that	O
9	homo	O
10	-	O
11	and	O
12	heterodimerization	O
13	occurs	O
14	between	O
15	cKrox	O
16	family	O
17	members	O
18	.	O

0	Expression	O
1	of	O
2	human	O
3	RACK1	O
4	efficiently	O
5	relieves	O
6	E1A	O
7	-	O
8	mediated	O
9	growth	O
10	inhibition	O
11	in	O
12	HF7c	O
13	and	O
14	protects	O
15	human	O
16	tumor	O
17	cells	O
18	from	O
19	E1A	O
20	-	O
21	induced	O
22	apoptosis	O
23	.	O

0	By	O
1	using	O
2	space	O
3	-	O
4	discrete	O
5	/	O
6	continuous	O
7	metapopulation	O
8	dynamic	O
9	models	O
10	and	O
11	computer	O
12	simulations	O
13	,	O
14	we	O
15	show	O
16	that	O
17	there	O
18	can	O
19	be	O
20	two	O
21	principally	O
22	different	O
23	regimes	O
24	of	O
25	metapopulation	O
26	dynamics	O
27	.	O

0	Arterial	O
1	blood	O
2	gas	O
3	tensions	O
4	were	O
5	similar	O
6	across	O
7	all	O
8	ventilation	O
9	modes	O
10	.	O

0	Four	O
1	casein	O
2	kinase	O
3	I	O
4	isoforms	O
5	are	O
6	differentially	O
7	partitioned	O
8	between	O
9	nucleus	O
10	and	O
11	cytoplasm	O
12	.	O

0	CONCLUSION	O
1	:	O
2	Extrusion	O
3	cooking	O
4	is	O
5	effective	O
6	for	O
7	the	O
8	inactivation	O
9	of	O
10	DON	O
11	but	O
12	is	O
13	of	O
14	limited	O
15	value	O
16	for	O
17	AFB1	O
18	,	O
19	even	O
20	if	O
21	metabisulphite	O
22	is	O
23	added	O
24	.	O

0	Also	O
1	,	O
2	the	O
3	EWS	O
4	protein	O
5	stimulates	O
6	transcription	O
7	mediated	O
8	by	O
9	the	O
10	COOH	O
11	-	O
12	terminal	O
13	transactivation	O
14	domain	O
15	of	O
16	the	O
17	cofactor	O
18	CREB	O
19	-	O
20	binding	O
21	protein	O
22	(	O
23	CBP	O
24	).	O

0	HSF	O
1	binds	O
2	DNA	O
3	as	O
4	a	O
5	trimer	O
6	,	O
7	and	O
8	additional	O
9	trimers	O
10	can	O
11	bind	O
12	DNA	O
13	co	O
14	-	O
15	operatively	O
16	.	O

0	Two	O
1	cases	O
2	with	O
3	marked	O
4	chronic	O
5	arm	O
6	lymphoedema	O
7	reported	O
8	major	O
9	and	O
10	persistent	O
11	improvements	O
12	in	O
13	arm	O
14	volume	O
15	for	O
16	at	O
17	least	O
18	12	O
19	months	O
20	after	O
21	treatment	O
22	with	O
23	HBO2	O
24	.	O

0	Growth	O
1	hormone	O
2	and	O
3	insulin	O
4	-	O
5	like	O
6	growth	O
7	factor	O
8	I	O
9	receptors	O
10	in	O
11	the	O
12	temporomandibular	O
13	joint	O
14	of	O
15	the	O
16	rat	O
17	.	O

0	Folate	O
1	metabolism	O
2	in	O
3	the	O
4	human	O
5	malaria	O
6	parasite	O
7	Plasmodium	O
8	falciparum	O
9	is	O
10	an	O
11	essential	O
12	activity	O
13	for	O
14	cell	O
15	growth	O
16	and	O
17	replication	O
18	,	O
19	and	O
20	the	O
21	target	O
22	of	O
23	an	O
24	important	O
25	class	O
26	of	O
27	therapeutic	O
28	agents	O
29	in	O
30	widespread	O
31	use	O
32	.	O

0	These	O
1	results	O
2	indicate	O
3	that	O
4	BACM	O
5	has	O
6	antiplaque	O
7	and	O
8	stronger	O
9	antidegradation	O
10	effects	O
11	than	O
12	GLCM	O
13	.	O

0	A	O
1	mutation	O
2	in	O
3	the	O
4	C	O
5	domain	O
6	of	O
7	Rb	O
8	,	O
9	L901Q	O
10	,	O
11	has	O
12	been	O
13	identified	O
14	that	O
15	completely	O
16	abolishes	O
17	cdk4	O
18	/	O
19	D1	O
20	phosphorylation	O
21	of	O
22	the	O
23	isolated	O
24	C	O
25	domain	O
26	.	O

0	Homo	O
1	-	O
2	oligomerisation	O
3	and	O
4	nuclear	O
5	localisation	O
6	of	O
7	mouse	O
8	histone	O
9	deacetylase	O
10	1	O
11	.	O

0	Energy	O
1	expenditure	O
2	was	O
3	obtained	O
4	using	O
5	a	O
6	primed	O
7	,	O
8	3	O
9	-	O
10	hour	O
11	infusion	O
12	of	O
13	NaH	O
14	(	O
15	13	O
16	)	O
17	CO	O
18	(	O
19	3	O
20	'),	O
21	breath	O
22	(	O
23	13	O
24	)	O
25	CO	O
26	(	O
27	2	O
28	)	O
29	enrichment	O
30	determination	O
31	by	O
32	isotope	O
33	ratio	O
34	mass	O
35	spectroscopy	O
36	,	O
37	and	O
38	the	O
39	application	O
40	of	O
41	a	O
42	standard	O
43	regression	O
44	equation	O
45	.	O

0	Fasting	O
1	gastrin	O
2	levels	O
3	(	O
4	normal	O
5	range	O
6	:	O
7	25	O
8	-	O
9	110	O
10	mU	O
11	/	O
12	L	O
13	)	O
14	varied	O
15	from	O
16	48	O
17	.	O
18	78	O
19	mU	O
20	/	O
21	L	O
22	-	O
23	168	O
24	.	O
25	20	O
26	(	O
27	mean	O
28	:	O
29	85	O
30	.	O
31	23	O
32	mU	O
33	/	O
34	L	O
35	).	O

0	Identification	O
1	of	O
2	pulmonary	O
3	vein	O
4	stenosis	O
5	after	O
6	radiofrequency	O
7	ablation	O
8	for	O
9	atrial	O
10	fibrillation	O
11	using	O
12	MRI	O
13	.	O

0	The	O
1	continuing	O
2	development	O
3	of	O
4	ligands	O
5	that	O
6	function	O
7	as	O
8	selective	O
9	estrogens	O
10	or	O
11	antiestrogens	O
12	for	O
13	ERalpha	O
14	or	O
15	ERbeta	O
16	should	O
17	allow	O
18	optimized	O
19	tissue	O
20	selectivity	O
21	of	O
22	these	O
23	agents	O
24	for	O
25	menopausal	O
26	hormone	O
27	replacement	O
28	therapy	O
29	and	O
30	the	O
31	treatment	O
32	and	O
33	prevention	O
34	of	O
35	breast	O
36	cancer	O
37	.	O

0	Baseline	O
1	variables	O
2	associated	O
3	with	O
4	CD	O
5	included	O
6	a	O
7	less	O
8	frequent	O
9	use	O
10	of	O
11	prestroke	O
12	aspirin	O
13	and	O
14	a	O
15	higher	O
16	incidence	O
17	of	O
18	early	O
19	CT	O
20	changes	O
21	of	O
22	edema	O
23	or	O
24	mass	O
25	effect	O
26	or	O
27	dense	O
28	middle	O
29	cerebral	O
30	artery	O
31	sign	O
32	.	O

0	A	O
1	peculiar	O
2	people	O
3	:	O
4	"	O
5	the	O
6	physiological	O
7	aspects	O
8	of	O
9	Mormonism	O
10	1850	O
11	-	O
12	1975	O
13	."	O

0	SH2D1A	O
1	protein	O
2	levels	O
3	are	O
4	up	O
5	-	O
6	regulated	O
7	by	O
8	CD40	O
9	cross	O
10	-	O
11	linking	O
12	and	O
13	down	O
14	-	O
15	regulated	O
16	by	O
17	B	O
18	cell	O
19	receptor	O
20	ligation	O
21	.	O

0	The	O
1	Genescan	O
2	program	O
3	predicted	O
4	an	O
5	open	O
6	reading	O
7	frame	O
8	of	O
9	a	O
10	novel	O
11	,	O
12	intron	O
13	-	O
14	less	O
15	gene	O
16	adjacent	O
17	to	O
18	the	O
19	B236	O
20	spot	O
21	that	O
22	encodes	O
23	a	O
24	putative	O
25	493	O
26	-	O
27	amino	O
28	acid	O
29	protein	O
30	containing	O
31	the	O
32	SNAG	O
33	repressor	O
34	motif	O
35	in	O
36	the	O
37	NH2	O
38	-	O
39	terminal	O
40	region	O
41	and	O
42	five	O
43	C2H2	O
44	-	O
45	type	O
46	zinc	O
47	finger	O
48	motifs	O
49	in	O
50	the	O
51	COOH	O
52	-	O
53	terminal	O
54	half	O
55	.	O

0	Under	O
1	our	O
2	conditions	O
3	,	O
4	the	O
5	combination	O
6	O3	O
7	/	O
8	UV	O
9	did	O
10	not	O
11	improve	O
12	the	O
13	degradation	O
14	rate	O
15	obtained	O
16	by	O
17	ozonation	O
18	.	O

0	The	O
1	metabolic	O
2	events	O
3	occurring	O
4	at	O
5	or	O
6	near	O
7	that	O
8	structure	O
9	and	O
10	involving	O
11	cyclin	O
12	D3	O
13	cause	O
14	the	O
15	translocation	O
16	of	O
17	ICP0	O
18	to	O
19	the	O
20	cytoplasm	O
21	.	O

0	In	O
1	the	O
2	single	O
3	case	O
4	the	O
5	restoration	O
6	of	O
7	a	O
8	structured	O
9	daily	O
10	routine	O
11	represents	O
12	the	O
13	presupposition	O
14	for	O
15	a	O
16	cognitive	O
17	therapy	O
18	.	O

0	Immunofluorescence	O
1	studies	O
2	in	O
3	C2C12	O
4	myotubes	O
5	show	O
6	that	O
7	Smad2	O
8	and	O
9	MEF2A	O
10	co	O
11	-	O
12	localise	O
13	in	O
14	the	O
15	nucleus	O
16	of	O
17	multinuclear	O
18	myotubes	O
19	during	O
20	differentiation	O
21	.	O

0	In	O
1	35	O
2	of	O
3	those	O
4	patients	O
5	DD	O
6	was	O
7	measured	O
8	also	O
9	with	O
10	microlatex	O
11	tests	O
12	--	O
13	Tinaquant	O
14	and	O
15	BC	O
16	d	O
17	-	O
18	dimer	O
19	.	O

0	Simulating	O
1	the	O
2	impact	O
3	during	O
4	human	O
5	jumping	O
6	by	O
7	means	O
8	of	O
9	a	O
10	4	O
11	-	O
12	degrees	O
13	-	O
14	of	O
15	-	O
16	freedom	O
17	model	O
18	with	O
19	time	O
20	-	O
21	dependent	O
22	properties	O
23	.	O

0	A	O
1	novel	O
2	approach	O
3	was	O
4	developed	O
5	for	O
6	identifying	O
7	transcription	O
8	factor	O
9	activities	O
10	associated	O
11	with	O
12	NGF	O
13	-	O
14	activated	O
15	,	O
16	but	O
17	not	O
18	EGF	O
19	-	O
20	activated	O
21	,	O
22	signaling	O
23	,	O
24	using	O
25	random	O
26	oligonucleotide	O
27	clones	O
28	from	O
29	a	O
30	DNA	O
31	recognition	O
32	library	O
33	to	O
34	isolate	O
35	specific	O
36	DNA	O
37	binding	O
38	proteins	O
39	from	O
40	PC12	O
41	nuclear	O
42	extracts	O
43	.	O

0	Atheroma	O
1	appears	O
2	as	O
3	a	O
4	very	O
5	low	O
6	signal	O
7	intensity	O
8	area	O
9	on	O
10	2	O
11	-	O
12	dimensional	O
13	time	O
14	-	O
15	of	O
16	-	O
17	flight	O
18	(	O
19	TOF	O
20	)	O
21	magnetic	O
22	resonance	O
23	(	O
24	MR	O
25	)	O
26	images	O
27	,	O
28	and	O
29	its	O
30	components	O
31	have	O
32	various	O
33	signal	O
34	intensities	O
35	on	O
36	spin	O
37	-	O
38	echo	O
39	(	O
40	SE	O
41	)	O
42	images	O
43	.	O

0	Finally	O
1	a	O
2	10	O
3	-	O
4	nucleotide	O
5	region	O
6	flanking	O
7	the	O
8	exon	O
9	4	O
10	protein	O
11	-	O
12	binding	O
13	site	O
14	is	O
15	homologous	O
16	to	O
17	instability	O
18	elements	O
19	within	O
20	five	O
21	other	O
22	transcripts	O
23	,	O
24	suggesting	O
25	that	O
26	a	O
27	common	O
28	coding	O
29	region	O
30	determinant	O
31	may	O
32	exist	O
33	.	O

0	Chronic	O
1	nutritional	O
2	diseases	O
3	of	O
4	infectious	O
5	origin	O
6	:	O
7	an	O
8	assessment	O
9	of	O
10	a	O
11	nascent	O
12	field	O
13	.	O

0	The	O
1	cut	O
2	-	O
3	off	O
4	percentage	O
5	positivity	O
6	value	O
7	was	O
8	established	O
9	using	O
10	500	O
11	brucellosis	O
12	-	O
13	positive	O
14	and	O
15	500	O
16	brucellosis	O
17	-	O
18	negative	O
19	serum	O
20	samples	O
21	,	O
22	confirmed	O
23	with	O
24	reference	O
25	to	O
26	the	O
27	sample	O
28	data	O
29	using	O
30	the	O
31	indirect	O
32	ELISA	O
33	kit	O
34	.	O

0	PROCEDURE	O
1	:	O
2	Cannulas	O
3	were	O
4	surgically	O
5	positioned	O
6	in	O
7	the	O
8	abomasal	O
9	body	O
10	and	O
11	pyloric	O
12	antrum	O
13	of	O
14	each	O
15	calf	O
16	.	O

0	The	O
1	utilities	O
2	measured	O
3	in	O
4	our	O
5	study	O
6	can	O
7	be	O
8	applied	O
9	directly	O
10	to	O
11	quality	O
12	-	O
13	of	O
14	-	O
15	life	O
16	determinations	O
17	in	O
18	clinical	O
19	trials	O
20	of	O
21	adjuvant	O
22	IFN	O
23	alpha	O
24	-	O
25	2b	O
26	to	O
27	measure	O
28	the	O
29	net	O
30	benefit	O
31	of	O
32	therapy	O
33	.	O

0	Cells	O
1	lacking	O
2	p116	O
3	exhibit	O
4	a	O
5	striking	O
6	defect	O
7	in	O
8	the	O
9	formation	O
10	of	O
11	these	O
12	macropinocytic	O
13	structures	O
14	,	O
15	a	O
16	concomitant	O
17	reduction	O
18	in	O
19	the	O
20	rate	O
21	of	O
22	fluid	O
23	phase	O
24	pinocytosis	O
25	,	O
26	a	O
27	significant	O
28	decrease	O
29	in	O
30	the	O
31	efficiency	O
32	of	O
33	chemotactic	O
34	aggregation	O
35	,	O
36	and	O
37	a	O
38	decrease	O
39	in	O
40	cellular	O
41	F	O
42	-	O
43	actin	O
44	content	O
45	.	O

0	Ectopic	O
1	expression	O
2	of	O
3	the	O
4	dominant	O
5	mutant	O
6	Lg3	O
7	allele	O
8	is	O
9	believed	O
10	to	O
11	cause	O
12	the	O
13	phenotype	O
14	.	O

0	Specimen	O
1	mass	O
2	reduction	O
3	increased	O
4	with	O
5	irradiance	O
6	from	O
7	19	O
8	to	O
9	72	O
10	%	O
11	of	O
12	the	O
13	initial	O
14	mass	O
15	for	O
16	9	O
17	--	O
18	31	O
19	W	O
20	/	O
21	cm	O
22	(	O
23	2	O
24	),	O
25	respectively	O
26	.	O

0	Analysis	O
1	of	O
2	the	O
3	genome	O
4	sequence	O
5	revealed	O
6	26	O
7	,	O
8	588	O
9	protein	O
10	-	O
11	encoding	O
12	transcripts	O
13	for	O
14	which	O
15	there	O
16	was	O
17	strong	O
18	corroborating	O
19	evidence	O
20	and	O
21	an	O
22	additional	O
23	approximately	O
24	12	O
25	,	O
26	000	O
27	computationally	O
28	derived	O
29	genes	O
30	with	O
31	mouse	O
32	matches	O
33	or	O
34	other	O
35	weak	O
36	supporting	O
37	evidence	O
38	.	O

0	The	O
1	other	O
2	inhibitor	O
3	was	O
4	a	O
5	single	O
6	TAR	O
7	decoy	O
8	,	O
9	driven	O
10	by	O
11	the	O
12	U6	O
13	small	O
14	nuclear	O
15	RNA	O
16	promoter	O
17	(	O
18	U6	O
19	-	O
20	P	O
21	).	O

0	By	O
1	comparison	O
2	,	O
3	in	O
4	nontumorigenic	O
5	Ad5	O
6	cells	O
7	,	O
8	class	O
9	I	O
10	expression	O
11	is	O
12	high	O
13	due	O
14	to	O
15	negligible	O
16	binding	O
17	of	O
18	COUP	O
19	-	O
20	TF	O
21	and	O
22	strong	O
23	binding	O
24	of	O
25	NF	O
26	-	O
27	kappaB	O
28	.	O

0	Moreover	O
1	,	O
2	a	O
3	complex	O
4	containing	O
5	PTP	O
6	phi	O
7	,	O
8	paxillin	O
9	,	O
10	and	O
11	a	O
12	paxillin	O
13	-	O
14	associated	O
15	tyrosine	O
16	kinase	O
17	,	O
18	Pyk2	O
19	,	O
20	can	O
21	be	O
22	immunoprecipitated	O
23	from	O
24	macrophage	O
25	lysates	O
26	,	O
27	and	O
28	the	O
29	catalytic	O
30	domain	O
31	of	O
32	PTP	O
33	phi	O
34	selectively	O
35	binds	O
36	paxillin	O
37	and	O
38	Pyk2	O
39	in	O
40	vitro	O
41	.	O

0	Our	O
1	previous	O
2	studies	O
3	have	O
4	shown	O
5	that	O
6	SHP	O
7	-	O
8	1	O
9	,	O
10	a	O
11	SH2	O
12	domain	O
13	-	O
14	containing	O
15	protein	O
16	-	O
17	tyrosine	O
18	phosphatase	O
19	,	O
20	is	O
21	expressed	O
22	not	O
23	only	O
24	in	O
25	cells	O
26	of	O
27	hematopoietic	O
28	lineages	O
29	,	O
30	but	O
31	also	O
32	in	O
33	many	O
34	non	O
35	-	O
36	hematopoietic	O
37	cells	O
38	under	O
39	the	O
40	control	O
41	of	O
42	an	O
43	alternative	O
44	tissue	O
45	-	O
46	specific	O
47	promoter	O
48	,	O
49	P1	O
50	.	O

0	Whereas	O
1	Smad2	O
2	was	O
3	rapidly	O
4	phosphorylated	O
5	by	O
6	TGF	O
7	-	O
8	beta	O
9	and	O
10	involved	O
11	in	O
12	the	O
13	initial	O
14	activation	O
15	of	O
16	Agc	O
17	expression	O
18	in	O
19	confluent	O
20	cells	O
21	,	O
22	Smad2	O
23	activation	O
24	was	O
25	not	O
26	required	O
27	for	O
28	maintaining	O
29	the	O
30	high	O
31	level	O
32	of	O
33	Agc	O
34	expression	O
35	.	O

0	The	O
1	astronaut	O
2	crew	O
3	operates	O
4	the	O
5	payload	O
6	and	O
7	documents	O
8	its	O
9	operation	O
10	.	O

0	This	O
1	molecule	O
2	,	O
3	wH22xeGFP	O
4	,	O
5	consists	O
6	of	O
7	the	O
8	entire	O
9	humanized	O
10	anti	O
11	-	O
12	FcgammaRI	O
13	mAb	O
14	H22	O
15	with	O
16	eGFP	O
17	genetically	O
18	fused	O
19	to	O
20	the	O
21	C	O
22	-	O
23	terminal	O
24	end	O
25	of	O
26	each	O
27	CH3	O
28	domain	O
29	.	O
30	wH22xeGFP	O
31	binds	O
32	within	O
33	the	O
34	ligand	O
35	-	O
36	binding	O
37	region	O
38	by	O
39	its	O
40	Fc	O
41	end	O
42	,	O
43	as	O
44	well	O
45	as	O
46	outside	O
47	the	O
48	ligand	O
49	-	O
50	binding	O
51	region	O
52	by	O
53	its	O
54	Fab	O
55	ends	O
56	,	O
57	thereby	O
58	cross	O
59	-	O
60	linking	O
61	FcgammaRI	O
62	.	O

0	On	O
1	the	O
2	other	O
3	hand	O
4	,	O
5	hepatic	O
6	arterial	O
7	infusion	O
8	therapy	O
9	prolongs	O
10	the	O
11	survival	O
12	of	O
13	H3	O
14	patients	O
15	only	O
16	.	O

0	Hepatitis	O
1	B	O
2	and	O
3	C	O
4	seroprevalence	O
5	rates	O
6	among	O
7	high	O
8	-	O
9	risk	O
10	adolescents	O
11	are	O
12	lower	O
13	in	O
14	El	O
15	Paso	O
16	than	O
17	in	O
18	other	O
19	similar	O
20	US	O
21	populations	O
22	,	O
23	presenting	O
24	an	O
25	ideal	O
26	climate	O
27	for	O
28	prevention	O
29	programs	O
30	.	O

0	We	O
1	found	O
2	that	O
3	the	O
4	SOCS	O
5	box	O
6	interacted	O
7	with	O
8	Cullin	O
9	-	O
10	2	O
11	and	O
12	promoted	O
13	ubiquitination	O
14	of	O
15	TEL	O
16	-	O
17	JAK2	O
18	.	O

0	A	O
1	patient	O
2	is	O
3	described	O
4	with	O
5	skin	O
6	lesions	O
7	resembling	O
8	Kaposi	O
9	'	O
10	s	O
11	sarcoma	O
12	(	O
13	KS	O
14	).	O

0	Special	O
1	issues	O
2	devoted	O
3	to	O
4	the	O
5	biosynthesis	O
6	of	O
7	woody	O
8	plant	O
9	biopolymers	O
10	and	O
11	related	O
12	substances	O
13	.	O

0	These	O
1	data	O
2	suggest	O
3	that	O
4	ADAM	O
5	-	O
6	TS12	O
7	may	O
8	play	O
9	roles	O
10	in	O
11	pulmonary	O
12	cells	O
13	during	O
14	fetal	O
15	development	O
16	or	O
17	in	O
18	tumor	O
19	processes	O
20	through	O
21	its	O
22	proteolytic	O
23	activity	O
24	or	O
25	as	O
26	a	O
27	molecule	O
28	potentially	O
29	involved	O
30	in	O
31	regulation	O
32	of	O
33	cell	O
34	adhesion	O
35	.	O

0	Progressive	O
1	study	O
2	and	O
3	robustness	O
4	test	O
5	of	O
6	QSAR	O
7	model	O
8	based	O
9	on	O
10	quantum	O
11	chemical	O
12	parameters	O
13	for	O
14	predicting	O
15	BCF	O
16	of	O
17	selected	O
18	polychlorinated	O
19	organic	O
20	compounds	O
21	(	O
22	PCOCs	O
23	).	O

0	Additional	O
1	deletion	O
2	mutations	O
3	revealed	O
4	a	O
5	new	O
6	,	O
7	67	O
8	-	O
9	amino	O
10	-	O
11	acid	O
12	functional	O
13	domain	O
14	within	O
15	the	O
16	proline	O
17	-	O
18	rich	O
19	region	O
20	of	O
21	SLP	O
22	-	O
23	76	O
24	,	O
25	which	O
26	we	O
27	have	O
28	termed	O
29	the	O
30	P	O
31	-	O
32	1	O
33	domain	O
34	.	O

0	Patients	O
1	with	O
2	type	O
3	III	O
4	SOD	O
5	may	O
6	have	O
7	visceral	O
8	hyperalgesia	O
9	;	O
10	a	O
11	trial	O
12	of	O
13	antidepressants	O
14	or	O
15	a	O
16	therapeutic	O
17	trial	O
18	with	O
19	botulinum	O
20	toxin	O
21	injection	O
22	into	O
23	the	O
24	ampulla	O
25	should	O
26	be	O
27	considered	O
28	prior	O
29	to	O
30	more	O
31	invasive	O
32	endoscopic	O
33	therapy	O
34	.	O

0	We	O
1	have	O
2	now	O
3	tested	O
4	all	O
5	known	O
6	mammalian	O
7	Groucho	O
8	family	O
9	members	O
10	for	O
11	their	O
12	ability	O
13	to	O
14	interact	O
15	specifically	O
16	with	O
17	individual	O
18	Tcf	O
19	/	O
20	Lef	O
21	family	O
22	members	O
23	.	O

0	Body	O
1	weight	O
2	reduction	O
3	increases	O
4	insulin	O
5	sensitivity	O
6	and	O
7	improves	O
8	both	O
9	blood	O
10	glucose	O
11	and	O
12	blood	O
13	pressure	O
14	control	O
15	.	O

0	Sequence	O
1	analysis	O
2	indicates	O
3	that	O
4	RBP21	O
5	shares	O
6	homology	O
7	with	O
8	other	O
9	retinoblastoma	O
10	-	O
11	binding	O
12	proteins	O
13	in	O
14	the	O
15	pRb	O
16	-	O
17	binding	O
18	motif	O
19	LxCxE	O
20	at	O
21	the	O
22	C	O
23	-	O
24	terminal	O
25	region	O
26	.	O

0	Tolerance	O
1	in	O
2	renal	O
3	transplantation	O
4	after	O
5	allogeneic	O
6	bone	O
7	marrow	O
8	transplantation	O
9	-	O
10	6	O
11	-	O
12	year	O
13	follow	O
14	-	O
15	up	O
16	.	O

0	By	O
1	analyzing	O
2	5	O
3	'-	O
4	deletion	O
5	insulin	O
6	promoter	O
7	-	O
8	reporter	O
9	constructs	O
10	in	O
11	transient	O
12	transfections	O
13	of	O
14	clonal	O
15	INS	O
16	-	O
17	1	O
18	beta	O
19	-	O
20	cells	O
21	,	O
22	we	O
23	located	O
24	activating	O
25	Hh	O
26	-	O
27	responsive	O
28	regions	O
29	within	O
30	the	O
31	rat	O
32	insulin	O
33	I	O
34	promoter	O
35	that	O
36	include	O
37	the	O
38	glucose	O
39	-	O
40	response	O
41	elements	O
42	Far	O
43	(	O
44	E2	O
45	)	O
46	and	O
47	Flat	O
48	(	O
49	A2	O
50	/	O
51	A3	O
52	).	O

0	However	O
1	,	O
2	when	O
3	directed	O
4	to	O
5	the	O
6	nucleosome	O
7	by	O
8	fusion	O
9	to	O
10	core	O
11	histone	O
12	H2A	O
13	or	O
14	H2B	O
15	,	O
16	the	O
17	non	O
18	-	O
19	histone	O
20	tail	O
21	forms	O
22	an	O
23	MCB	O
24	that	O
25	appears	O
26	identical	O
27	to	O
28	that	O
29	of	O
30	the	O
31	endogenous	O
32	protein	O
33	.	O

0	Data	O
1	were	O
2	obtained	O
3	from	O
4	2	O
5	undergraduate	O
6	student	O
7	samples	O
8	,	O
9	a	O
10	self	O
11	-	O
12	report	O
13	group	O
14	(	O
15	n	O
16	=	O
17	132	O
18	)	O
19	who	O
20	provided	O
21	NEO	O
22	-	O
23	PI	O
24	-	O
25	R	O
26	self	O
27	-	O
28	ratings	O
29	on	O
30	2	O
31	occasions	O
32	separated	O
33	by	O
34	a	O
35	7	O
36	-	O
37	to	O
38	14	O
39	-	O
40	day	O
41	interval	O
42	and	O
43	an	O
44	informant	O
45	group	O
46	(	O
47	n	O
48	=	O
49	109	O
50	)	O
51	who	O
52	provided	O
53	ratings	O
54	of	O
55	well	O
56	-	O
57	known	O
58	friends	O
59	or	O
60	relatives	O
61	on	O
62	2	O
63	occasions	O
64	separated	O
65	by	O
66	a	O
67	6	O
68	month	O
69	interval	O
70	.	O

0	Pulmonary	O
1	embolectomy	O
2	and	O
3	lung	O
4	transplantation	O
5	are	O
6	the	O
7	main	O
8	indications	O
9	for	O
10	the	O
11	use	O
12	of	O
13	heart	O
14	-	O
15	lung	O
16	-	O
17	machine	O
18	.	O

0	Comparison	O
1	of	O
2	German	O
3	language	O
4	versions	O
5	of	O
6	the	O
7	QWB	O
8	-	O
9	SA	O
10	and	O
11	SF	O
12	-	O
13	36	O
14	evaluating	O
15	outcomes	O
16	for	O
17	patients	O
18	with	O
19	prostate	O
20	disease	O
21	.	O

0	The	O
1	median	O
2	preoperative	O
3	best	O
4	-	O
5	corrected	O
6	visual	O
7	acuity	O
8	of	O
9	0	O
10	.	O
11	08	O
12	(	O
13	range	O
14	hand	O
15	motions	O
16	/	O
17	0	O
18	.	O
19	003	O
20	to	O
21	0	O
22	.	O
23	4	O
24	),	O
25	improved	O
26	by	O
27	5	O
28	lines	O
29	to	O
30	a	O
31	median	O
32	final	O
33	postoperative	O
34	best	O
35	-	O
36	corrected	O
37	visual	O
38	acuity	O
39	of	O
40	0	O
41	.	O
42	25	O
43	(	O
44	range	O
45	0	O
46	.	O
47	025	O
48	-	O
49	0	O
50	.	O
51	5	O
52	)	O
53	(	O
54	P	O
55	=	O
56	0	O
57	.	O
58	001	O
59	).	O

0	Angina	O
1	(	O
2	Q	O
3	)	O
4	persistence	O
5	showed	O
6	marked	O
7	associations	O
8	with	O
9	previous	O
10	myocardial	O
11	infarction	O
12	,	O
13	diagnosed	O
14	angina	O
15	,	O
16	electrocardiogram	O
17	ischemia	O
18	,	O
19	and	O
20	subsequent	O
21	major	O
22	ischemic	O
23	heart	O
24	disease	O
25	events	O
26	from	O
27	Q5	O
28	onward	O
29	.	O

0	Site	O
1	-	O
2	directed	O
3	mutagenesis	O
4	of	O
5	CAR	O
6	revealed	O
7	that	O
8	CAR	O
9	residues	O
10	Leu73	O
11	and	O
12	Lys121	O
13	and	O
14	/	O
15	or	O
16	Lys123	O
17	are	O
18	critical	O
19	contact	O
20	residues	O
21	,	O
22	with	O
23	Tyr80	O
24	and	O
25	Tyr83	O
26	being	O
27	peripherally	O
28	involved	O
29	in	O
30	the	O
31	binding	O
32	interaction	O
33	with	O
34	the	O
35	Ad5	O
36	,	O
37	Ad9	O
38	,	O
39	Ad12	O
40	,	O
41	and	O
42	Ad41L	O
43	fiber	O
44	knobs	O
45	.	O

0	Transforming	O
1	growth	O
2	factor	O
3	-	O
4	beta	O
5	(	O
6	TGF	O
7	-	O
8	beta	O
9	)	O
10	induced	O
11	growth	O
12	arrest	O
13	of	O
14	cells	O
15	involves	O
16	regulation	O
17	of	O
18	the	O
19	activities	O
20	of	O
21	both	O
22	D	O
23	-	O
24	and	O
25	E	O
26	-	O
27	type	O
28	cyclin	O
29	kinase	O
30	complexes	O
31	thought	O
32	to	O
33	be	O
34	mediated	O
35	primarily	O
36	by	O
37	the	O
38	regulation	O
39	of	O
40	p15	O
41	(	O
42	Ink4b	O
43	)	O
44	and	O
45	p27	O
46	(	O
47	Kip1	O
48	)	O
49	cyclin	O
50	kinase	O
51	inhibitors	O
52	.	O

0	These	O
1	data	O
2	indicate	O
3	that	O
4	the	O
5	SmSmad2	O
6	responds	O
7	to	O
8	the	O
9	TGF	O
10	-	O
11	beta	O
12	signals	O
13	by	O
14	interaction	O
15	with	O
16	receptor	O
17	I	O
18	,	O
19	which	O
20	phosphorylates	O
21	it	O
22	,	O
23	whereupon	O
24	it	O
25	translocates	O
26	into	O
27	the	O
28	nucleus	O
29	presumably	O
30	to	O
31	regulate	O
32	target	O
33	gene	O
34	transcription	O
35	and	O
36	consequently	O
37	elicit	O
38	a	O
39	specific	O
40	TGF	O
41	-	O
42	beta	O
43	effect	O
44	.	O

0	We	O
1	propose	O
2	that	O
3	TFOs	O
4	represent	O
5	a	O
6	therapeutic	O
7	potential	O
8	to	O
9	specifically	O
10	diminish	O
11	the	O
12	expression	O
13	of	O
14	c	O
15	-	O
16	sis	O
17	/	O
18	PDGF	O
19	-	O
20	B	O
21	proto	O
22	-	O
23	oncogene	O
24	in	O
25	various	O
26	pathologic	O
27	settings	O
28	where	O
29	constitutive	O
30	expression	O
31	of	O
32	this	O
33	gene	O
34	has	O
35	been	O
36	observed	O
37	.	O

0	The	O
1	increased	O
2	clearance	O
3	observed	O
4	in	O
5	young	O
6	infants	O
7	is	O
8	in	O
9	contrast	O
10	to	O
11	other	O
12	opioids	O
13	.	O

0	Peripheral	O
1	metabolism	O
2	of	O
3	androgens	O
4	takes	O
5	place	O
6	in	O
7	various	O
8	areas	O
9	within	O
10	the	O
11	pilosebaceous	O
12	unit	O
13	,	O
14	as	O
15	indicated	O
16	by	O
17	local	O
18	differences	O
19	in	O
20	the	O
21	activities	O
22	of	O
23	aromatase	O
24	,	O
25	5alpha	O
26	-	O
27	reductase	O
28	as	O
29	well	O
30	as	O
31	of	O
32	the	O
33	presence	O
34	of	O
35	the	O
36	androgen	O
37	receptors	O
38	.	O

0	This	O
1	unique	O
2	location	O
3	of	O
4	cavernous	O
5	malformation	O
6	is	O
7	associated	O
8	with	O
9	a	O
10	risk	O
11	of	O
12	permanent	O
13	loss	O
14	of	O
15	the	O
16	vision	O
17	.	O

0	The	O
1	JHRLSS	O
2	has	O
3	been	O
4	used	O
5	in	O
6	prior	O
7	studies	O
8	to	O
9	assess	O
10	RLS	O
11	severity	O
12	,	O
13	but	O
14	has	O
15	not	O
16	previously	O
17	been	O
18	validated	O
19	in	O
20	relation	O
21	to	O
22	direct	O
23	measures	O
24	of	O
25	the	O
26	morbidity	O
27	associated	O
28	with	O
29	RLS	O
30	.	O

0	Consistent	O
1	effects	O
2	on	O
3	pVHL	O
4	function	O
5	were	O
6	observed	O
7	for	O
8	all	O
9	mutations	O
10	within	O
11	each	O
12	subclass	O
13	.	O

0	Interestingly	O
1	,	O
2	the	O
3	CYP71D20	O
4	-	O
5	encoded	O
6	enzyme	O
7	activity	O
8	was	O
9	capable	O
10	of	O
11	converting	O
12	both	O
13	5	O
14	-	O
15	epi	O
16	-	O
17	aristolochene	O
18	and	O
19	1	O
20	-	O
21	deoxycapsidiol	O
22	to	O
23	capsidiol	O
24	in	O
25	vitro	O
26	,	O
27	consistent	O
28	with	O
29	the	O
30	notion	O
31	that	O
32	this	O
33	P450	O
34	enzyme	O
35	catalyzes	O
36	both	O
37	hydroxylations	O
38	of	O
39	its	O
40	hydrocarbon	O
41	substrate	O
42	.	O

0	A	O
1	new	O
2	species	O
3	of	O
4	Euspondylus	O
5	is	O
6	described	O
7	based	O
8	on	O
9	a	O
10	female	O
11	(	O
12	taken	O
13	within	O
14	a	O
15	bromeliad	O
16	)	O
17	from	O
18	Cerro	O
19	El	O
20	Humo	O
21	,	O
22	Sucre	O
23	,	O
24	northeastern	O
25	Venezuela	O
26	.	O

0	The	O
1	most	O
2	important	O
3	finding	O
4	,	O
5	however	O
6	,	O
7	was	O
8	that	O
9	IMT	O
10	values	O
11	were	O
12	related	O
13	with	O
14	24	O
15	h	O
16	SBP	O
17	or	O
18	PP	O
19	standard	O
20	deviation	O
21	(	O
22	P	O
23	<	O
24	0	O
25	.	O
26	001	O
27	),	O
28	a	O
29	measure	O
30	of	O
31	overall	O
32	SBP	O
33	or	O
34	PP	O
35	variability	O
36	.	O

0	In	O
1	addition	O
2	,	O
3	severe	O
4	vision	O
5	loss	O
6	can	O
7	be	O
8	seen	O
9	with	O
10	interferon	O
11	alfa	O
12	-	O
13	2b	O
14	-	O
15	associated	O
16	retinopathy	O
17	.	O

0	FLP	O
1	and	O
2	Cre	O
3	recombinase	O
4	function	O
5	in	O
6	Xenopus	O
7	embryos	O
8	.	O

0	Keratoconjunctivitis	O
1	sicca	O
2	appears	O
3	to	O
4	be	O
5	a	O
6	common	O
7	ocular	O
8	complication	O
9	and	O
10	all	O
11	children	O
12	with	O
13	JRA	O
14	should	O
15	be	O
16	screened	O
17	for	O
18	it	O
19	with	O
20	a	O
21	comprehensive	O
22	battery	O
23	of	O
24	tests	O
25	.	O

0	Moreover	O
1	,	O
2	PTax	O
3	expressed	O
4	higher	O
5	background	O
6	activities	O
7	than	O
8	PTF	O
9	,	O
10	indicating	O
11	that	O
12	the	O
13	sequence	O
14	of	O
15	the	O
16	synthetic	O
17	regulatory	O
18	region	O
19	can	O
20	influence	O
21	background	O
22	levels	O
23	.	O

0	After	O
1	allowing	O
2	time	O
3	for	O
4	absorption	O
5	,	O
6	participants	O
7	completed	O
8	a	O
9	bridge	O
10	simulator	O
11	task	O
12	.	O

0	The	O
1	cleavage	O
2	site	O
3	between	O
4	VPg	O
5	and	O
6	RNA	O
7	dependent	O
8	RNA	O
9	polymerase	O
10	was	O
11	predicted	O
12	to	O
13	be	O
14	E445	O
15	-	O
16	T446	O
17	based	O
18	on	O
19	the	O
20	amino	O
21	acid	O
22	sequence	O
23	analysis	O
24	of	O
25	the	O
26	polyprotein	O
27	from	O
28	different	O
29	sobemoviruses	O
30	.	O

0	Conformational	O
1	changes	O
2	of	O
3	the	O
4	ferric	O
5	uptake	O
6	regulation	O
7	protein	O
8	upon	O
9	metal	O
10	activation	O
11	and	O
12	DNA	O
13	binding	O
14	;	O
15	first	O
16	evidence	O
17	of	O
18	structural	O
19	homologies	O
20	with	O
21	the	O
22	diphtheria	O
23	toxin	O
24	repressor	O
25	.	O

0	At	O
1	visit	O
2	5	O
3	,	O
4	the	O
5	isokinetic	O
6	test	O
7	showed	O
8	impaired	O
9	muscle	O
10	function	O
11	recovery	O
12	from	O
13	23	O
14	%	O
15	to	O
16	32	O
17	%,	O
18	while	O
19	the	O
20	manual	O
21	test	O
22	showed	O
23	almost	O
24	full	O
25	recovery	O
26	.	O

0	Constitutive	O
1	phosphorylation	O
2	and	O
3	nuclear	O
4	localization	O
5	of	O
6	Smad3	O
7	are	O
8	correlated	O
9	with	O
10	increased	O
11	collagen	O
12	gene	O
13	transcription	O
14	in	O
15	activated	O
16	hepatic	O
17	stellate	O
18	cells	O
19	.	O

0	Cholesteryl	O
1	ester	O
2	transfer	O
3	protein	O
4	and	O
5	atherosclerosis	O
6	in	O
7	Japanese	O
8	subjects	O
9	:	O
10	a	O
11	study	O
12	based	O
13	on	O
14	coronary	O
15	angiography	O
16	.	O

0	And	O
1	,	O
2	most	O
3	importantly	O
4	,	O
5	reconstitution	O
6	of	O
7	a	O
8	consensus	O
9	CRE	O
10	,	O
11	within	O
12	the	O
13	21	O
14	-	O
15	bp	O
16	enhancers	O
17	increases	O
18	binding	O
19	of	O
20	CREB	O
21	/	O
22	ATF	O
23	proteins	O
24	but	O
25	abrogates	O
26	basal	O
27	repression	O
28	of	O
29	LTR	O
30	-	O
31	directed	O
32	transcription	O
33	in	O
34	vitro	O
35	.	O

0	Stable	O
1	transfection	O
2	of	O
3	human	O
4	CHOP	O
5	cDNA	O
6	into	O
7	mammary	O
8	carcinoma	O
9	cells	O
10	demonstrated	O
11	that	O
12	CHOP	O
13	functioned	O
14	not	O
15	as	O
16	a	O
17	mediator	O
18	of	O
19	hGH	O
20	-	O
21	stimulated	O
22	mitogenesis	O
23	but	O
24	rather	O
25	enhanced	O
26	the	O
27	protection	O
28	from	O
29	apoptosis	O
30	afforded	O
31	by	O
32	hGH	O
33	in	O
34	a	O
35	p38	O
36	MAPK	O
37	-	O
38	dependent	O
39	manner	O
40	.	O

0	The	O
1	combination	O
2	of	O
3	ifosfamide	O
4	,	O
5	epirubicin	O
6	and	O
7	etoposide	O
8	(	O
9	IEV	O
10	)	O
11	is	O
12	an	O
13	effective	O
14	salvage	O
15	regimen	O
16	for	O
17	lymphoproliferative	O
18	disease	O
19	.	O

0	Interestingly	O
1	,	O
2	the	O
3	activity	O
4	of	O
5	IkappaB	O
6	kinase	O
7	(	O
8	IKK	O
9	-	O
10	beta	O
11	),	O
12	which	O
13	plays	O
14	an	O
15	essential	O
16	role	O
17	in	O
18	NF	O
19	-	O
20	kappaB	O
21	activation	O
22	through	O
23	IkappaB	O
24	phosphorylation	O
25	,	O
26	was	O
27	largely	O
28	enhanced	O
29	in	O
30	paclitaxel	O
31	-	O
32	treated	O
33	cells	O
34	,	O
35	detected	O
36	as	O
37	IkappaBalpha	O
38	phosphorylation	O
39	.	O

0	The	O
1	recessive	O
2	hos1	O
3	mutation	O
4	causes	O
5	enhanced	O
6	induction	O
7	of	O
8	the	O
9	CBF	O
10	transcription	O
11	factors	O
12	by	O
13	low	O
14	temperature	O
15	as	O
16	well	O
17	as	O
18	of	O
19	their	O
20	downstream	O
21	cold	O
22	-	O
23	responsive	O
24	genes	O
25	.	O

0	Apart	O
1	from	O
2	antimicrobial	O
3	properties	O
4	,	O
5	recent	O
6	data	O
7	indicate	O
8	that	O
9	PMN	O
10	also	O
11	exert	O
12	anti	O
13	-	O
14	inflammatory	O
15	effects	O
16	by	O
17	stimulation	O
18	and	O
19	release	O
20	of	O
21	cytokine	O
22	antagonists	O
23	such	O
24	as	O
25	interleukin	O
26	-	O
27	1	O
28	receptor	O
29	antagonist	O
30	(	O
31	IL	O
32	-	O
33	1ra	O
34	).	O

0	Early	O
1	indicators	O
2	of	O
3	the	O
4	effect	O
5	of	O
6	a	O
7	breast	O
8	cancer	O
9	screening	O
10	program	O
11	for	O
12	low	O
13	-	O
14	income	O
15	women	O
16	.	O

0	An	O
1	association	O
2	was	O
3	demonstrated	O
4	between	O
5	the	O
6	expression	O
7	of	O
8	aberrantly	O
9	and	O
10	/	O
11	or	O
12	alternatively	O
13	spliced	O
14	mdm2	O
15	mRNAs	O
16	and	O
17	a	O
18	lack	O
19	of	O
20	progesterone	O
21	receptor	O
22	.	O

0	BACKGROUND	O
1	:	O
2	Dermoscopy	O
3	is	O
4	a	O
5	noninvasive	O
6	technique	O
7	that	O
8	increases	O
9	the	O
10	diagnostic	O
11	accuracy	O
12	of	O
13	pigmented	O
14	skin	O
15	lesions	O
16	,	O
17	particularly	O
18	improving	O
19	the	O
20	diagnosis	O
21	of	O
22	patients	O
23	with	O
24	cutaneous	O
25	melanoma	O
26	in	O
27	situ	O
28	(	O
29	CMIS	O
30	)	O
31	and	O
32	early	O
33	invasive	O
34	melanoma	O
35	.	O

0	Increased	O
1	erythropoietin	O
2	synthesis	O
3	in	O
4	patients	O
5	with	O
6	COLD	O
7	or	O
8	left	O
9	heart	O
10	failure	O
11	is	O
12	related	O
13	to	O
14	alterations	O
15	in	O
16	renal	O
17	haemodynamics	O
18	.	O

0	The	O
1	(	O
2	two	O
3	-	O
4	motif	O
5	)	O
6	domain	O
7	fold	O
8	contains	O
9	a	O
10	pair	O
11	of	O
12	calcium	O
13	binding	O
14	sites	O
15	very	O
16	similar	O
17	to	O
18	those	O
19	found	O
20	in	O
21	a	O
22	two	O
23	-	O
24	domain	O
25	prokaryotic	O
26	betagamma	O
27	-	O
28	crystallin	O
29	fold	O
30	family	O
31	member	O
32	,	O
33	Protein	O
34	S	O
35	.	O

0	Twenty	O
1	-	O
2	five	O
3	patients	O
4	also	O
5	received	O
6	PET	O
7	examinations	O
8	during	O
9	the	O
10	staging	O
11	procedures	O
12	.	O

0	In	O
1	the	O
2	last	O
3	case	O
4	,	O
5	both	O
6	hydroxychloroquine	O
7	,	O
8	carbamazepine	O
9	and	O
10	fluvoxamine	O
11	had	O
12	a	O
13	common	O
14	imputability	O
15	which	O
16	was	O
17	plausible	O
18	.	O

0	In	O
1	all	O
2	of	O
3	these	O
4	cases	O
5	,	O
6	expression	O
7	of	O
8	the	O
9	implicated	O
10	genes	O
11	was	O
12	absent	O
13	.	O

0	A	O
1	subset	O
2	of	O
3	patients	O
4	(	O
5	n	O
6	=	O
7	30	O
8	)	O
9	underwent	O
10	multichannel	O
11	pressure	O
12	flow	O
13	studies	O
14	,	O
15	which	O
16	demonstrated	O
17	that	O
18	transrectal	O
19	HIFU	O
20	reduces	O
21	bladder	O
22	outflow	O
23	obstruction	O
24	.	O

0	Biochemical	O
1	experiments	O
2	have	O
3	shown	O
4	that	O
5	CopG	O
6	co	O
7	-	O
8	operatively	O
9	associates	O
10	to	O
11	its	O
12	target	O
13	DNA	O
14	at	O
15	low	O
16	protein	O
17	:	O
18	DNA	O
19	ratios	O
20	,	O
21	completely	O
22	protecting	O
23	four	O
24	helical	O
25	turns	O
26	on	O
27	the	O
28	same	O
29	face	O
30	of	O
31	the	O
32	double	O
33	helix	O
34	in	O
35	both	O
36	directions	O
37	from	O
38	the	O
39	inverted	O
40	repeat	O
41	that	O
42	constitutes	O
43	the	O
44	CopG	O
45	primary	O
46	target	O
47	.	O

0	The	O
1	mechanism	O
2	of	O
3	ligand	O
4	-	O
5	activated	O
6	estrogen	O
7	receptor	O
8	alpha	O
9	(	O
10	ERalpha	O
11	)-	O
12	dependent	O
13	activation	O
14	of	O
15	gene	O
16	expression	O
17	through	O
18	the	O
19	SRE	O
20	was	O
21	determined	O
22	by	O
23	mutational	O
24	analysis	O
25	of	O
26	the	O
27	promoter	O
28	,	O
29	analysis	O
30	of	O
31	mitogen	O
32	-	O
33	activated	O
34	protein	O
35	kinase	O
36	(	O
37	MAPK	O
38	)	O
39	pathway	O
40	activation	O
41	by	O
42	E2	O
43	,	O
44	and	O
45	transforming	O
46	growth	O
47	factor	O
48	alpha	O
49	(	O
50	TGF	O
51	-	O
52	alpha	O
53	)	O
54	as	O
55	a	O
56	positive	O
57	control	O
58	.	O

0	This	O
1	study	O
2	investigated	O
3	whether	O
4	boron	O
5	would	O
6	enhance	O
7	the	O
8	ability	O
9	of	O
10	17beta	O
11	-	O
12	estradiol	O
13	(	O
14	E2	O
15	)	O
16	or	O
17	parathyroid	O
18	hormone	O
19	(	O
20	PTH	O
21	)	O
22	to	O
23	improve	O
24	bone	O
25	quality	O
26	in	O
27	ovariectomized	O
28	OVX	O
29	rats	O
30	.	O

0	2001	O
1	.	O

0	The	O
1	Gap69C	O
2	is	O
3	a	O
4	single	O
5	-	O
6	copy	O
7	gene	O
8	producing	O
9	a	O
10	major	O
11	2	O
12	.	O
13	1	O
14	-	O
15	kb	O
16	mRNA	O
17	throughout	O
18	development	O
19	,	O
20	but	O
21	its	O
22	amount	O
23	is	O
24	decreased	O
25	in	O
26	larvae	O
27	.	O

0	In	O
1	the	O
2	long	O
3	term	O
4	,	O
5	questions	O
6	still	O
7	remain	O
8	about	O
9	whether	O
10	pre	O
11	-	O
12	dialysis	O
13	rHu	O
14	EPO	O
15	either	O
16	speeds	O
17	up	O
18	or	O
19	delays	O
20	the	O
21	onset	O
22	of	O
23	dialysis	O
24	.	O

0	The	O
1	validity	O
2	of	O
3	the	O
4	FPS	O
5	-	O
6	R	O
7	was	O
8	further	O
9	supported	O
10	by	O
11	strong	O
12	positive	O
13	correlations	O
14	with	O
15	the	O
16	VAS	O
17	(	O
18	r	O
19	=	O
20	0	O
21	.	O
22	92	O
23	,	O
24	N	O
25	=	O
26	45	O
27	)	O
28	and	O
29	the	O
30	CAS	O
31	(	O
32	r	O
33	=	O
34	0	O
35	.	O
36	84	O
37	,	O
38	N	O
39	=	O
40	45	O
41	)	O
42	in	O
43	this	O
44	clinical	O
45	sample	O
46	.	O

0	The	O
1	BFA	O
2	System	O
3	reads	O
4	a	O
5	text	O
6	file	O
7	with	O
8	flows	O
9	,	O
10	measured	O
11	with	O
12	fluorescent	O
13	microsphere	O
14	technique	O
15	,	O
16	and	O
17	constructs	O
18	the	O
19	lung	O
20	anatomy	O
21	with	O
22	volumetric	O
23	pixels	O
24	showing	O
25	the	O
26	flows	O
27	with	O
28	a	O
29	color	O
30	schema	O
31	.	O

0	Therefore	O
1	,	O
2	to	O
3	understand	O
4	how	O
5	ErbB1	O
6	/	O
7	ErbB2	O
8	signaling	O
9	contributes	O
10	to	O
11	this	O
12	process	O
13	,	O
14	we	O
15	used	O
16	the	O
17	ErbB	O
18	kinase	O
19	inhibitor	O
20	AG1478in	O
21	ErbB2	O
22	-	O
23	dependent	O
24	BT	O
25	-	O
26	474	O
27	and	O
28	SKBR	O
29	-	O
30	3	O
31	human	O
32	breast	O
33	cancer	O
34	cells	O
35	.	O

0	Deletion	O
1	analyses	O
2	implicate	O
3	the	O
4	N	O
5	-	O
6	terminal	O
7	110	O
8	amino	O
9	acids	O
10	of	O
11	Grb14	O
12	and	O
13	ankyrin	O
14	repeats	O
15	10	O
16	-	O
17	19	O
18	of	O
19	tankyrase	O
20	2	O
21	in	O
22	mediating	O
23	this	O
24	interaction	O
25	.	O

0	Hormonal	O
1	regulation	O
2	of	O
3	multiple	O
4	promoters	O
5	of	O
6	the	O
7	rat	O
8	mitochondrial	O
9	glycerol	O
10	-	O
11	3	O
12	-	O
13	phosphate	O
14	dehydrogenase	O
15	gene	O
16	:	O
17	identification	O
18	of	O
19	a	O
20	complex	O
21	hormone	O
22	-	O
23	response	O
24	element	O
25	in	O
26	the	O
27	ubiquitous	O
28	promoter	O
29	B	O
30	.	O

0	SAMPLE	O
1	POPULATION	O
2	:	O
3	MCB	O
4	from	O
5	7	O
6	racing	O
7	Greyhounds	O
8	euthanatized	O
9	for	O
10	reasons	O
11	unrelated	O
12	to	O
13	MCB	O
14	abnormalities	O
15	.	O

0	Structural	O
1	studies	O
2	have	O
3	shown	O
4	that	O
5	class	O
6	I	O
7	major	O
8	histocompatibility	O
9	complex	O
10	(	O
11	MHC	O
12	)-	O
13	restricted	O
14	peptide	O
15	-	O
16	specific	O
17	T	O
18	cell	O
19	receptor	O
20	(	O
21	TCR	O
22	)-	O
23	alpha	O
24	/	O
25	betas	O
26	make	O
27	multiple	O
28	contacts	O
29	with	O
30	the	O
31	alpha1	O
32	and	O
33	alpha2	O
34	helices	O
35	of	O
36	the	O
37	MHC	O
38	,	O
39	but	O
40	it	O
41	is	O
42	unclear	O
43	which	O
44	or	O
45	how	O
46	many	O
47	of	O
48	these	O
49	interactions	O
50	contribute	O
51	to	O
52	functional	O
53	binding	O
54	.	O

0	Fans	O
1	in	O
2	tunnels	O
3	and	O
4	open	O
5	windows	O
6	at	O
7	aboveground	O
8	locations	O
9	appeared	O
10	to	O
11	greatly	O
12	reduce	O
13	the	O
14	likelihood	O
15	of	O
16	high	O
17	PH3	O
18	concentrations	O
19	in	O
20	enclosed	O
21	areas	O
22	.	O

0	In	O
1	DNA	O
2	strand	O
3	exchange	O
4	reactions	O
5	using	O
6	oligonucleotides	O
7	,	O
8	we	O
9	found	O
10	that	O
11	Rec2	O
12	exhibited	O
13	a	O
14	pairing	O
15	bias	O
16	that	O
17	is	O
18	opposite	O
19	that	O
20	of	O
21	RecA	O
22	.	O

0	A	O
1	major	O
2	mechanism	O
3	by	O
4	which	O
5	estrogens	O
6	prevent	O
7	osteoporosis	O
8	seems	O
9	to	O
10	be	O
11	repression	O
12	of	O
13	transcription	O
14	of	O
15	NF	O
16	-	O
17	kappa	O
18	B	O
19	target	O
20	genes	O
21	,	O
22	such	O
23	as	O
24	the	O
25	osteoclast	O
26	-	O
27	activating	O
28	cytokines	O
29	interleukin	O
30	-	O
31	6	O
32	and	O
33	interleukin	O
34	-	O
35	1	O
36	.	O

0	Linear	O
1	eight	O
2	-	O
3	or	O
4	nine	O
5	-	O
6	residue	O
7	D	O
8	-	O
9	peptides	O
10	derived	O
11	from	O
12	the	O
13	pocket	O
14	-	O
15	binding	O
16	domain	O
17	of	O
18	the	O
19	cyclic	O
20	molecules	O
21	also	O
22	bind	O
23	specifically	O
24	.	O

0	As	O
1	expected	O
2	,	O
3	homologous	O
4	loxP	O
5	sequences	O
6	efficiently	O
7	underwent	O
8	Cre	O
9	-	O
10	mediated	O
11	recombination	O
12	.	O

0	Multistage	O
1	models	O
2	and	O
3	the	O
4	A	O
5	-	O
6	bomb	O
7	survivor	O
8	data	O
9	:	O
10	implications	O
11	for	O
12	carcinogenic	O
13	mechanisms	O
14	?	O

0	The	O
1	results	O
2	indicate	O
3	that	O
4	a	O
5	more	O
6	differentiated	O
7	diagnosis	O
8	of	O
9	the	O
10	molar	O
11	relationship	O
12	will	O
13	allow	O
14	for	O
15	a	O
16	more	O
17	causally	O
18	directed	O
19	correction	O
20	of	O
21	Class	O
22	II	O
23	molar	O
24	relationship	O
25	.	O

0	It	O
1	is	O
2	surprising	O
3	that	O
4	dnaE173	O
5	,	O
6	a	O
7	potent	O
8	mutator	O
9	mutation	O
10	specific	O
11	for	O
12	sequence	O
13	substitution	O
14	as	O
15	well	O
16	as	O
17	single	O
18	-	O
19	base	O
20	frameshift	O
21	,	O
22	did	O
23	not	O
24	enhance	O
25	the	O
26	frequency	O
27	of	O
28	the	O
29	hot	O
30	-	O
31	spot	O
32	frameshift	O
33	mutation	O
34	.	O

0	Hypercalcemia	O
1	associated	O
2	with	O
3	elevated	O
4	serum	O
5	PTH	O
6	concentration	O
7	indicating	O
8	primary	O
9	hyperparathyroidism	O
10	was	O
11	found	O
12	in	O
13	7	O
14	BC	O
15	patients	O
16	(	O
17	7	O
18	%)	O
19	and	O
20	in	O
21	none	O
22	of	O
23	healthy	O
24	women	O
25	or	O
26	patients	O
27	with	O
28	thyroid	O
29	cancer	O
30	.	O

0	[	O
1	figure	O
2	:	O
3	see	O
4	text	O
5	]	O
6	The	O
7	Stille	O
8	coupling	O
9	reaction	O
10	has	O
11	been	O
12	performed	O
13	in	O
14	1	O
15	-	O
16	butyl	O
17	-	O
18	3	O
19	-	O
20	methylimidazolium	O
21	tetrafluoroborate	O
22	(	O
23	BMIM	O
24	BF4	O
25	),	O
26	a	O
27	room	O
28	-	O
29	temperature	O
30	ionic	O
31	liquid	O
32	(	O
33	RTIL	O
34	).	O

0	Examination	O
1	of	O
2	various	O
3	promoter	O
4	deletion	O
5	mutants	O
6	indicated	O
7	that	O
8	SF	O
9	-	O
10	1	O
11	acts	O
12	through	O
13	the	O
14	proximal	O
15	promoter	O
16	region	O
17	and	O
18	upstream	O
19	promoter	O
20	sequences	O
21	.	O

0	ORF1	O
1	(	O
2	1029	O
3	bp	O
4	;	O
5	EMBL	O
6	databank	O
7	,	O
8	Accession	O
9	No	O
10	.	O

0	Vector	O
1	stocks	O
2	containing	O
3	envelope	O
4	proteins	O
5	from	O
6	three	O
7	different	O
8	SIVmac	O
9	clones	O
10	,	O
11	namely	O
12	,	O
13	SIVmac239	O
14	(	O
15	T	O
16	-	O
17	lymphocyte	O
18	tropic	O
19	[	O
20	T	O
21	-	O
22	tropic	O
23	]),	O
24	SIVmac316	O
25	(	O
26	macrophage	O
27	tropic	O
28	[	O
29	M	O
30	-	O
31	tropic	O
32	]),	O
33	and	O
34	SIVmac1A11	O
35	(	O
36	dualtropic	O
37	),	O
38	were	O
39	tested	O
40	.	O

0	ISS	O
1	and	O
2	the	O
3	acute	O
4	physiology	O
5	and	O
6	chronic	O
7	health	O
8	evaluation	O
9	(	O
10	APACHE	O
11	II	O
12	)	O
13	calculated	O
14	on	O
15	admission	O
16	.	O

0	Ga	O
1	-	O
2	67	O
3	and	O
4	Tl	O
5	-	O
6	201	O
7	scintigraphy	O
8	in	O
9	extramedullary	O
10	plasmacytoma	O
11	:	O
12	a	O
13	case	O
14	report	O
15	.	O

0	Finally	O
1	,	O
2	there	O
3	are	O
4	a	O
5	growing	O
6	number	O
7	of	O
8	arguments	O
9	favouring	O
10	the	O
11	use	O
12	of	O
13	ACE	O
14	inhibitors	O
15	very	O
16	early	O
17	in	O
18	patients	O
19	with	O
20	diabetes	O
21	mellitus	O
22	.	O

0	This	O
1	paper	O
2	describes	O
3	the	O
4	results	O
5	of	O
6	an	O
7	initial	O
8	study	O
9	on	O
10	the	O
11	application	O
12	of	O
13	linear	O
14	solvation	O
15	energy	O
16	relationships	O
17	(	O
18	LSERs	O
19	)	O
20	to	O
21	the	O
22	prediction	O
23	of	O
24	internal	O
25	standard	O
26	compounds	O
27	in	O
28	reversed	O
29	-	O
30	phase	O
31	liquid	O
32	chromatographic	O
33	(	O
34	RPLC	O
35	)	O
36	method	O
37	development	O
38	.	O

0	A	O
1	38	O
2	-	O
3	year	O
4	-	O
5	old	O
6	woman	O
7	with	O
8	ulcerative	O
9	colitis	O
10	subsequently	O
11	developed	O
12	sarcoidosis	O
13	.	O

0	Blood	O
1	from	O
2	dams	O
3	was	O
4	collected	O
5	prior	O
6	to	O
7	inoculation	O
8	and	O
9	at	O
10	time	O
11	of	O
12	necropsy	O
13	for	O
14	measurement	O
15	of	O
16	IgM	O
17	and	O
18	IgG	O
19	antibodies	O
20	to	O
21	M	O
22	.	O
23	pulmonis	O
24	.	O

0	She	O
1	has	O
2	since	O
3	developed	O
4	a	O
5	positive	O
6	anti	O
7	-	O
8	cardiolipin	O
9	antibody	O
10	but	O
11	does	O
12	not	O
13	meet	O
14	diagnostic	O
15	criteria	O
16	for	O
17	systemic	O
18	lupus	O
19	erythematosis	O
20	.	O
21	CONCLUSION	O
22	:	O
23	The	O
24	presence	O
25	of	O
26	known	O
27	autoimmune	O
28	disease	O
29	in	O
30	a	O
31	woman	O
32	with	O
33	POF	O
34	should	O
35	not	O
36	dissuade	O
37	the	O
38	clinician	O
39	from	O
40	evaluating	O
41	for	O
42	a	O
43	potential	O
44	genetic	O
45	cause	O
46	.	O

0	The	O
1	mutation	O
2	experiments	O
3	showed	O
4	that	O
5	the	O
6	most	O
7	critical	O
8	sequence	O
9	for	O
10	the	O
11	repression	O
12	of	O
13	PTH	O
14	was	O
15	5	O
16	'-	O
17	GGGGGAGGGGAG	O
18	-	O
19	3	O
20	'	O
21	(+	O
22	1	O
23	to	O
24	+	O
25	12	O
26	)	O
27	of	O
28	PTHSR	O
29	.	O

0	Thus	O
1	,	O
2	while	O
3	the	O
4	folds	O
5	of	O
6	all	O
7	Myb	O
8	domains	O
9	resemble	O
10	each	O
11	other	O
12	closely	O
13	,	O
14	the	O
15	function	O
16	of	O
17	each	O
18	Myb	O
19	domain	O
20	depends	O
21	on	O
22	the	O
23	amino	O
24	acid	O
25	residues	O
26	that	O
27	are	O
28	located	O
29	on	O
30	the	O
31	surface	O
32	of	O
33	each	O
34	protein	O
35	.	O

0	A	O
1	cDNA	O
2	clone	O
3	encoding	O
4	C2H2	O
5	-	O
6	type	O
7	zinc	O
8	finger	O
9	protein	O
10	,	O
11	SCOF	O
12	-	O
13	1	O
14	,	O
15	was	O
16	isolated	O
17	from	O
18	soybean	O
19	.	O

0	The	O
1	purpose	O
2	of	O
3	this	O
4	study	O
5	was	O
6	to	O
7	evaluate	O
8	simplified	O
9	methods	O
10	for	O
11	estimation	O
12	of	O
13	Technetium	O
14	Tc	O
15	99m	O
16	(	O
17	99mTc	O
18	)-	O
19	pentetate	O
20	and	O
21	orthoiodohippurate	O
22	I	O
23	131	O
24	(	O
25	131I	O
26	-	O
27	OIH	O
28	)	O
29	plasma	O
30	clearance	O
31	in	O
32	dogs	O
33	and	O
34	cats	O
35	with	O
36	1	O
37	and	O
38	2	O
39	blood	O
40	samples	O
41	.	O

0	Sevelamer	O
1	hydrochloride	O
2	(	O
3	Renagel	O
4	)	O
5	is	O
6	a	O
7	nonabsorbed	O
8	phosphate	O
9	-	O
10	binding	O
11	polymer	O
12	marketed	O
13	for	O
14	the	O
15	treatment	O
16	of	O
17	hyperphosphatemia	O
18	in	O
19	adult	O
20	patients	O
21	receiving	O
22	hemodialysis	O
23	.	O

0	Using	O
1	a	O
2	novel	O
3	method	O
4	combining	O
5	chromatin	O
6	immunoprecipitation	O
7	and	O
8	genomic	O
9	array	O
10	hybridization	O
11	,	O
12	we	O
13	have	O
14	identified	O
15	a	O
16	460	O
17	-	O
18	kb	O
19	CENP	O
20	-	O
21	A	O
22	-	O
23	binding	O
24	DNA	O
25	domain	O
26	of	O
27	a	O
28	neocentromere	O
29	derived	O
30	from	O
31	the	O
32	20p12	O
33	region	O
34	of	O
35	an	O
36	invdup	O
37	(	O
38	20p	O
39	)	O
40	human	O
41	marker	O
42	chromosome	O
43	.	O

0	Cases	O
1	of	O
2	lung	O
3	cancer	O
4	with	O
5	intramedullary	O
6	metastasis	O
7	are	O
8	rare	O
9	,	O
10	especially	O
11	those	O
12	diagnosed	O
13	before	O
14	death	O
15	.	O

0	Direct	O
1	current	O
2	polarography	O
3	and	O
4	differential	O
5	pulse	O
6	polarographic	O
7	methods	O
8	have	O
9	been	O
10	developed	O
11	for	O
12	the	O
13	qualitative	O
14	as	O
15	well	O
16	as	O
17	quantitative	O
18	analysis	O
19	of	O
20	vitamin	O
21	B1	O
22	,	O
23	B2	O
24	and	O
25	B6	O
26	.	O

0	Fluorimetric	O
1	determination	O
2	of	O
3	methylmercury	O
4	as	O
5	an	O
6	ion	O
7	-	O
8	association	O
9	complex	O
10	with	O
11	rhodamine	O
12	B	O
13	in	O
14	the	O
15	presence	O
16	of	O
17	iodide	O
18	.	O

0	The	O
1	corresponding	O
2	genotype	O
3	was	O
4	determined	O
5	with	O
6	a	O
7	restriction	O
8	enzyme	O
9	-	O
10	based	O
11	assay	O
12	.	O

0	Patients	O
1	were	O
2	divided	O
3	into	O
4	two	O
5	group	O
6	;	O
7	Control	O
8	group	O
9	A	O
10	in	O
11	which	O
12	a	O
13	hot	O
14	-	O
15	water	O
16	circulating	O
17	system	O
18	was	O
19	used	O
20	and	O
21	group	O
22	B	O
23	in	O
24	which	O
25	a	O
26	transtracheal	O
27	heating	O
28	and	O
29	humidification	O
30	system	O
31	by	O
32	ANAMED	O
33	HUMITUBE	O
34	was	O
35	used	O
36	,	O
37	during	O
38	gastric	O
39	cancer	O
40	operation	O
41	.	O

0	Mental	O
1	rotation	O
2	of	O
3	paired	O
4	figures	O
5	engendered	O
6	activation	O
7	in	O
8	the	O
9	left	O
10	superior	O
11	parietal	O
12	lobule	O
13	and	O
14	the	O
15	right	O
16	frontal	O
17	medial	O
18	gyrus	O
19	.	O

0	Here	O
1	we	O
2	demonstrate	O
3	that	O
4	the	O
5	Ras	O
6	-	O
7	activated	O
8	Raf	O
9	-	O
10	MEK	O
11	-	O
12	extracellular	O
13	signal	O
14	-	O
15	regulated	O
16	kinase	O
17	(	O
18	ERK	O
19	)	O
20	signaling	O
21	pathway	O
22	can	O
23	specifically	O
24	control	O
25	the	O
26	expression	O
27	of	O
28	individual	O
29	integrin	O
30	subunits	O
31	in	O
32	a	O
33	variety	O
34	of	O
35	human	O
36	and	O
37	mouse	O
38	cell	O
39	lines	O
40	.	O

0	These	O
1	TxRE	O
2	contain	O
3	cyclic	O
4	AMP	O
5	-	O
6	responsive	O
7	elements	O
8	(	O
9	CRE	O
10	),	O
11	but	O
12	,	O
13	remarkably	O
14	,	O
15	the	O
16	"	O
17	TGACGTCA	O
18	"	O
19	consensus	O
20	is	O
21	never	O
22	strictly	O
23	conserved	O
24	in	O
25	any	O
26	viral	O
27	strain	O
28	(	O
29	e	O
30	.	O
31	g	O
32	.,	O
33	AGACGTCA	O
34	,	O
35	TGACGGCA	O
36	,	O
37	TGACCTCA	O
38	).	O

0	The	O
1	hatcher	O
2	incubators	O
3	of	O
4	both	O
5	companies	O
6	were	O
7	also	O
8	persistently	O
9	contaminated	O
10	with	O
11	Salmonella	O
12	livingstone	O
13	and	O
14	Salmonella	O
15	thomasville	O
16	in	O
17	company	O
18	A	O
19	and	O
20	with	O
21	Salmonella	O
22	senftenberg	O
23	in	O
24	company	O
25	B	O
26	.	O

0	Binding	O
1	of	O
2	cell	O
3	type	O
4	-	O
5	specific	O
6	nuclear	O
7	proteins	O
8	to	O
9	the	O
10	5	O
11	'-	O
12	flanking	O
13	region	O
14	of	O
15	maize	O
16	C4	O
17	phosphoenolpyruvate	O
18	carboxylase	O
19	gene	O
20	confers	O
21	its	O
22	differential	O
23	transcription	O
24	in	O
25	mesophyll	O
26	cells	O
27	.	O

0	Susceptibility	O
1	to	O
2	ischemia	O
3	-	O
4	induced	O
5	arrhythmias	O
6	was	O
7	lower	O
8	in	O
9	1	O
10	-	O
11	week	O
12	diabetics	O
13	:	O
14	only	O
15	42	O
16	%	O
17	of	O
18	diabetic	O
19	hearts	O
20	exhibited	O
21	ventricular	O
22	tachycardia	O
23	(	O
24	VT	O
25	)	O
26	and	O
27	16	O
28	%	O
29	had	O
30	short	O
31	episodes	O
32	of	O
33	ventricular	O
34	fibrillation	O
35	(	O
36	VF	O
37	)	O
38	as	O
39	compared	O
40	to	O
41	VT	O
42	100	O
43	%	O
44	and	O
45	VF	O
46	70	O
47	%	O
48	(	O
49	including	O
50	sustained	O
51	VF	O
52	36	O
53	%)	O
54	in	O
55	the	O
56	non	O
57	-	O
58	diabetics	O
59	(	O
60	P	O
61	<	O
62	0	O
63	.	O
64	05	O
65	).	O

0	CONCLUSIONS	O
1	:	O
2	The	O
3	methodology	O
4	of	O
5	LHR	O
6	measurement	O
7	significantly	O
8	influences	O
9	the	O
10	clinical	O
11	contribution	O
12	of	O
13	Tl	O
14	-	O
15	201	O
16	lung	O
17	uptake	O
18	evaluation	O
19	.	O

0	The	O
1	authors	O
2	made	O
3	an	O
4	analysis	O
5	of	O
6	social	O
7	-	O
8	economical	O
9	conditions	O
10	limiting	O
11	the	O
12	possibilities	O
13	of	O
14	rendering	O
15	cardiosurgical	O
16	care	O
17	to	O
18	children	O
19	.	O

0	METHODS	O
1	:	O
2	Experiments	O
3	testing	O
4	the	O
5	new	O
6	catheter	O
7	and	O
8	comparing	O
9	it	O
10	to	O
11	the	O
12	existing	O
13	catheter	O
14	included	O
15	:	O
16	(	O
17	1	O
18	)	O
19	measurement	O
20	of	O
21	the	O
22	laser	O
23	output	O
24	beam	O
25	sizes	O
26	and	O
27	divergences	O
28	;	O
29	(	O
30	2	O
31	)	O
32	evaluation	O
33	of	O
34	particulate	O
35	matter	O
36	generation	O
37	during	O
38	ablation	O
39	of	O
40	atherosclerotic	O
41	tissue	O
42	;	O
43	(	O
44	3	O
45	)	O
46	measurement	O
47	of	O
48	ablation	O
49	hole	O
50	sizes	O
51	and	O
52	tissue	O
53	penetration	O
54	rates	O
55	;	O
56	(	O
57	4	O
58	)	O
59	histopathologic	O
60	examination	O
61	of	O
62	laser	O
63	-	O
64	induced	O
65	in	O
66	vivo	O
67	vessel	O
68	wall	O
69	injury	O
70	.	O

0	The	O
1	reproductive	O
2	effects	O
3	of	O
4	the	O
5	administration	O
6	of	O
7	4	O
8	-	O
9	chloro	O
10	-	O
11	2	O
12	-	O
13	methylphenoxyacetic	O
14	acid	O
15	(	O
16	MCPA	O
17	)	O
18	to	O
19	rats	O
20	were	O
21	evaluated	O
22	through	O
23	two	O
24	generations	O
25	,	O
26	from	O
27	prior	O
28	to	O
29	mating	O
30	,	O
31	throughout	O
32	mating	O
33	,	O
34	to	O
35	gestation	O
36	and	O
37	lactation	O
38	.	O

0	Here	O
1	we	O
2	suggest	O
3	that	O
4	uvrA	O
5	and	O
6	the	O
7	nucleotide	O
8	excision	O
9	repair	O
10	pathway	O
11	are	O
12	involved	O
13	in	O
14	the	O
15	repair	O
16	of	O
17	acid	O
18	-	O
19	induced	O
20	DNA	O
21	damage	O
22	and	O
23	are	O
24	associated	O
25	with	O
26	successful	O
27	adaptation	O
28	of	O
29	S	O
30	.	O
31	mutans	O
32	to	O
33	low	O
34	pH	O
35	.	O

0	The	O
1	improved	O
2	CSF	O
3	outflow	O
4	conductance	O
5	may	O
6	increase	O
7	the	O
8	intracranial	O
9	compliance	O
10	and	O
11	thereby	O
12	dampen	O
13	a	O
14	pathological	O
15	ICP	O
16	waveform	O
17	.	O

0	These	O
1	studies	O
2	demonstrate	O
3	that	O
4	site	O
5	-	O
6	specific	O
7	recognition	O
8	of	O
9	the	O
10	bxd	O
11	PRE	O
12	by	O
13	d	O
14	(	O
15	GA	O
16	)(	O
17	n	O
18	)	O
19	repeat	O
20	binding	O
21	activities	O
22	mediates	O
23	PcG	O
24	-	O
25	dependent	O
26	silencing	O
27	.	O

0	The	O
1	gonadotrope	O
2	-	O
3	specific	O
4	and	O
5	regulated	O
6	expression	O
7	of	O
8	the	O
9	GnRH	O
10	receptor	O
11	(	O
12	GnRH	O
13	-	O
14	R	O
15	)	O
16	gene	O
17	is	O
18	dependent	O
19	on	O
20	multiple	O
21	transcription	O
22	factors	O
23	that	O
24	interact	O
25	with	O
26	the	O
27	noncanonical	O
28	GnRH	O
29	-	O
30	R	O
31	activating	O
32	sequence	O
33	(	O
34	GRAS	O
35	),	O
36	the	O
37	activator	O
38	protein	O
39	-	O
40	1	O
41	(	O
42	AP	O
43	-	O
44	1	O
45	)	O
46	element	O
47	,	O
48	and	O
49	the	O
50	steroidogenic	O
51	factor	O
52	-	O
53	1	O
54	(	O
55	SF	O
56	-	O
57	1	O
58	)	O
59	binding	O
60	site	O
61	.	O

0	Before	O
1	PO3	O
2	administration	O
3	,	O
4	more	O
5	than	O
6	half	O
7	(	O
8	57	O
9	.	O
10	4	O
11	%)	O
12	of	O
13	the	O
14	patients	O
15	received	O
16	only	O
17	1	O
18	or	O
19	2	O
20	antituberculous	O
21	drugs	O
22	(	O
23	ethambutole	O
24	and	O
25	ethionamide	O
26	or	O
27	ethambutole	O
28	and	O
29	oprofloxacin	O
30	).	O

0	Using	O
1	the	O
2	presented	O
3	categorical	O
4	structure	O
5	as	O
6	domain	O
7	model	O
8	a	O
9	prototype	O
10	DSS	O
11	for	O
12	dipslide	O
13	urine	O
14	cultures	O
15	has	O
16	been	O
17	developed	O
18	.	O

0	Conclusion	O
1	:	O
2	The	O
3	Lp	O
4	(	O
5	a	O
6	)	O
7	levels	O
8	in	O
9	these	O
10	children	O
11	were	O
12	the	O
13	lower	O
14	ever	O
15	reported	O
16	.	O

0	Foxp1	O
1	and	O
2	Foxp2	O
3	are	O
4	expressed	O
5	at	O
6	high	O
7	levels	O
8	in	O
9	the	O
10	lung	O
11	as	O
12	early	O
13	as	O
14	E12	O
15	.	O
16	5	O
17	of	O
18	mouse	O
19	development	O
20	with	O
21	Foxp2	O
22	expression	O
23	restricted	O
24	to	O
25	the	O
26	airway	O
27	epithelium	O
28	.	O

0	Audiological	O
1	findings	O
2	in	O
3	pregnancy	O
4	.	O

0	Children	O
1	who	O
2	developed	O
3	lower	O
4	respiratory	O
5	tract	O
6	infections	O
7	or	O
8	PCP	O
9	had	O
10	increased	O
11	rates	O
12	of	O
13	decline	O
14	of	O
15	CD4	O
16	cell	O
17	counts	O
18	during	O
19	the	O
20	first	O
21	6	O
22	months	O
23	of	O
24	life	O
25	.	O

0	A	O
1	randomized	O
2	mix	O
3	of	O
4	180	O
5	sections	O
6	(	O
7	10	O
8	samples	O
9	x	O
10	3	O
11	tissues	O
12	x	O
13	3	O
14	stains	O
15	x	O
16	2	O
17	)	O
18	gave	O
19	90	O
20	matched	O
21	pairs	O
22	.	O

0	Sural	O
1	nerve	O
2	biopsy	O
3	showed	O
4	mild	O
5	thickening	O
6	of	O
7	the	O
8	perineurium	O
9	,	O
10	vascular	O
11	alterations	O
12	with	O
13	inflammatory	O
14	cell	O
15	infiltration	O
16	in	O
17	the	O
18	perineurium	O
19	,	O
20	and	O
21	remarkable	O
22	loss	O
23	of	O
24	large	O
25	and	O
26	small	O
27	myelinated	O
28	fibers	O
29	.	O

0	OBJECTIVES	O
1	:	O
2	The	O
3	objective	O
4	of	O
5	this	O
6	review	O
7	was	O
8	to	O
9	assess	O
10	the	O
11	effects	O
12	of	O
13	prophylactic	O
14	prostaglandin	O
15	use	O
16	in	O
17	the	O
18	third	O
19	stage	O
20	of	O
21	labour	O
22	.	O

0	Testing	O
1	was	O
2	associated	O
3	with	O
4	a	O
5	history	O
6	of	O
7	nonsexual	O
8	risk	O
9	behavior	O
10	,	O
11	increased	O
12	knowledge	O
13	of	O
14	the	O
15	hepatitis	O
16	C	O
17	virus	O
18	,	O
19	and	O
20	healthcare	O
21	provider	O
22	communication	O
23	.	O

0	Cytomegalovirus	O
1	,	O
2	Chlamydia	O
3	pneumoniae	O
4	,	O
5	and	O
6	Helicobacter	O
7	pylori	O
8	IgG	O
9	antibodies	O
10	and	O
11	restenosis	O
12	after	O
13	stent	O
14	implantation	O
15	:	O
16	an	O
17	angiographic	O
18	and	O
19	intravascular	O
20	ultrasound	O
21	study	O
22	.	O

0	A	O
1	5	O
2	-	O
3	month	O
4	-	O
5	old	O
6	infant	O
7	with	O
8	persistent	O
9	congenital	O
10	stridor	O
11	and	O
12	acute	O
13	respiratory	O
14	distress	O
15	is	O
16	presented	O
17	.	O

0	OBJECTIVE	O
1	:	O
2	To	O
3	determine	O
4	whether	O
5	RSTD	O
6	predicts	O
7	coronary	O
8	anatomy	O
9	during	O
10	acute	O
11	coronary	O
12	occlusion	O
13	.	O

0	Even	O
1	if	O
2	the	O
3	electrocardiographic	O
4	signs	O
5	are	O
6	subdued	O
7	,	O
8	the	O
9	underlying	O
10	blockade	O
11	of	O
12	I	O
13	(	O
14	Kr	O
15	)	O
16	current	O
17	may	O
18	precipitate	O
19	the	O
20	occurrence	O
21	of	O
22	arrhythmia	O
23	.	O

0	Acetoin	O
1	can	O
2	be	O
3	reused	O
4	by	O
5	the	O
6	bacteria	O
7	during	O
8	stationary	O
9	phase	O
10	when	O
11	other	O
12	carbon	O
13	sources	O
14	have	O
15	been	O
16	depleted	O
17	.	O

0	Analysis	O
1	of	O
2	the	O
3	promoter	O
4	sequence	O
5	revealed	O
6	the	O
7	presence	O
8	of	O
9	a	O
10	major	O
11	transcriptional	O
12	start	O
13	site	O
14	,	O
15	a	O
16	canonical	O
17	TATA	O
18	box	O
19	and	O
20	putative	O
21	cis	O
22	regulatory	O
23	elements	O
24	for	O
25	pituitary	O
26	specific	O
27	expression	O
28	as	O
29	well	O
30	as	O
31	an	O
32	E	O
33	-	O
34	responsive	O
35	element	O
36	.	O

0	IL	O
1	-	O
2	1beta	O
3	was	O
4	significantly	O
5	higher	O
6	in	O
7	endometrioma	O
8	than	O
9	in	O
10	lesions	O
11	of	O
12	other	O
13	localizations	O
14	.	O

0	An	O
1	economic	O
2	analysis	O
3	using	O
4	West	O
5	of	O
6	Scotland	O
7	Coronary	O
8	Prevention	O
9	Study	O
10	(	O
11	WOSCOPS	O
12	)	O
13	findings	O
14	indicates	O
15	that	O
16	statin	O
17	treatment	O
18	would	O
19	have	O
20	prevented	O
21	318	O
22	events	O
23	per	O
24	10	O
25	,	O
26	000	O
27	patients	O
28	in	O
29	a	O
30	population	O
31	similar	O
32	to	O
33	that	O
34	in	O
35	WOSCOPS	O
36	(	O
37	average	O
38	1	O
39	.	O
40	5	O
41	%	O
42	annual	O
43	risk	O
44	of	O
45	a	O
46	cardiovascular	O
47	event	O
48	)	O
49	at	O
50	a	O
51	discounted	O
52	cost	O
53	per	O
54	life	O
55	-	O
56	year	O
57	gained	O
58	of	O
59	20	O
60	,	O
61	375	O
62	pounds	O
63	($	O
64	31	O
65	,	O
66	818	O
67	).	O

0	Hydrogels	O
1	for	O
2	tissue	O
3	engineering	O
4	.	O

0	No	O
1	mutation	O
2	of	O
3	the	O
4	NRL	O
5	gene	O
6	was	O
7	found	O
8	in	O
9	any	O
10	of	O
11	the	O
12	two	O
13	families	O
14	.	O

0	However	O
1	,	O
2	most	O
3	produced	O
4	significant	O
5	alteration	O
6	of	O
7	small	O
8	intestinal	O
9	permeability	O
10	.	O

0	Our	O
1	results	O
2	show	O
3	that	O
4	CVN	O
5	specifically	O
6	recognizes	O
7	with	O
8	nanomolar	O
9	affinity	O
10	Man	O
11	(	O
12	9	O
13	)	O
14	GlcNAc	O
15	(	O
16	2	O
17	)	O
18	and	O
19	the	O
20	D1D3	O
21	isomer	O
22	of	O
23	Man	O
24	(	O
25	8	O
26	)	O
27	GlcNAc	O
28	(	O
29	2	O
30	).	O

0	Saccharomyces	O
1	cerevisiae	O
2	activates	O
3	a	O
4	regulatory	O
5	network	O
6	called	O
7	"	O
8	general	O
9	control	O
10	"	O
11	that	O
12	provides	O
13	the	O
14	cell	O
15	with	O
16	sufficient	O
17	amounts	O
18	of	O
19	protein	O
20	precursors	O
21	during	O
22	amino	O
23	acid	O
24	starvation	O
25	.	O

0	In	O
1	Saccharomyces	O
2	cerevisiae	O
3	,	O
4	entry	O
5	into	O
6	mitosis	O
7	requires	O
8	activation	O
9	of	O
10	the	O
11	cyclin	O
12	-	O
13	dependent	O
14	kinase	O
15	Cdc28	O
16	in	O
17	its	O
18	cyclin	O
19	B	O
20	(	O
21	Clb	O
22	)-	O
23	associated	O
24	form	O
25	.	O

0	Data	O
1	from	O
2	in	O
3	vitro	O
4	splicing	O
5	assays	O
6	,	O
7	UV	O
8	crosslinking	O
9	and	O
10	RNA	O
11	-	O
12	binding	O
13	competition	O
14	experiments	O
15	indicates	O
16	a	O
17	strong	O
18	correlation	O
19	between	O
20	the	O
21	binding	O
22	affinities	O
23	of	O
24	PSI	O
25	for	O
26	the	O
27	SELEX	O
28	sequences	O
29	and	O
30	their	O
31	ability	O
32	to	O
33	modulate	O
34	splicing	O
35	of	O
36	P	O
37	element	O
38	IVS3	O
39	in	O
40	vitro	O
41	.	O

0	The	O
1	sensitivity	O
2	of	O
3	human	O
4	neuroblastoma	O
5	cells	O
6	SK	O
7	-	O
8	N	O
9	-	O
10	SH	O
11	to	O
12	undergo	O
13	apoptosis	O
14	induced	O
15	by	O
16	thapsigargin	O
17	was	O
18	examined	O
19	.	O

0	A	O
1	.,	O
2	Slatkin	O
3	,	O
4	D	O
5	.	O

0	Multiparous	O
1	women	O
2	presented	O
3	higher	O
4	BMI	O
5	(	O
6	P	O
7	=	O
8	0	O
9	.	O
10	01	O
11	)	O
12	and	O
13	PBF	O
14	(	O
15	P	O
16	=	O
17	0	O
18	.	O
19	03	O
20	)	O
21	compared	O
22	with	O
23	primi	O
24	-	O
25	and	O
26	nulliparous	O
27	groups	O
28	.	O

0	CONCLUSIONS	O
1	AND	O
2	CLINICAL	O
3	RELEVANCE	O
4	:	O
5	Increased	O
6	cortical	O
7	thickness	O
8	and	O
9	geometric	O
10	properties	O
11	of	O
12	left	O
13	MCB	O
14	-	O
15	IV	O
16	and	O
17	-	O
18	V	O
19	of	O
20	Greyhounds	O
21	,	O
22	together	O
23	with	O
24	altered	O
25	turnover	O
26	and	O
27	orientation	O
28	of	O
29	osteons	O
30	in	O
31	the	O
32	dorsal	O
33	quadrants	O
34	of	O
35	left	O
36	MCB	O
37	,	O
38	are	O
39	site	O
40	-	O
41	specific	O
42	adaptive	O
43	responses	O
44	associated	O
45	with	O
46	asymmetric	O
47	cyclic	O
48	loading	O
49	as	O
50	a	O
51	result	O
52	of	O
53	racing	O
54	on	O
55	circular	O
56	tracks	O
57	.	O

0	To	O
1	examine	O
2	transcriptional	O
3	regulation	O
4	of	O
5	the	O
6	rat	O
7	eIF4E	O
8	gene	O
9	,	O
10	2	O
11	.	O
12	1	O
13	kB	O
14	of	O
15	the	O
16	rat	O
17	eIF4E	O
18	promoter	O
19	region	O
20	was	O
21	cloned	O
22	and	O
23	the	O
24	contribution	O
25	of	O
26	specific	O
27	elements	O
28	in	O
29	regulating	O
30	transcription	O
31	was	O
32	determined	O
33	in	O
34	primary	O
35	cultures	O
36	of	O
37	rat	O
38	cardiocytes	O
39	and	O
40	in	O
41	a	O
42	murine	O
43	C	O
44	(	O
45	2	O
46	)	O
47	C	O
48	(	O
49	12	O
50	)	O
51	myoblast	O
52	cell	O
53	line	O
54	.	O

0	The	O
1	prevalence	O
2	of	O
3	tobacco	O
4	dependence	O
5	diagnosed	O
6	according	O
7	to	O
8	the	O
9	ICD	O
10	-	O
11	10	O
12	criteria	O
13	was	O
14	higher	O
15	in	O
16	alcohol	O
17	-	O
18	dependent	O
19	individuals	O
20	(	O
21	58	O
22	.	O
23	1	O
24	%)	O
25	than	O
26	in	O
27	nondrinkers	O
28	or	O
29	social	O
30	drinkers	O
31	(	O
32	12	O
33	.	O
34	8	O
35	%).	O

0	Management	O
1	of	O
2	postvitrectomy	O
3	diabetic	O
4	vitreous	O
5	hemorrhage	O
6	with	O
7	tissue	O
8	plasminogen	O
9	activator	O
10	(	O
11	t	O
12	-	O
13	PA	O
14	)	O
15	and	O
16	volume	O
17	homeostatic	O
18	fluid	O
19	-	O
20	fluid	O
21	exchanger	O
22	.	O

0	Transactivation	O
1	of	O
2	oIFNtau	O
3	enhancer	O
4	-	O
5	reporter	O
6	constructs	O
7	was	O
8	primarily	O
9	regulated	O
10	by	O
11	three	O
12	regions	O
13	containing	O
14	AP	O
15	-	O
16	1	O
17	site	O
18	,	O
19	GATA	O
20	like	O
21	sequence	O
22	and	O
23	site	O
24	(	O
25	s	O
26	)	O
27	unidentified	O
28	.	O

0	SELECTION	O
1	CRITERIA	O
2	:	O
3	Randomised	O
4	controlled	O
5	trials	O
6	of	O
7	cabergoline	O
8	versus	O
9	placebo	O
10	in	O
11	patients	O
12	with	O
13	a	O
14	clinical	O
15	diagnosis	O
16	of	O
17	idiopathic	O
18	Parkinson	O
19	'	O
20	s	O
21	disease	O
22	and	O
23	long	O
24	-	O
25	term	O
26	complications	O
27	of	O
28	levodopa	O
29	therapy	O
30	.	O

0	0	O
1	%)	O
2	and	O
3	IL	O
4	-	O
5	12	O
6	(	O
7	42	O
8	.	O
9	6	O
10	%	O
11	vs	O
12	.	O

0	Copyright	O
1	2000	O
2	John	O
3	Wiley	O
4	&	O
5	Sons	O
6	,	O
7	Ltd	O
8	.	O

0	Here	O
1	we	O
2	demonstrate	O
3	that	O
4	native	O
5	MRCK	O
6	exists	O
7	in	O
8	high	O
9	-	O
10	molecular	O
11	-	O
12	weight	O
13	complexes	O
14	.	O

0	METHODS	O
1	:	O
2	This	O
3	retrospective	O
4	review	O
5	comprised	O
6	2711	O
7	eyes	O
8	that	O
9	had	O
10	LASIK	O
11	between	O
12	September	O
13	1996	O
14	and	O
15	September	O
16	1999	O
17	.	O

0	Sixty	O
1	-	O
2	one	O
3	cases	O
4	of	O
5	cholera	O
6	,	O
7	all	O
8	caused	O
9	by	O
10	V	O
11	.	O
12	cholerae	O
13	O1	O
14	,	O
15	were	O
16	reported	O
17	.	O

0	This	O
1	could	O
2	lead	O
3	to	O
4	subsequent	O
5	outbreaks	O
6	if	O
7	Babesia	O
8	carrier	O
9	animals	O
10	were	O
11	to	O
12	be	O
13	introduced	O
14	into	O
15	the	O
16	herd	O
17	.	O

0	Instead	O
1	,	O
2	TRPS1	O
3	potently	O
4	and	O
5	specifically	O
6	represses	O
7	transcriptional	O
8	activation	O
9	mediated	O
10	by	O
11	other	O
12	GATA	O
13	factors	O
14	.	O

0	Eliminating	O
1	any	O
2	subset	O
3	of	O
4	ASCUS	O
5	reduces	O
6	the	O
7	ASCUS	O
8	/	O
9	SIL	O
10	ratio	O
11	but	O
12	also	O
13	significantly	O
14	diminishes	O
15	the	O
16	sensitivity	O
17	of	O
18	the	O
19	Papanicolaou	O
20	test	O
21	.	O

0	In	O
1	order	O
2	to	O
3	overcome	O
4	the	O
5	false	O
6	positive	O
7	readings	O
8	that	O
9	are	O
10	possible	O
11	in	O
12	sphincter	O
13	manometry	O
14	,	O
15	we	O
16	proposed	O
17	to	O
18	use	O
19	secretin	O
20	stimulated	O
21	endoscopic	O
22	ultrasound	O
23	(	O
24	SSEUS	O
25	)	O
26	to	O
27	measure	O
28	pancreatic	O
29	ductal	O
30	response	O
31	as	O
32	an	O
33	adjunctive	O
34	method	O
35	to	O
36	aid	O
37	and	O
38	supplement	O
39	the	O
40	diagnosis	O
41	.	O

0	Endovascular	O
1	aneurysm	O
2	repair	O
3	with	O
4	the	O
5	AneuRx	O
6	stent	O
7	-	O
8	graft	O
9	is	O
10	safe	O
11	,	O
12	but	O
13	is	O
14	it	O
15	effective	O
16	?	O

0	The	O
1	difference	O
2	of	O
3	hardness	O
4	over	O
5	time	O
6	of	O
7	composite	O
8	specimens	O
9	was	O
10	measured	O
11	using	O
12	Knoop	O
13	hardness	O
14	measurements	O
15	taken	O
16	at	O
17	the	O
18	top	O
19	and	O
20	bottom	O
21	surfaces	O
22	of	O
23	resin	O
24	specimens	O
25	made	O
26	in	O
27	a	O
28	Teflon	O
29	mold	O
30	the	O
31	same	O
32	dimensions	O
33	as	O
34	the	O
35	cavity	O
36	prepared	O
37	in	O
38	dentin	O
39	.	O

0	Implications	O
1	in	O
2	biomonitoring	O
3	of	O
4	the	O
5	observed	O
6	accumulation	O
7	patterns	O
8	,	O
9	especially	O
10	in	O
11	the	O
12	different	O
13	tissues	O
14	of	O
15	Posidonia	O
16	oceanica	O
17	,	O
18	are	O
19	discussed	O
20	.	O

0	Based	O
1	on	O
2	mutational	O
3	data	O
4	and	O
5	possible	O
6	mRNA	O
7	structure	O
8	,	O
9	we	O
10	hypothesized	O
11	about	O
12	the	O
13	effect	O
14	of	O
15	mRNA	O
16	structure	O
17	on	O
18	translation	O
19	of	O
20	the	O
21	two	O
22	major	O
23	C	O
24	/	O
25	EBPepsilon	O
26	isoforms	O
27	:	O
28	p32	O
29	and	O
30	p30	O
31	.	O

0	Retinoids	O
1	participate	O
2	in	O
3	the	O
4	onset	O
5	of	O
6	differentiation	O
7	,	O
8	apoptosis	O
9	and	O
10	the	O
11	inhibition	O
12	of	O
13	growth	O
14	in	O
15	a	O
16	wide	O
17	variety	O
18	of	O
19	normal	O
20	and	O
21	cancerous	O
22	cells	O
23	.	O

0	We	O
1	conclude	O
2	that	O
3	RPMS	O
4	acts	O
5	as	O
6	a	O
7	negative	O
8	regulator	O
9	of	O
10	EBNA2	O
11	and	O
12	Notch	O
13	activity	O
14	through	O
15	its	O
16	interactions	O
17	with	O
18	the	O
19	CBF1	O
20	-	O
21	associated	O
22	corepressor	O
23	complex	O
24	.	O

0	Isolated	O
1	Systolic	O
2	Hypertension	O
3	:	O
4	An	O
5	Update	O
6	.	O

0	Transfection	O
1	of	O
2	EGFP	O
3	-	O
4	tagged	O
5	DENTT	O
6	NLS	O
7	deletion	O
8	constructs	O
9	lacking	O
10	the	O
11	bipartite	O
12	NLS	O
13	-	O
14	1	O
15	were	O
16	excluded	O
17	from	O
18	the	O
19	nucleolus	O
20	.	O

0	VE	O
1	-	O
2	DEF	O
3	animals	O
4	had	O
5	significantly	O
6	higher	O
7	(	O
8	p	O
9	<	O
10	0	O
11	.	O
12	05	O
13	)	O
14	levels	O
15	of	O
16	myocardial	O
17	lipid	O
18	peroxidation	O
19	and	O
20	lower	O
21	(	O
22	p	O
23	<	O
24	0	O
25	.	O
26	05	O
27	)	O
28	protein	O
29	thiols	O
30	following	O
31	I	O
32	-	O
33	R	O
34	compared	O
35	to	O
36	the	O
37	CON	O
38	animals	O
39	.	O

0	The	O
1	position	O
2	of	O
3	the	O
4	analyst	O
5	as	O
6	expert	O
7	:	O
8	yesterday	O
9	and	O
10	today	O
11	.	O

0	Furthermore	O
1	,	O
2	we	O
3	showed	O
4	that	O
5	ERSF	O
6	including	O
7	NF	O
8	-	O
9	Y	O
10	and	O
11	ATF6alpha	O
12	and	O
13	/	O
14	or	O
15	beta	O
16	and	O
17	capable	O
18	of	O
19	binding	O
20	to	O
21	ERSE	O
22	is	O
23	indeed	O
24	formed	O
25	when	O
26	the	O
27	cellular	O
28	UPR	O
29	is	O
30	activated	O
31	.	O

0	We	O
1	performed	O
2	the	O
3	present	O
4	study	O
5	to	O
6	clarify	O
7	the	O
8	relationship	O
9	between	O
10	the	O
11	DOX	O
12	binding	O
13	ability	O
14	(%	O
15	DB	O
16	)	O
17	and	O
18	the	O
19	histologic	O
20	response	O
21	,	O
22	rate	O
23	of	O
24	decrease	O
25	in	O
26	tumor	O
27	volume	O
28	of	O
29	malignant	O
30	soft	O
31	tissue	O
32	tumors	O
33	after	O
34	preoperative	O
35	chemotherapy	O
36	and	O
37	prognosis	O
38	.	O

0	We	O
1	have	O
2	also	O
3	isolated	O
4	and	O
5	analyzed	O
6	the	O
7	5	O
8	'	O
9	flanking	O
10	region	O
11	of	O
12	the	O
13	pea	O
14	33RNP	O
15	gene	O
16	.	O

0	We	O
1	have	O
2	previously	O
3	shown	O
4	that	O
5	the	O
6	adenoviral	O
7	12S	O
8	E1A	O
9	protein	O
10	modulates	O
11	the	O
12	phosphorylation	O
13	status	O
14	of	O
15	p130	O
16	and	O
17	p107	O
18	without	O
19	apparent	O
20	changes	O
21	in	O
22	the	O
23	cell	O
24	cycle	O
25	dependent	O
26	phosphorylation	O
27	of	O
28	the	O
29	retinoblastoma	O
30	protein	O
31	.	O

0	Baseline	O
1	MBF	O
2	in	O
3	females	O
4	was	O
5	significantly	O
6	(	O
7	P	O
8	<	O
9	0	O
10	.	O
11	001	O
12	)	O
13	higher	O
14	than	O
15	in	O
16	males	O
17	.	O

0	Only	O
1	nine	O
2	patients	O
3	were	O
4	offered	O
5	surgery	O
6	(	O
7	six	O
8	were	O
9	resected	O
10	and	O
11	three	O
12	were	O
13	found	O
14	inoperable	O
15	).	O

0	The	O
1	deubiquitinating	O
2	enzyme	O
3	DUB	O
4	-	O
5	2	O
6	is	O
7	induced	O
8	in	O
9	response	O
10	to	O
11	IL	O
12	-	O
13	2	O
14	but	O
15	as	O
16	yet	O
17	its	O
18	function	O
19	has	O
20	not	O
21	been	O
22	determined	O
23	.	O

0	A	O
1	split	O
2	motor	O
3	domain	O
4	in	O
5	a	O
6	cytoplasmic	O
7	dynein	O
8	.	O

0	Immunological	O
1	and	O
2	biochemical	O
3	characterization	O
4	of	O
5	streptococcal	O
6	pyrogenic	O
7	exotoxins	O
8	I	O
9	and	O
10	J	O
11	(	O
12	SPE	O
13	-	O
14	I	O
15	and	O
16	SPE	O
17	-	O
18	J	O
19	)	O
20	from	O
21	Streptococcus	O
22	pyogenes	O
23	.	O

0	Five	O
1	modalities	O
2	of	O
3	nonpharmacologic	O
4	approaches	O
5	are	O
6	recommended	O
7	at	O
8	present	O
9	for	O
10	lifestyle	O
11	modification	O
12	and	O
13	control	O
14	of	O
15	arterial	O
16	blood	O
17	pressure	O
18	elevation	O
19	:	O
20	1	O
21	)	O
22	weight	O
23	reduction	O
24	to	O
25	ideal	O
26	body	O
27	weight	O
28	,	O
29	since	O
30	it	O
31	reduces	O
32	risk	O
33	of	O
34	hypertension	O
35	as	O
36	well	O
37	as	O
38	overall	O
39	cardiovascular	O
40	morbidity	O
41	and	O
42	mortality	O
43	;	O
44	2	O
45	)	O
46	dietary	O
47	sodium	O
48	restriction	O
49	to	O
50	less	O
51	than	O
52	2	O
53	g	O
54	a	O
55	day	O
56	,	O
57	without	O
58	assurance	O
59	that	O
60	it	O
61	will	O
62	normalize	O
63	arterial	O
64	pressure	O
65	although	O
66	it	O
67	may	O
68	help	O
69	reduce	O
70	dosage	O
71	and	O
72	numbers	O
73	of	O
74	prescribed	O
75	antihypertensive	O
76	drugs	O
77	;	O
78	3	O
79	)	O
80	moderation	O
81	of	O
82	alcohol	O
83	consumption	O
84	to	O
85	less	O
86	than	O
87	1	O
88	ounce	O
89	a	O
90	day	O
91	;	O
92	4	O
93	)	O
94	a	O
95	regular	O
96	isotonic	O
97	exercise	O
98	program	O
99	;	O
100	and	O
101	5	O
102	)	O
103	cessation	O
104	of	O
105	tobacco	O
106	consumption	O
107	.	O

0	Descriptions	O
1	of	O
2	this	O
3	locus	O
4	would	O
5	allow	O
6	comparison	O
7	with	O
8	functionally	O
9	relevant	O
10	molecular	O
11	genetic	O
12	features	O
13	of	O
14	other	O
15	species	O
16	'	O
17	homologous	O
18	loci	O
19	including	O
20	the	O
21	single	O
22	-	O
23	copy	O
24	equid	O
25	LH	O
26	/	O
27	CGbeta	O
28	gene	O
29	and	O
30	the	O
31	primate	O
32	LHbeta	O
33	-	O
34	CGbeta	O
35	gene	O
36	cluster	O
37	locus	O
38	.	O

0	METHODS	O
1	:	O
2	One	O
3	hundred	O
4	fourteen	O
5	consecutive	O
6	patients	O
7	(	O
8	mean	O
9	age	O
10	61	O
11	years	O
12	)	O
13	with	O
14	focal	O
15	pancreatic	O
16	masses	O
17	,	O
18	detected	O
19	on	O
20	CT	O
21	,	O
22	underwent	O
23	EUS	O
24	-	O
25	FNA	O
26	by	O
27	using	O
28	a	O
29	linear	O
30	-	O
31	array	O
32	echoendoscope	O
33	and	O
34	22	O
35	-	O
36	gauge	O
37	needles	O
38	.	O

0	The	O
1	effects	O
2	of	O
3	chlordiazepoxide	O
4	(	O
5	2	O
6	.	O
7	5	O
8	-	O
9	15	O
10	.	O
11	0mg	O
12	/	O
13	kg	O
14	),	O
15	a	O
16	full	O
17	benzodiazepine	O
18	receptor	O
19	agonist	O
20	,	O
21	and	O
22	bretazenil	O
23	(	O
24	5	O
25	.	O
26	0	O
27	-	O
28	30	O
29	.	O
30	0mg	O
31	/	O
32	kg	O
33	),	O
34	a	O
35	partial	O
36	benzodiazepine	O
37	receptor	O
38	agonist	O
39	,	O
40	were	O
41	examined	O
42	in	O
43	the	O
44	murine	O
45	elevated	O
46	plus	O
47	-	O
48	maze	O
49	paradigm	O
50	.	O

0	Acute	O
1	effects	O
2	of	O
3	LI	O
4	160	O
5	(	O
6	extract	O
7	of	O
8	Hypericum	O
9	perforatum	O
10	,	O
11	St	O
12	John	O
13	'	O
14	s	O
15	wort	O
16	)	O
17	and	O
18	two	O
19	of	O
20	its	O
21	constituents	O
22	on	O
23	neuroendocrine	O
24	responses	O
25	in	O
26	the	O
27	rat	O
28	.	O

0	Guidelines	O
1	for	O
2	performing	O
3	a	O
4	routine	O
5	spiral	O
6	assay	O
7	are	O
8	presented	O
9	,	O
10	and	O
11	alternative	O
12	test	O
13	methods	O
14	intended	O
15	to	O
16	overcome	O
17	a	O
18	variety	O
19	of	O
20	technical	O
21	difficulties	O
22	(	O
23	such	O
24	as	O
25	restricted	O
26	sample	O
27	availability	O
28	,	O
29	sample	O
30	viscosity	O
31	or	O
32	volatility	O
33	,	O
34	etc	O
35	.)	O
36	are	O
37	recommended	O
38	.	O

0	An	O
1	additional	O
2	9	O
3	patients	O
4	achieved	O
5	normal	O
6	levels	O
7	with	O
8	adjunctive	O
9	drug	O
10	therapy	O
11	.	O

0	Anti	O
1	-	O
2	nucleolin	O
3	mAb	O
4	was	O
5	used	O
6	to	O
7	confirm	O
8	the	O
9	antigenic	O
10	properties	O
11	of	O
12	this	O
13	p95	O
14	component	O
15	.	O

0	Eliminating	O
1	any	O
2	subset	O
3	of	O
4	ASCUS	O
5	reduces	O
6	the	O
7	ASCUS	O
8	/	O
9	SIL	O
10	ratio	O
11	but	O
12	also	O
13	significantly	O
14	diminishes	O
15	the	O
16	sensitivity	O
17	of	O
18	the	O
19	Papanicolaou	O
20	test	O
21	.	O

0	Prrp	O
1	can	O
2	also	O
3	associate	O
4	with	O
5	the	O
6	EVH1	O
7	domain	O
8	of	O
9	Mena	O
10	,	O
11	another	O
12	microfilament	O
13	-	O
14	associated	O
15	protein	O
16	.	O

0	Experience	O
1	with	O
2	xylene	O
3	-	O
4	free	O
5	sections	O
6	since	O
7	1995	O
8	at	O
9	the	O
10	Vrinnevi	O
11	Hospital	O
12	is	O
13	favorable	O
14	.	O

0	Acquired	O
1	antithrombin	O
2	deficiency	O
3	in	O
4	sepsis	O
5	.	O

0	SIP1	O
1	(	O
2	Smad	O
3	interacting	O
4	protein	O
5	1	O
6	)	O
7	and	O
8	deltaEF1	O
9	(	O
10	delta	O
11	-	O
12	crystallin	O
13	enhancer	O
14	binding	O
15	factor	O
16	)	O
17	are	O
18	structurally	O
19	similar	O
20	transcriptional	O
21	repressors	O
22	.	O

0	SERS	O
1	spectra	O
2	were	O
3	obtained	O
4	by	O
5	vacuum	O
6	evaporation	O
7	and	O
8	casting	O
9	of	O
10	p	O
11	-	O
12	NTP	O
13	onto	O
14	silver	O
15	island	O
16	films	O
17	,	O
18	and	O
19	also	O
20	from	O
21	colloidal	O
22	silver	O
23	solutions	O
24	.	O

0	The	O
1	moduli	O
2	of	O
3	elasticity	O
4	of	O
5	the	O
6	gray	O
7	and	O
8	white	O
9	matter	O
10	were	O
11	3	O
12	.	O
13	4	O
14	+/-	O
15	1	O
16	.	O
17	4	O
18	kPa	O
19	(	O
20	mean	O
21	+/-	O
22	standard	O
23	deviation	O
24	)	O
25	and	O
26	3	O
27	.	O
28	4	O
29	+/-	O
30	0	O
31	.	O
32	9	O
33	kPa	O
34	in	O
35	the	O
36	axial	O
37	section	O
38	,	O
39	3	O
40	+/-	O
41	0	O
42	.	O
43	3	O
44	kPa	O
45	and	O
46	3	O
47	.	O
48	5	O
49	+/-	O
50	0	O
51	.	O
52	5	O
53	kPa	O
54	in	O
55	the	O
56	frontal	O
57	section	O
58	,	O
59	and	O
60	3	O
61	.	O
62	5	O
63	+/-	O
64	0	O
65	.	O
66	9	O
67	kPa	O
68	and	O
69	2	O
70	.	O
71	8	O
72	+/-	O
73	0	O
74	.	O
75	4	O
76	kPa	O
77	in	O
78	the	O
79	sagittal	O
80	section	O
81	,	O
82	respectively	O
83	.	O

0	[	O
1	Clinical	O
2	and	O
3	epidemiological	O
4	characteristics	O
5	of	O
6	squamous	O
7	cell	O
8	carcinoma	O
9	of	O
10	the	O
11	oral	O
12	cavity	O
13	in	O
14	women	O
15	]	O
16	BACKGROUND	O
17	:	O
18	Squamous	O
19	cell	O
20	carcinoma	O
21	(	O
22	SCC	O
23	)	O
24	of	O
25	the	O
26	oral	O
27	cavity	O
28	occurs	O
29	mainly	O
30	in	O
31	the	O
32	male	O
33	population	O
34	.	O

0	The	O
1	core	O
2	promoter	O
3	of	O
4	human	O
5	thioredoxin	O
6	reductase	O
7	1	O
8	:	O
9	cloning	O
10	,	O
11	transcriptional	O
12	activity	O
13	,	O
14	and	O
15	Oct	O
16	-	O
17	1	O
18	,	O
19	Sp1	O
20	,	O
21	and	O
22	Sp3	O
23	binding	O
24	reveal	O
25	a	O
26	housekeeping	O
27	-	O
28	type	O
29	promoter	O
30	for	O
31	the	O
32	AU	O
33	-	O
34	rich	O
35	element	O
36	-	O
37	regulated	O
38	gene	O
39	.	O

0	Phase	O
1	II	O
2	trial	O
3	of	O
4	the	O
5	anti	O
6	-	O
7	G	O
8	(	O
9	D2	O
10	)	O
11	monoclonal	O
12	antibody	O
13	3F8	O
14	and	O
15	granulocyte	O
16	-	O
17	macrophage	O
18	colony	O
19	-	O
20	stimulating	O
21	factor	O
22	for	O
23	neuroblastoma	O
24	.	O

0	A	O
1	log	O
2	-	O
3	linear	O
4	dose	O
5	-	O
6	response	O
7	was	O
8	obtained	O
9	for	O
10	the	O
11	average	O
12	increase	O
13	in	O
14	FEV1	O
15	up	O
16	to	O
17	6	O
18	h	O
19	(	O
20	AUC0	O
21	-	O
22	6	O
23	h	O
24	)	O
25	and	O
26	peak	O
27	FEV1	O
28	across	O
29	the	O
30	dose	O
31	range	O
32	administered	O
33	by	O
34	Respimat	O
35	.	O

0	Plasma	O
1	DHE	O
2	concentration	O
3	rose	O
4	promptly	O
5	above	O
6	5	O
7	ng	O
8	/	O
9	ml	O
10	after	O
11	the	O
12	application	O
13	of	O
14	the	O
15	PSA	O
16	tape	O
17	onto	O
18	the	O
19	damaged	O
20	skin	O
21	in	O
22	hairless	O
23	rat	O
24	.	O

0	A	O
1	complete	O
2	drug	O
3	history	O
4	was	O
5	compiled	O
6	,	O
7	specifying	O
8	the	O
9	amount	O
10	and	O
11	duration	O
12	of	O
13	VGB	O
14	medication	O
15	.	O

0	Epithelial	O
1	cytotoxicity	O
2	of	O
3	combined	O
4	antibiotics	O
5	was	O
6	additive	O
7	,	O
8	with	O
9	no	O
10	evidence	O
11	of	O
12	competition	O
13	or	O
14	synergism	O
15	.	O

0	In	O
1	Cd	O
2	-	O
3	spiked	O
4	OECD	O
5	soil	O
6	,	O
7	internal	O
8	Cd	O
9	levels	O
10	were	O
11	linearly	O
12	related	O
13	to	O
14	external	O
15	Cd	O
16	concentrations	O
17	,	O
18	whereas	O
19	the	O
20	springtails	O
21	maintained	O
22	fixed	O
23	internal	O
24	levels	O
25	of	O
26	Cu	O
27	and	O
28	Zn	O
29	regardless	O
30	of	O
31	spiked	O
32	concentrations	O
33	.	O

0	Interestingly	O
1	,	O
2	the	O
3	similarities	O
4	with	O
5	the	O
6	endophilin	O
7	proteins	O
8	cover	O
9	the	O
10	entire	O
11	sequence	O
12	of	O
13	the	O
14	SH3GLB	O
15	family	O
16	,	O
17	suggesting	O
18	a	O
19	common	O
20	fold	O
21	and	O
22	presumably	O
23	a	O
24	common	O
25	mode	O
26	of	O
27	action	O
28	.	O

0	Reovirus	O
1	mRNAs	O
2	are	O
3	efficiently	O
4	translated	O
5	within	O
6	host	O
7	cells	O
8	despite	O
9	the	O
10	absence	O
11	of	O
12	3	O
13	'	O
14	polyadenylated	O
15	tails	O
16	.	O

0	Grippers	O
1	with	O
2	integrated	O
3	piezoresistive	O
4	force	O
5	sensors	O
6	and	O
7	with	O
8	attached	O
9	strain	O
10	gauges	O
11	have	O
12	been	O
13	reported	O
14	.	O

0	Both	O
1	Z	O
2	and	O
3	R	O
4	expression	O
5	resulted	O
6	in	O
7	PML	O
8	dispersion	O
9	in	O
10	EBV	O
11	-	O
12	positive	O
13	cells	O
14	.	O

0	The	O
1	small	O
2	copepod	O
3	Pseudonychocamptus	O
4	proximus	O
5	progressively	O
6	replaced	O
7	the	O
8	large	O
9	Tisbe	O
10	furcata	O
11	in	O
12	sand	O
13	filters	O
14	during	O
15	the	O
16	fall	O
17	of	O
18	1995	O
19	and	O
20	was	O
21	responsible	O
22	for	O
23	the	O
24	large	O
25	increase	O
26	in	O
27	meiofaunal	O
28	biomass	O
29	observed	O
30	after	O
31	spring	O
32	1996	O
33	.	O

0	Evidence	O
1	-	O
2	based	O
3	care	O
4	:	O
5	a	O
6	new	O
7	formula	O
8	for	O
9	an	O
10	old	O
11	problem	O
12	?	O

0	Nrf2	O
1	regulates	O
2	expression	O
3	of	O
4	genes	O
5	encoding	O
6	enzymes	O
7	with	O
8	antioxidant	O
9	(	O
10	e	O
11	.	O
12	g	O
13	.	O
14	heme	O
15	oxygenase	O
16	-	O
17	1	O
18	(	O
19	HO	O
20	-	O
21	1	O
22	))	O
23	or	O
24	xenobiotic	O
25	detoxification	O
26	(	O
27	e	O
28	.	O
29	g	O
30	.	O

0	Workload	O
1	,	O
2	UAPs	O
3	,	O
4	and	O
5	you	O
6	.	O

0	RESULTS	O
1	:	O
2	At	O
3	latest	O
4	examination	O
5	,	O
6	mean	O
7	UPDRS	O
8	II	O
9	and	O
10	III	O
11	scores	O
12	had	O
13	improved	O
14	by	O
15	30	O
16	%	O
17	(	O
18	on	O
19	stimulation	O
20	,	O
21	off	O
22	therapy	O
23	)	O
24	with	O
25	mean	O
26	50	O
27	%	O
28	reduction	O
29	in	O
30	daily	O
31	off	O
32	time	O
33	.	O

0	Perfusion	O
1	technique	O
2	for	O
3	perfusion	O
4	-	O
5	assisted	O
6	direct	O
7	coronary	O
8	artery	O
9	bypass	O
10	(	O
11	PADCAB	O
12	).	O

0	Copyright	O
1	2001	O
2	Academic	O
3	Press	O
4	.	O

